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Abstract 
Phage display technology is a powerful platform for the generation of highly specific human 
monoclonal antibodies (Abs) with potential use in clinical applications. Moreover, this technique has 
also proven to be a reliable approach in identifying and validating new cancer-related targets. For 
scientific or medical applications, different types of Ab libraries can be constructed. The use of Fab 
Immune libraries allows the production of high quality and affinity antigen-specific Abs. In this work, 
two immune human phage display IgG Fab libraries were generated from the Ab repertoire of 16 
breast cancer patients, in order to obtain a tool for the development of new therapeutic Abs for breast 
cancer, a condition that has great impact worldwide. The generated libraries are estimated to contain 
more than 108 independent clones and a diversity over 90%. 
Libraries validation was pursued by selection against BSA, a foreign and highly immunogenic 
protein, and HER2, a well established cancer target. Preliminary results suggested that phage pools 
with affinity for these antigens were selected and enriched. Individual clones were isolated, however, it 
was not possible to obtain enough data to further characterize them. Selection against the DLL1 
protein was also performed, once it is a known ligand of the Notch pathway, whose deregulation is 
associated to breast cancer, making it an interesting target for the generation of function-blocking Abs. 
Selection resulted in the isolation of a clone with low affinity and Fab expression levels. The validation 
process was not completed and further effort will have to be put in this task in the future.  
Although immune libraries concept implies limited applicability, the library reported here has a 
wide range of use possibilities, since it was not restrained to a single antigen but instead thought to be 
used against any breast cancer associated target, thus being a valuable tool.  
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Resumo 
A tecnologia de phage display é uma poderosa plataforma para criação de anticorpos (Acs) 
monoclonais humanos altamente específicos com potenciais aplicações clínicas. Esta técnica tem 
provado ser uma abordagem confiável para identificação e validação de novo alvos relacionados com 
cancro. Diferentes tipos de bibliotecas de Acs podem ser construídas para aplicações científicas e 
médicas. As bibliotecas imunes de fragmentos Fab permitem produzir Acs específicos de elevada 
qualidade e afinidade. Neste trabalho, duas bibliotecas imunes de phage display de Fabs de IgG 
humanos foram geradas do repertório de Acs de 16 pacientes de cancro de mama, para a obtenção 
de uma ferramenta para desenvolvimento de novos Acs terapêuticos para esta patologia de grande 
impacto mundial. Estimou-se que as bibliotecas geradas contêm mais de 108 clones independentes e 
uma diversidade acima de 90%. 
 Pretendeu-se validar as bibliotecas selecionando-as contra BSA, uma proteína altamente 
imunogénica, e HER2, um reconhecido alvo de cancro. Resultados preliminares sugerem que ocorreu 
seleção e enriquecimento de pools de fagos com afinidade para estes antigénios. Isolaram-se clones 
individuais, no entanto não foi possível obter informação suficiente para os caracterizar mais 
profundamente. Também se realizou seleção contra DLL1, dado ser um conhecido ligando da via 
Notch, cuja desregulação está associada ao cancro de mama, tornando-a um alvo de interesse para 
criação de Acs bloqueadores de função. O resultado foi o isolamento de um clone com baixa 
afinidade e baixos níveis de expressão de Fabs. O processo de validação não foi concluído, pelo que 
futuramente se deverão investir esforços nessa tarefa. 
Embora o conceito de biblioteca imune implique uma aplicabilidade limitada, a biblioteca aqui 
descrita tem vastas possibilidades de uso, pois não está restringida a um único antigénio; pelo 
contrário, foi idealizada para ser usada contra qualquer alvo associado a cancro de mama, sendo 
portanto uma ferramenta valiosa. 
 
 
Palavras-chave: 
Phage display; Cancro de mama; Via Notch; DLL1; Biblioteca imune de Fabs humanos; Anticorpos 
terapêuticos 
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1. Introduction 
1.1 Breast Cancer 
Breast cancer is by far the most common cancer in women worldwide and the second most 
common cancer overall (Bray et al., 2013). Nearly 1.7 million new cases were diagnosed in 2012, 
which represents about 12% of all new cancer cases and 25% of all cancers in women. Over 522 000 
women died in 2012 due to breast cancer, being also the first to second (in less developed and more 
developed countries, respectively) leading cause of cancer associated deaths in women and the fifth 
in both sexes (Ferlay, et al. 2013). Breast cancer incidence rates vary greatly worldwide, being higher 
in developed countries (Figure 1.1). However, almost 50% of breast cancer cases and 58% of deaths 
occur in less developed countries, where incidence is rising due to life expectancy and urbanization 
increase, and also due to adoption of western lifestyles (WHO, 2014). In Portugal, breast cancer is the 
cancer with the highest incidence rate; in 2012, over 6000 new cases were diagnosed and it caused 
over 1500 deaths (Ferlay, et al. 2013). Breast cancer survival rates vary greatly worldwide, ranging 
from 80% or over in North America, Sweden and Japan to around 60% in middle-income countries, 
and below 40% in low-income countries (Coleman et al., 2008). The low survival rates in less 
developed countries are mainly due to the lack of early detection programmes, which results in a high 
proportion of women that are diagnosed with late-stage disease, as well as by the lack of adequate 
treatment facilities (WHO, 2014). 
	  
Figure 1.1 - Estimated breast cancer incidence worldwide in 2012. Estimated age-standardized rates 
(world) per 100 000. Source: Ferlay et al, 2013. 
The most effective way to fight and control breast cancer is early detection, which 
considerably improves the disease outcome and survival rate (WHO, 2014). However, this does not 
always happen, as the above numbers indicate. Those reflect the impact of breast cancer in the world, 
which is increased by affecting an organ of great symbolism for femininity individually and socially. 
Considering all this, it is clear the need and importance of optimizing and discovering new possibilities 
for breast cancer therapy, which keeps on being a major area of research in medical oncology 
(Stopeck et al., 2012). 
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1.1.1 Breast Cancer Treatment: Targeted Therapy Relevance 
For most patients with operable breast cancer, the primary therapy consists in tumor 
(sometimes along with regional lymph nodes) removal by surgery (Akram and Siddiqui, 2012; National 
Cancer Institute, 2009). Depending on the tumor characteristics and the stage of the disease several 
treatment options may be viable, and must be considered by the doctor (or specialist team in charge 
of the case) and the patient together (Cancer Research UK, 2014a). Also, neoadjuvant therapy may 
be needed in locally advanced breast cancer cases to reduce the tumor before surgery, so that it may 
result in more effective and less invasive outcome (National Cancer Institute, 2009). 
After surgery, many strategies may be used to increase the chance of long-term disease-free 
survival, and these are specially indicated for patients who have a higher risk of breast cancer 
recurrence. Adjuvant therapy intends to kill or stop the growth of any cancer cells that remain in the 
patient’s body and might not be detected. These kinds of therapies can include chemotherapy, 
hormonal therapy, targeted drugs (i.e. trastuzumab Herceptin®), radiation therapy, or a combination of 
treatments. Radiation therapy acts locally, and is aimed at cancer cells that may have been left in 
tissues in close proximity to the breast after surgery, such as those from the chest wall or nearby 
lymph nodes. On the other hand, systemic therapies can also reach and affect cells that may have 
spread to other locations (National Cancer Institute, 2009).  Chemotherapy is a standard option that 
consists in the administration of cytotoxic drugs that interfere with cells with a high proliferating index, 
like cancer cells. However, since enhanced proliferation is also detected in epithelia and bone marrow 
cells, these drugs are highly toxic for the organism, resulting in the side effects commonly associated 
with chemotherapy (National Cancer Institute, 2014; Stopeck et al., 2012). 
These potentially harmful and severe side effects should be taken into account before 
treatment, so that patients that are not likely expected to benefit from chemotherapy should not have 
to be subjected to it (Akram and Siddiqui, 2012). Nevertheless, chemotherapy is a conventional 
choice, once it is usually considered that if this treatment brings a small advantage to the patient even 
regarding the side effects, then this is better than none at all (Stopeck et al., 2012).  
Although there are standard therapy procedures adopted in most breast cancer cases, it is 
long known and increasingly clear that, as for other cancers, there are molecularly distinct subtypes of 
breast cancers, that may require or take a greater benefit from different therapeutic approaches 
(Jackson and Chester, 2014).  
Accordingly, breast cancer tumors are tested to check hormone receptors (estrogen receptor, 
ER, or progesterone receptor, PR) and human epidermal growth factor receptor 2 (HER2) status, 
which allows the identification of key molecular subtypes of human breast tumors and currently guide 
choice of therapy. For patients with hormone-receptor positive (ER- or PR-positive) breast cancer, 
hormone therapy with tamoxifen (drug that prevents estrogen from binding to the ER) and aromatase 
inhibitors (that block estrogen production by the body), or ovarian suppression (in premenopausal 
patients) represent the backbone of treatment, along with chemotherapy (Akram and Siddiqui, 2012). 
Since ER and PR are not exclusive to the neoplastic cells, hormone therapies can affect other tissues 
and organs that express them, with the possibility of causing some side effects, making hormone 
therapies ‘semi-targeted’ (Stopeck et al., 2012). 
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For patients with HER2-positive breast cancer, regardless of any other characteristics, the 
introduction of therapies directed against HER2 has dramatically improved prognosis (Akram and 
Siddiqui, 2012). HER2 (neu, C-erb B2) is a transmembrane receptor that belongs to the EGFR family 
of receptor tyrosine kinases. Contrarily to the other receptors of the HER family, no known natural 
ligand exists for HER2 (Mukai, 2010). HER2 can be overexpressed in breast cancer and in other solid 
tumors; HER2 gene amplification and protein overexpression is present in 15–30% of breast cancers 
and is directly linked to deregulated activation of the intracellular mitogenic signaling, leading to a 
more aggressive behavior and therefore poor prognosis (Akram and Siddiqui, 2012; Elloumi et al., 
2012; Mukai, 2010; Stopeck et al., 2012) Anti-HER2 targeted agents are an example of molecularly 
targeted therapy, a type of treatment that blocks the growth and spread of cancer by interfering with 
specific molecules and pathways related to tumor progression and malignancy. These agents can act 
by inducing apoptosis of cancer cells, by blocking specific enzymes and growth factor receptors 
involved in cancer cell proliferation, cellular invasion and metastasis, or by modifying the function of 
proteins that regulate gene expression and other cellular functions. Since targeted therapy focuses on 
molecular abnormalities specific to cancer, it is expected to be similar, or even more effective, and 
less harmful to normal cells than systemic chemotherapy, which simply interferes with all rapidly 
dividing cells (Huang et al., 2014; Joo et al., 2013). 
Trastuzumab (Herceptin®), an IgG1 humanized monoclonal antibody (mAb) that specifically 
binds to the extracellular domain of human HER2, has been a major success story in the field of 
targeted drugs (Mukai, 2010; Ribatti, 2014). Herceptin® was the first anti-HER2 targeted agent 
approved for clinical use in breast cancer patients (Mukai, 2010). This antibody (Ab) binds to the extra-
cellular domain of HER2 receptor on the cells, and consequently induces the expression of anti-
angiogenic factors, suppresses pro-angiogenic factors, and mediates Ab-dependent cytoxicity (Ribatti, 
2014). Its clinical development relied upon selecting only those patients with the highest likelihood of 
response, or HER2 overexpressing tumors – “HER2 positive” (HER2+) – based on the principle that 
the target is also the best predictor of response. HER2+ classification is carefully attributed by 
measuring and scoring HER2 expression by standard clinical assays and accepted criteria. HER2 
overexpression is thought to be a signal of the reliance of the cancer cell on HER2 signaling 
(“oncogene addiction”). Therefore, inhibition of HER2 signaling should result in a therapeutic effect 
mostly, if not exclusively, within cancer cells that are HER2+ and not be toxic to normal cells (Stopeck 
et al., 2012). 
Despite its added value, 70% of HER2+ patients do not respond to treatment with 
Trastuzumab. In addition, acquired resistance to trastuzumab develops in a majority of patients with 
metastatic breast cancer, due to progression of the disease. This is mainly due to the development of 
mutations within the specific target-encoding gene, which can lead to a decrease in the affinity of the 
Ab towards it (Elloumi et al., 2012; Mukai, 2010). This problem has been managed by the introduction 
of other HER2-targeting agents with different mechanisms of action that can complement 
trastuzumab, and thus be an option in cases of resistance. Lapatinib (Tykerb®) is an oral dual tyrosine 
kinase inhibitor targeting HER1 and HER2 which blocks the downstream signaling pathways of these 
receptors (Mukai, 2010). Pertuzumab (Perjeta®) is also a mAb but this molecule targets a different 
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extracellular domain of HER2, specifically the dimerization region so that its binding inhibits HER2 
dimerization with other HER receptors. This results in critical cell signaling inhibition and Ab-
dependent cellular cytotoxicity activation. Furthermore, combined administration of pertuzumab and 
trastuzumab has demonstrated superior antitumor effects compared to either Ab alone in preclinical 
experiments (Joo et al., 2013; Stopeck et al., 2012). This leads to a second way of dealing with the 
limited efficacy of trastuzumab: combinatory therapy. This approach is becoming obligatory and these 
kinds of treatments are now being studied not only as monotherapies, but also in combination with 
other targeted therapies or with chemotherapy, with the goal of establishing the most effective 
combinations, with minimal side effects and a low damage to normal dividing cells (Elloumi et al, 2012; 
Joo et al., 2013; Stopeck et al., 2012). In this context, the Ab-cytotoxic drug conjugate ado-
trastuzumab emtansine (Kadcyla®), was recently approved by the FDA (2013) (Joo et al., 2013). It 
consists in trastuzumab linked to the cytotoxic agent mertansine (DM1). DM1 inhibits tubulin 
polymerization, interfering with mitosis and promoting apoptosis. Kadcyla® combines the anti-HER2 
activity of trastuzumab with the targeted intracellular delivery of DM1, with the advantage that its 
cytotoxic activity will be specifically carried out in HER2+ tumor cells (Ballantyne and Dhillon, 2013; 
Breastcancer.org, 2014a). 
There are also some targeted therapies specific for other molecules that can be used in breast 
cancer; everolimus (Afinitor®) is indicated in advanced hormone receptor-positive, HER2-negative 
tumors; it is a transduction signal inhibitor targeting mTOR complex 1, consequently reducing the 
activity of its downstream effectors, which results in a decrease in cell proliferation, angiogenesis and 
glucose uptake (National Cancer Institute, 2014). Bevacizumab (Avastin®) is a recombinant 
humanized mAb that binds to vascular endothelial growth factor A (VEGF-A) and blocks angiogenesis 
(Elloumi et al., 2012). However, these are not consensually approved (Cancer Research UK, 2014b; 
Elloumi et al., 2012; Pazdur, 2013). 
Clearly, the progress in targeted therapies for breast cancer has mainly been made on anti-
HER2 drugs, which means other types of breast cancer are currently not benefiting from this type of 
treatment. Yet, breast cancer heterogeneity is not limited to the presence or absence of ER, PR and 
HER2 expression – tumors that are negative for all these three conditions are called triple negative. 
These correspond to 15 to 20% of breast cancers, and are more often high grade, highly proliferative, 
and locally advanced at diagnosis. However, triple negative cancers are not a single type of disease, 
harboring distinct phenotypic and functional characteristics resulting from genetic diversities and non-
genetic influences (Huang et al., 2014; Stopeck et al., 2012). Consequently, no single therapy is likely 
to be effective for all patients and current treatment options are limited, so their management is 
challenging (Akram and Siddiqui, 2012; Stopeck et al., 2012). Although a subset of types of cancer 
may respond to chemotherapy, advantage may come from the identification of new specific pathways 
and targets for therapy (Akram and Siddiqui, 2012; Joo et al., 2013). Even if triple negative cases are 
those who have more to gain with the discovery of new targets for therapy, the remaining could also 
benefit. Surely, some ER, PR and HER2 positive cancers may express other molecules that are 
targeting candidates, given that the oncogenic process implies the deregulation of several proteins 
and signal transduction pathways at the same time. Despite the several options of treatment available, 
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there are always cases of failure, and new therapeutic options targeting other molecules would be 
welcome and allow improving the chances of success, when patients are appropriately selected 
accordingly to the alternative predictive biomarkers they express (Jackson and Chester, 2014). 
1.2 The Notch Signaling Pathway 
Notch signaling is an evolutionarily conserved developmental pathway, expressed in a wide 
range of tissues and organisms, indicating its multiplicity of functions (Calaf et al., 2014; Izrailit and 
Reedijk, 2012; Takebe et al., 2014). During development, it is critical for cell fate determination and 
homeostasis, by controlling cell growth and proliferation, migration, differentiation and apoptosis, and 
participating in tissue patterning, morphogenesis, organogenesis and angiogenesis (Aste-Amézaga et 
al., 2010; Calaf et al., 2014; Han et al., 2011; Takebe et al., 2014). Although classically known for its 
vital role in embryogenesis, it is also implicated in postnatal hematopoiesis, breast development, 
gastrointestinal epithelial maturation, immune regulation, vascular development and somatic stem cell 
maintenance, renewal and differentiation (Sethi et al., 2011; Takebe et al., 2014). Given this diversity, 
Notch signaling outcome largely depends on the cell-context, microenvironment and crosstalk with 
other signaling pathways (Takebe et al., 2014). 
 Different Notch receptors have different functions and regulate cell fates differently. In 
mammals, they are four (Notch1, 2, 3 and 4) and each of them have five ligands (Jagged 1 – Jag1 and 
Jagged2 – Jag2, and Delta-like 1 – DLL1, 3 – DLL3 and 4 – DLL4) (Sharma et al., 2012; Takebe et al., 
2014). All Notch receptors and their ligands are single-pass transmembrane proteins, so the Notch 
signaling is activated by direct cell–cell contact, consisting of a short-range intercellular 
communication system between neighboring cells (Izrailit and Reedijk, 2012; Suman et al., 2013; 
Takebe et al., 2014). 
	  
Figure 1.2 - Notch canonical signaling pathway overview. Red arrows – proteolytic cleavages. Adapted 
from Ersvaer et al., 2011. 
The Notch receptors and their ligands contain multiple epidermal growth factor (EGF)-like 
repeats in the extracellular region required for their binding. In the receptors, follows a negative 
regulatory domain (NRR) that, in the absence of ligand, maintains the receptor in a protease-resistant 
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conformation (Aste-Amézaga et al., 2010; Takebe et al., 2014). Ligand binding activates the pathway 
by triggering a conformational change in the receptor NRR that is followed by two sequential 
proteolytic cleavages; the first is in the extracellular domain and is mediated by metalloproteases of 
the ADAM (A Disintegrin And Metalloproteinase) family, and the second occurs within the 
transmembrane domain and is mediated by the γ-secretase complex. This results in the release and 
translocation of the active Notch intracellular domain (NICD) into the nucleus, where it interacts with 
the DNA-binding protein CSL (C-promoter binding factor 1, CBF1 in humans), converting it from a 
transcriptional repressor to activator by recruiting cofactors such as Mastermind-like proteins. This 
activates the transcription of Notch target genes, like HES1, HES5, HEY2, NRARP, DELTEX1, and c-
MYC (Figure 1.2) (Aste-Amézaga et al., 2010; Izrailit and Reedijk, 2012; Takebe et al., 2014). 
1.2.1 Notch Signaling Pathway and Breast Cancer 
Deregulated Notch signaling is associated with numerous human diseases, including a broad 
spectrum of cancers. It is generally physiologically involved in the development and maintenance of 
normal tissues that originate and are recapitulated in those different forms of cancer. Deregulation of 
the pathway might affect normal cell differentiation and metabolism, cell cycle progression, 
angiogenesis and possibly self-renewal and immune function (Bolós et al., 2013; Calaf et al., 2014). 
Moreover, some of the Notch target genes are well known to have significant roles in carcinogenesis 
and tumor progression (Takebe et al., 2014). 
An oncogenic role for Notch was first discovered in T-cell lymphoblastic leukemias (T-ALL), in 
which Notch-1 gain-of-function mutations are found in over 50% of cases. Since then, aberrant Notch 
signaling was subsequently identified in many solid tumors, including pancreatic, prostate, renal, lung, 
glioblastoma multiforme, sarcomas, gastroenteropancreatic neuroendocrine tumors, cervical, 
melanoma, head and neck, and breast cancers. In those, however, current evidence suggests that 
aberrant Notch activation occurs through transcriptional and post-translational mechanisms resulting 
in ligand/receptor abundance rather than activating mutations or amplification of the Notch loci. 
Ligands mutations are also infrequent (Izrailit and Reedijk, 2012; Takebe et al., 2014). 
High expression of Notch receptors and ligands has been recently implicated in breast cancer 
pathogenesis and associated to poor clinical outcomes. Reedjik et al (2005) identified high levels of 
Jag1 or Notch1 in about 25% of human breast tumors by in situ hybridization, and associated high 
levels of co-expression of Notch1 and Jag1 with reduced overall survival. Immunohistochemistry 
studies revealed increased expression of several Notch receptors and ligands in human breast cancer 
specimens compared to normal breast tissue, and different co-expression patterns (Rizzo et al., 2008; 
Mittal et al., 2009). Notch1 down-regulation and inhibition by several methods in human breast cancer 
cell lines has demonstrated anti-tumor effects, like inhibition of invasion and metastasis (Wang et al., 
2011), proliferation inhibition and apoptosis induction (Sharma et al., 2012), mammosphere formation 
inhibition and size reduction (Simmons et al., 2012; Suman et al., 2013). Mammary tumor regression 
and disease recurrence prevention were also demonstrated in transgenic mice models (Simmons et 
al., 2012). 
Notch association to worse prognosis has also been exploited. As in the case of normal stem 
cells, Notch signaling plays an important role in maintenance of cancer stem cells (CSCs), capable of 
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self-renewal and differentiation in malignant cells (Joo et al., 2013; Sharma et al., 2012). The CSCs 
are believed to constitute a subpopulation in various cancers that is responsible for tumor initiation, 
progression, metastasis, and also resistance to therapy, being therefore the source of recurrence (Joo 
et al., 2013; Suman et al., 2013; Takebe et al., 2014). Notch activity was identified as a marker for 
cells with stem cell-like properties, and there is evidence that it is required for breast CSCs renewal 
and expansion, more specifically, that Notch4 has a role in their maintenance and tumor initiation, 
while Notch1 participates in tumor growth and proliferation (Izrailit and Reedijk, 2012; Takebe et al., 
2014). Furthermore, Notch1 inhibition sensitizes breast cancer cells to chemotherapy (Suman et al., 
2013). 
Another connection between Notch signaling and poor clinical outcomes is the correlation 
between ligand Jag1 expression in breast cancer cells and bone metastasis, which correspond to 70% 
of metastatic breast cancer. Sethi et al (2011) identified Jag1 as a clinically and functionally important 
mediator of bone metastasis by activating the Notch pathway in bone cells. 
Considering the above mentioned, it is clear that Notch signaling provides a potential 
therapeutic target for breast cancer treatment. 
1.2.2 Notch-Targeting Therapeutic Agents 
Different strategies are being developed to block Notch signaling for therapeutic purposes. 
One approach is to prevent the proteolytic cleavages that result in the release of NICD by treatment 
with γ-secretase inhibitors (GSIs) (Aste-Amézaga et al., 2010; Sharma et al., 2012). GSI treatment of 
Notch-induced breast cancer cells in vitro reduces Notch activity and tumor proliferation, and inhibits 
metastasis of mammary tumors (Groth and Fortini, 2012; Izrailit and Reedijk, 2012). However, this 
method has poor selectivity, interfering with the proteolysis of all four Notch receptors as well as with 
multiple additional proteins involved in other signaling pathways. This leads to significant limitations to 
their therapeutic potential, namely severe adverse effects resulting from GSI-induced toxicity and 
dysfunction of several systems (Aste-Amézaga et al., 2010; Izrailit and Reedijk, 2012; Sharma et al., 
2012). 
The second most explored class of agents under development is mAbs, which are expected to 
overcome GSIs restraints (Takebe et al., 2014). mAbs have the advantage of specificity, but also 
versatility, once they can be developed against any relevant member of the pathway. It has already 
been demonstrated that mAbs developed against Notch1 specifically bind to and inhibit Notch1 
signaling (Aste-Amézaga et al., 2010), inhibit Notch1-driven tumors growth, and have reduced side 
effects (Wu et al., 2010). In fact, several Notch-targeting mAbs are currently in early phase clinical 
development, including mAbs against Notch1, Notch2/3 and DLL4, whose effects are being studied in 
subjects with solid tumors (Takebe et al., 2014). 
1.3 Antibodies 
Antibodies (Abs) belong to a family of globular proteins called immunoglobulins (Igs) and are 
the antigen-binding proteins present on the B-cell membrane and secreted by plasma cells (Elgert, 
2009; Goldsby et al., 2003). They have a fundamental role in the humoral response of the immune 
system, having functions like binding specifically to the pathogen or its products that elicit the immune 
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response, and recruiting other cells and molecules to destroy the pathogen once the antibody has 
bound (Murphy, 2012). 
1.3.1 Antibodies Structure 
All Abs share a common structure (Figure 1.3 A) of four peptide chains that consist of two 
identical light chains (LC), of about 25 kDa each, and two identical heavy chains (HC), larger 
polypeptides of 50 kDa or more each. The two HC are linked to each other by disulfide bonds, and 
each HC is linked to a LC by a disulfide bond  (Goldsby et al., 2003; Murphy, 2012). There are two 
types of LC, lambda (λ) and kappa (κ). A single Ab molecule contains only one LC type, never both, 
and no functional difference has been found between Abs having each of them (Murphy, 2012). 
The class and thus the effector function of an Ab is defined by the structure of its HC, more 
specifically by its carboxy (C)-terminal part or constant region. There are five main HC classes or 
isotypes, some of which have several subtypes, and these determine the functional activity of an Ab 
molecule. The five major classes of Igs are IgG (γ), IgM (µ), IgA (α), IgE (ε) and IgD (δ). IgG is the 
most abundant Ig. Each class can have either a λ or κ LC (Goldsby et al., 2003; Murphy, 2012). 
 
Figure 1.3 – The Ab molecule. A – Schematic diagram of Ig structure. B – Fab and Fc fragments; Grey – 
LC; Blue – HC. Adapted from Goldsby et al., 2003. 
The first 100-113 amino acids of the amino (N)-terminal region of a LC or HC greatly vary 
between Abs of different specificity. These segments of highly variable sequence are called V regions: 
VL in LC and VH in HC (Elgert, 2009; Goldsby et al., 2003). Since the amino acid sequence dictates 
the three-dimensional structure of the protein, the unique sequence of amino acid residues for each V 
region leads to a large diversity of structures, which accounts for antibody specificity (Elgert, 2009). In 
contrast, the remaining portion of the molecule has a relatively constant sequence within the same Ab 
class, making up the C regions (CL in light chains and CH in heavy). The HC C region contains 
multiple domains, either three or four, depending on the antibody class, and those are numbered from 
the N-terminal end to the C-terminus CH1, CH2, CH3, and CH4 (Goldsby et al., 2003). 
The LC and HC association forms the Ab molecule, which comprises three equal-sized 
globular portions of 50 kDa joined by a flexible polypeptide chain, the hinge region. The final result is a 
Y-shaped structure; the two upper arms are identical and each is formed by the association of a LC 
with the amino-terminal half of the HC (Fd fragment). More specifically, the VL region interacts non-
covalently with the VH region, and the CL region with the CH1 region. These are called Fab fragments 
A B 
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(“fragment, antigen binding”), and contain the antigen binding activity. The other fragment is the Fc 
fragment (“fragment crystallizable”), which corresponds to the remaining constant HC domains, and is 
the part of the Ab molecule that interacts with effector molecules and cells (Figure 1.3 B) (Elgert, 2009; 
Murphy, 2012). 
Looking closer to the V regions organization, there are three particularly variable segments 
that can be identified in both VH and VL domains, designated as hypervariable regions or 
complementarity-determining regions (CDRs) – CDR1, CDR2, and CDR3. In the HC they are located 
roughly at residues 30 to 36, 49 to 65 and 95 to 103, respectively, and in the LC at residues 28 to 35, 
49 to 59 and 92 to 103 (Murphy, 2012). The regions between the CDRs, which comprise the rest of 
the V domain (about 85%), show less variability and are termed the framework regions (FR). There 
are four in each V domain, FR1, FR2, FR3 and FR4, and they are responsible for the CDRs 
positioning on the surface of the chain, when the VH and VL domains are joined. This creates a single 
hypervariable region at the end of each Fab. Due to the fact that the amino acid sequences and length 
of the CDRs determine the shape and ionic properties of the antigen-binding site, the CDRs define the 
specificity of the antibody (Elgert, 2009; Murphy, 2012). 
The Abs diversity is generated by somatic recombination in B lymphocytes, whereby V-gene 
segments are linked to other gene segments. The LC families contain VL, JL, and CL gene segments 
and the HC family contains VH, DH, JH, and CH gene segments. C gene segments encode the 
constant regions (Goldsby et al., 2003). In the final assembled LC V domain, the VL gene segment 
encodes FR1 to 3, CDR1 and 2, and two thirds of CDR3, while JL encodes the rest of CDR3 and FR4. 
In the HC V domain, VH gene segment encodes FR1 to 3 and CDR1 and 2 and JH encodes FR4. HC 
CDR3 is created de novo in developing B cells by the joining process, containing the entire DH as well 
as portions of VH and JH gene segments (Figure 1.4) (Paul, 2013).  
	  
Figure 1.4 - Final assembly of the Ab gene segments. Variable chain gene segments contribution to the 
antigen-binding site. Adapted from Murphy, 2012. 
Additional diversity is generated during recombination by imprecise joining, especially at the 
VH-DH and DH-JH junctions, which allows nucleotides loss and gain. Altogether, this results in the 
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creation of nearly random HC CDR3 sequences, where the greatest diversity of an Ab repertoire is 
focused (Burton, 2001; Paul, 2013). 
Although the undeniably fundamental role of the V regions, CH1 and CL domains may also 
contribute to Ab diversity by allowing more random associations between VH and VL domains than 
would occur if these were driven by the VH/VL interaction alone. The presence of CH1 and CL 
appears to increase the number of stable VH and VL interactions that are possible, thus contributing to 
the overall diversity of Ab molecules that can be expressed by an animal. These considerations have 
important implications for building a diverse Ab repertoire (Goldsby et al., 2003). 
1.3.2 Therapeutic Antibodies 
Abs are important tools for research and medicine, being monoclonal antibodies (mAbs) the 
most useful (Goldsby et al., 2003). mAbs are monospecific Abs made by identical immune cells that 
derive from a unique clone and thus are specific for a single epitope (Goldsby et al., 2003; Xin et al., 
2013). 
Initially, in the clinical medicine field mAbs were used primarily as in vitro diagnostic reagents 
(Goldsby et al., 2003), but soon their value as therapy agents was noticed. Presently, Ab-based 
therapeutics is an important component in the treatment of an increasing number of human 
malignancies, including cancer, infectious diseases, transplantation, allergy, asthma, and some 
autoimmune diseases. The mechanism of action of a mAb includes neutralization of substances, 
blocking of receptors, binding to cells and modulating the host immune system by inducing effector 
functions, such as Ab-dependent cellular cytotoxicity, or a combination of these effects (Brissette et 
al., 2006; Schirrmann et al., 2011 ). These molecules can also be used as drug delivery systems or 
Ab-cytotoxic drug conjugates, specifically inducing death to target cells that engulf the conjugates after 
they bind (Joo et al., 2013). 
Abs are one key component of molecularly targeted therapy, perfectly fitting its demands 
given their target specificity and low toxicity, in addition to well-defined pharmacological properties, 
such as high affinity and long serum half-life (Brissette et al., 2006; Dantas-Barbosa et al., 2012).  
There are currently more than 250 therapeutic mAbs undergoing clinical trials (Ribatti, 2014). 
To date, a total of 39 therapeutic mAbs have already been approved by the U.S. Food and Drug 
Administration (FDA) and the European Medicines Agency (EMA), 15 of which are directed to cancer 
treatment, and 4 are under review for approval (2 of them also for cancer) (Landes Biosciences, 
2014). Furthermore, Abs comprise the second-largest category of biological medicines in clinical 
development (Dantas-Barbosa et al., 2012). Among the mAbs approved for cancer treatment are 
Trastuzumab, Pertuzumab and Trastuzumab emtansine, all for HER2+ breast cancer (see section 
1.1.1). 
Even though everything points to the successful establishment of Abs in therapeutics, the Ab 
development method chosen may limit the possibility of overcoming all challenges from idealization to 
approval. Among them are relatively long development times, high production costs, difficult 
manufacturing, poor effector functions and pharmacokinetics but, most importantly, safety concerns 
related to immunogenicity, when these are obtained by animal immunization and hybridoma 
technology (Brissette et al., 2006; Dantas-Barbosa et al., 2012; Ribatti, 2014; Schirrmann et al., 2011). 
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The latest problem has been solved by chimerization and humanization of mouse Abs using genetic 
engineering techniques, which are still popular alternatives. Chimeric Abs consist of a combination 
between the constant domain of human IgG and the variable antigen-specific mouse domain (30 to 
35% mouse proteins and 60 to 65% human proteins). Humanized mAbs are originated by the 
implantation of the mouse CDR in the framework of human IgG, and thus the human part of the Abs is 
between 90 to 95% (Elloumi et al., 2012). However, it is already possible to produce fully human Abs 
utilizing different approaches, such as phage display technology or genetically engineered mice (or 
other animals), which offer more advantages because they are less antigenic, better tolerated and 
have a longer circulation time (Dantas-Barbosa et al., 2012; Ribatti, 2014; Xin et al., 2013). In fact, of 
the 39 approved therapeutic mAbs, 11 are human, 4 derived from phage display technology and 7 
obtained by genetically engineered mice (Landes Bioscience, 2014). The latest were generated by 
replacement of animals’ native Ab genes by pure human homologues. Upon immunization, these 
animals develop human IgG in response to the antigen, which then can be produced by conventional 
hybridoma technology (Dübel, 2007; Ribatti, 2014). This implies that, despite solving the 
immunogenicity issue, this option is not free of the remaining hybridoma technology constraints; 
although well established, this technology is laborious, and it is limited by the possible instability of the 
aneuploid cell lines and by the animal immune system inability to provide high-affinity Ab against toxic 
or highly conserved mammal proteins (Dantas-Barbosa et al., 2012; Schirrmann et al., 2011). 
On the other hand, the phage display technology is completely independent from any immune 
system and uses a completely in vitro selection process, offering a rapid approach for generating and 
identifying highly specific reagents relatively quickly, with a resulting decrease in both development 
time and costs (Brissette et al., 2006; Schirrmann et al., 2011). Also, the first fully human therapeutic 
Ab to be approved was isolated by this method – the anti-TNF-α Ab adalimumab (Humira®) for 
rheumatoid arthritis treatment (Schirrmann et al., 2011).  
1.4 Phage Display Technology 
The phage display concept was first introduced by George Smith in 1985, when he 
demonstrated that foreign DNA fragments could be fused to a coat protein-coding gene of a non-lytic 
filamentous phage and expressed as a fusion protein on the virion surface without disturbing the 
infectivity of the phage (Ahmad et al., 2012). Five years later, McCafferty et al showed that cloned Ab 
fragments could be similarly displayed on phage particles as functional proteins that retained an active 
antigen-binding domain capability. Soon the first Ab gene repertoires or “libraries” had been generated 
for filamentous phage display and Ab selection (Ahmad et al., 2012; Schofield et al., 2014). Phage 
display is now a mainstream Ab and protein engineering platform, being one of its most successful 
applications the genetic selection of mAbs using large phage Ab libraries (Hoogenboom, 2005; 
Schofield et al., 2014).  
The ultimate aim of phage display is the selection of peptides or proteins that can bind to a 
target of interest with high affinity, from a huge number of nonspecific candidates (Ahmad et al., 2012). 
This is achieved by using large combinatorial repertoires or libraries. Phage display libraries are 
constructed by mass cloning of a pool of genes encoding millions of variants of certain ligands into an 
adequate vector (like the phage genome), without need of individual identification of each gene, 
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allowing the effortless construction of diverse and rich collections (Ebrahimizadeh and Rajabibazl, 
2014; Hoogenboom et al., 1998). This results in the fusion of those genes with a gene encoding one of 
the phage coat proteins that is carried by the vector. Upon expression, the coat protein fusion will be 
incorporated into new phage particles that are assembled in the bacterium (Hoogenboom et al., 1998). 
The fusion product is displayed on the phage surface, and can be selected for its specific binding 
properties (Hoogenboom et al., 1998; Schofield et al., 2014). Moreover, the genetic information 
encoding the displayed protein is contained within the phage particle, providing a direct link between 
phenotype and genotype, which is the fundamental aspect of phage display (Figure 1.5) (Carmen and 
Jermutus, 2002; Hoogenboom et al., 1998). This linkage allows the enrichment of the selected phages 
but also further manipulation and development of genetic studies of the correspondent displayed 
proteins, due to the possibility of recovering the genetic information (Brissette et al., 2006; Hammers 
and Stanley, 2014). 
	  
Figure 1.5 - Generic schematic representation of a protein-displaying phage particle. Adapted from 
Yamabai, 2014. 
Phage display technology is robust, simple to use, highly versatile, easy to implement and 
inexpensive (Dantas-Barbosa et al., 2012; Hoogenboom et al., 1998). It can be exploited in broad 
spectrum of biomedical and pharmaceutical researches, including: identification of cell/tissue or 
disease-specific biomarkers; protein-protein interaction; receptor-ligand characterization; epitope 
mapping; gene delivery/targeting; and proteomic and functional genomic approaches (Tohidkia et al., 
2012). Last but not least, it plays an important role in drug and vaccine discovery and development, 
which includes production of mAbs, with a number of molecules approved by FDA and many others in 
clinical trials (Dantas-Barbosa et al., 2012; Tohidkia et al., 2012) 
1.4.1 Phage Panning 
One of the advantages of phage display is the rapid identification and enrichment of target-
specific binders from a large excess of non-binding clones, through a process known as biopanning. 
This is achieved by multiple rounds of phage incubation with a chosen target, washing to remove non-
specific or low affinity phages, elution to retrieve specifically bound phages and their amplification 
(Figure 1.6) (Hoogenboom et al., 1998). In the first round, the selected subpopulation should be a 
small fraction of the very large initial library, so it will be amplified in the appropriate host cells in order 
to achieve a significantly higher representation of each individual phage in the amplified stock (Smith 
and Petrenko, 1997). A single round of selection can enrich for a specific phage 20 to 1000-fold. 
Performing multiple selection rounds with selected (eluted and amplified) phages increases the 
enrichment of specific binders (Watkins and Ouwehand, 2000), allowing the isolation of potentially 
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very rare antigen-binding clones (Hammers and Stanley, 2014). The panning steps should be 
repeated until the identification of optimal binders, which usually takes 3 to 5 rounds (Dantas-Barbosa 
et al., 2012).  
	  
Figure 1.6 - Phage display technology overview. Adapted from Biotem, 2011. 
The success of ligand phage display hinges on the combination of this display and enrichment 
method, with the synthesis of large combinatorial repertoires on phage (Hoogenboom et al., 1998). 
Various types of selection strategies can be used. The simplest and most common approach is to use 
a purified antigen immobilized on a solid support, which requires a good source of antigen (Watkins 
and Ouwehand, 2000), but affinity selection can be performed by using low antigen concentrations. 
Also, if the selection procedure is appropriately designed, antibodies can also be selected on the basis 
of kinetic properties, improved specificity, or phage infectivity (Ahmad et al., 2012). Other systems 
may be required when pure antigen is not available (Ahmad et al., 2012), or when the aim is to obtain 
Abs against unknown (e.g., novel markers studies) and non-immunogenic cell surface antigens in their 
native form (Dantas-Barbosa et al., 2012). These include the use of eukaryotic cells and tissue 
fragments as targets. Morover, in vivo and double recognition panning selections to select for 
bispecific mAbs have also been reported (Dantas-Barbosa et al., 2012; Hammers and Stanley, 2014). 
As the target antigen is presented in a more complex environment, such as cell surface, the selection 
procedure becomes more difficult, once many other antigens may be present and the expression 
levels may not be constant (Dantas-Barbosa et al., 2012), requiring more rounds of panning and more 
sophisticated protocols (Hammers and Stanley, 2014). 
1.4.2 Antibody Libraries 
Ab phage technology has revolutionized the way mAbs are produced, currently being the most 
widespread method for the display and selection of large collections of Abs and for the engineering of 
selected Abs (Hoogenboom, 2005; Sommavilla et al., 2010). As mentioned before, this technique has 
the advantage of allowing the direct isolation of fully human Abs (Dantas-Barbosa et al., 2012), which 
can subsequently be manufactured using fully in vitro processes, offering greater flexibility during their 
production and greater opportunities for optimization after their creation. Ab production and screening 
is cheaper, easier and faster by phage display, and it allows further manipulation of selected binders 
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due to the gene sequence availability (Hoogenboom et al., 1998; Shukra et al., 2014). Furthermore, it 
is a highly versatile technology (Hoogenboom et al., 1998). 
1.4.2.1 Formats for Antibody Display 
E. coli production or phage display of complete IgG molecules is problematic due to limitations 
of the prokaryotic folding machinery, so it has rarely been described (Schirrmann et al., 2011; 
Schofield et al., 2014). Therefore, smaller Ab fragments are used, and the most common are Fab 
fragments and single chain variable domains (scFv), which consist of only one polypeptide chain, 
composed of the VH and the VL Ab regions joined by a short peptide linker (Ahmad et al., 2012; 
Schofield et al., 2014). Although it shows up as a need, some authors believe the IgG phage display 
cannot compete with Fab or scFv display and the additional Fc part is not a benefit for the display of 
binders in this prokaryotic system (Schirrmann et al., 2011). 
The choice of which format to use should take into account the library’s final application. The 
smaller size of the scFv format makes these libraries genetically more stable and of simpler 
construction than Fab libraries (Burton, 2001). Also, the expression of these smaller fragments has a 
less toxic effect on the cell, so scFv’s are expressed at higher levels, increasing the library diversity 
(Carmen and Jermutus, 2002). On the disadvantage side, scFv’s have the tendency to form dimers 
and higher order multimers in a clone-dependent and relatively unpredictable way (de Haard et al., 
1999). This can be valuable in a certain context, namely if an enhanced binding avidity, which is the 
overall strength of the multiple binding interactions that may occur in a multivalent Ab-antigen complex 
(Goldsby et al., 2003), is useful to facilitate selection against some antigens. However, it usually 
complicates Ab selection and characterization, and the multimers avidity effect may lead to selection 
of fragments with very low affinity (Burton, 2001; Hoogenboom et al., 1998), which is the strength of 
interaction between a single epitope and a single antigen-binding site on an Ab (Goldsby et al., 2003). 
The use of Fab fragments avoids these inconveniences. In Fab selections, affinity dominates 
over avidity, both because of the lack of multimerization and lower display frequency. Furthermore, a 
Fab can be converted into a whole Ab with a predictable maintenance of, or increase in, antigen 
affinity, which is unlikely for scFv’s (Burton, 2001). 
1.4.2.2 Types of Antibody Libraries 
There are several types of libraries. Each type has its limitations and is best suitable for 
different purposes. They are categorized based on the source of Ab genes used for their construction 
(Ahmad et al., 2012). 
“Single-pot” libraries are called this way because they are designed to isolate Ab fragments 
against all or, at least, a wide variety of antigens. Once they are comprised of Ab fragments from a 
source of genes that is not biased to a specific antigen, they may be considered universal 
(Hoogenboom, 2005; Schirrmann et al., 2011). Nevertheless, they allow isolation of high-affinity Abs 
when very large repertoires are used. These libraries are particularly useful for the selection of human 
Abs to self, non-immunogenic or toxic antigens, which may be difficult to obtain with techniques that 
require immunization (Bazan et al., 2012; Hoogenboom et al., 1998). There are large pre-made non-
immune repertoires available that suit most applications and are extensively used in industry and for 
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academic purposes (Hoogenboom et al., 1998; Hoogenboom, 2005). “Single-pot” libraries include 
naïve, semi-synthetic and synthetic libraries (Hoogenboom et al., 1998). 
Naïve libraries are composed of natural rearranged V-genes from the IgM mRNA of B cells of 
non-immunized donors, isolated from diverse human or animal lymphoid sources. IgM Abs constitute 
the primary (unselected) Ab repertoire of an organism, and therefore their use reduces antigen-
induced biases, being more diverse. The affinity of Abs selected from a naïve library is proportional to 
the size of the library (Hoogenboom et al., 1998; Hoogenboom, 2005). The main disadvantages of the 
Naïve libraries are the unknown history of the B-cell donors, the tendency to achieve increased cross-
reactivity, and potentially limited diversity of the IgM repertoire (Bazan et al., 2012). However, random 
combination of VH and VL chains during the library construction will improve its diversity 
(Hoogenboom et al., 1998). 
Semi-synthetic libraries have combinations of natural and synthetic diversity in order to 
increase natural diversity (Hoogenboom, 2005). The most common approach is to introduce synthetic 
randomized CDRs into germline V-gene segments or rearranged V-gene. This is usually carried out 
within the CDR3 regions, since they are the most diverse and essentially responsible for antigen 
binding, specially the HC CDR3 (Ahmad et al., 2012; Hoogenboom et al., 1998). Randomization is 
done by PCR or oligonucleotide directed mutagenesis and it may also involve other or all the CDR 
regions, and even FR regions (Bazan et al., 2012; Hoogenboom et al., 1998; Hoogenboom, 2005). 
Synthetic libraries are constructed entirely in vitro, using fully synthetic sources. A certain 
number or, sometimes, a single artificially designed Ab framework is used as scaffold for the CDRs, 
which are all randomized, varying in composition and length (Ahmad et al., 2012; Schirrmann et al., 
2011 ). The framework may be based on a limited number of generic or consensus V-gene sequences 
that are assembled in vitro (Bazan et al., 2012). Synthetic diversity bypasses the natural biases and 
redundancies of Ab repertoires created in vivo and allows control over the genetic makeup of V genes 
and the introduction of diversity (Hoogenboom, 2005). Synthetic libraries are of particular importance 
in isolating Abs recognizing self-proteins, once these specificities are avoided by the mechanisms of 
self-tolerance and clonal deletion in vivo (Watkins and Ouwehand, 2000). 
Immune libraries are constructed with V-gene pools from the IgG mRNA of B cells from 
diverse lymphoid sources of immunized donors, i.e., which have an active immune response against a 
chosen antigen (Watkins and Ouwehand, 2000). An immune Ab repertoire will be enriched in Abs 
specific for that antigen, some of which will have been affinity matured by the host’s immune system, 
which allows achieving high-affinity Abs even when the library is relatively small (107 clones) (Bazan et 
al., 2012; Hoogenboom et al., 1998). The main disadvantage of immune libraries is that new Ab 
libraries have to be generated for every desired antigen making this a very laborious process (Watkins 
and Ouwehand, 2000). The immunization of animals is time consuming for itself, prediction of the 
immune response is not always possible, and it may be ineffective if self or toxic antigens are used 
(Bazan et al., 2012; Hoogenboom et al., 1998). Moreover, V gene combinatorial library construction is 
complex when both immune VH and VL genes are used (Watkins and Ouwehand, 2000). On the other 
hand, the availability of human immune libraries is limited due to ethical reasons; however, naturally 
immunized humans (by a infection or disease) may be used as donors, and a human library is the 
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obvious choice if the Abs are required for therapeutic purposes (Burton, 2001; Hoogenboom, 2005; 
Schirrmann et al., 2011). Nevertheless, immune libraries are valuable resources, typically generated 
and used in medical research to produce high quality and high affinity antigen-specific Abs that 
provide good analytical tools or when a range of different Abs for the same molecule is the goal 
(Bazan et al., 2012; Burton, 2001; Schirrmann et al., 2011). Further, human immune or disease-
associated Ab libraries have identified Abs with very interesting properties unlikely to be present in 
single-pot libraries, and rare Ab specificities can be enriched by in vitro selection. These libraries also 
facilitate the investigation of the humoral immune system at a molecular level (Hoogenboom, 2005). 
Finally, although an immune repertoire is generally restricted to generating Abs against the 
immunization antigen, it may contain a significant number of unimmunized clones and, if sufficiently 
large, it can be utilized similarly to a naïve library (Bazan et al., 2012). 
1.4.2.3 Combinatorial Antibody Libraries Construction 
The standard methodology for construction of natural source combinatorial phage Ab libraries 
consists in several straightforward steps. cDNA pools are produced from the mRNA extracted from the 
lymphoid source chosen, and used as template to amplify the VH and VL gene segments of a given Ig 
repertoire, by using specific primers that anneal to conserved regions of the V-gene families (Tohidkia 
et al., 2012). VH and VL chains may be separately amplified, and then randomly assembled by PCR 
to form the final Ab fragment. Those may also be randomly combined through sequential cloning of 
the VH and VL gene repertoires in the same vector (Frenzel et al., 2014; Watkins and Ouwehand, 
2000). These and other strategies, like using several donors for the construction of a single library, will 
increase the original repertoire diversity, one of the most significant characteristics of phage Ab 
libraries. Besides diversity, another important feature of an Ab library is the size, and both will define 
the affinity and specificity spectrum of the Abs a library can produce (Tohidkia et al., 2012). 
Library construction methods may differ in terms of origin of V-gene repertoires (immune, 
naïve, and synthetic library); number of donors; source of B-cells’ sample; and molecular methods for 
amplifying and engineering the V-gene repertoires (e.g., RNA extraction procedure, primer sets for 
synthesis of cDNA and the VH and VL genes, the V-genes assembly procedure and vectors) (Tohidkia 
et al., 2012). 
The key for a successful generation of Abs is the library used for the selection, and its 
performance depends both on technical aspects (such as library size and quality of cloning) and 
design features (which influence the percentage of functional clones in the library and their ability to be 
used for practical applications). Therefore, those should be carefully outlined (Frenzel et al., 2014). 
1.4.3 Phage Display Vectors  
A bacteriophage (phage) is a virus that specifically infects bacteria and replicates within it, and 
this explains why phages are commonly used as vectors for biotechnology and recombinant DNA 
research (Smith and Petrenko, 1997). Phage display, as its name indicates, is a technology that uses 
bacteriophages to connect proteins with the genetic information that encodes them, and allows the 
study of protein-protein, protein-peptide, and protein-DNA interactions.  
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1.4.3.1 Filamentous Bacteriophages 
Although different bacteriophages can be used in the phage display technique, the M13 
filamentous phage is the most used (Ebrahimizadeh and Rajabibazl, 2014). Filamentous phages 
contain a circular single-stranded (ss) DNA genome encased in a long protein capsid cylinder. Among 
them, the Ff phages are the best characterized. This group contains f1, fd and M13 phages, which 
specifically infect E. coli containing the F conjugative plasmid and thus express the F pilus 
(Ebrahimizadeh and Rajabibazl, 2014).  
 Ff phages have five coat proteins. The major coat protein is pVIII, it has 50 amino acid 
residues and is present in almost 2700 copies in the mature phage, forming the filament tube that 
encapsulates the DNA. The ends of the filament are built by two different pairs of proteins; the distal 
end is capped by pVII and pIX, 5 copies of each. At the proximal end, pVI and pIII are present in 4 to 5 
copies each (Carmen and Jermutus, 2002; Ebrahimizadeh and Rajabibazl, 2014). pIII has 406 amino 
acid residues and is responsible for phage infection, which is initiated by the specific attachment of pIII 
to the cell F pilus and ultimately results in the translocation of the phage genome into the cell 
cytoplasm. After replication, which involves both phage- and host-derived proteins, the viral particles 
are assembled in the periplasmic environment and then continuously released from the bacterial cell 
without lysing it. pIII is also related to the release process. Although the cell is not destroyed, its 
growth rate significantly decreases due to utilization of the bacterium machinery by the phage 
(Carmen and Jermutus, 2002; Ebrahimizadeh and Rajabibazl, 2014; Hoogenboom et al., 1998). 
 Ff phages reunite many other characteristics that make them appropriate for phage display 
applications: they are F-pilus dependent, and thus bacterial infection conditions can be controlled. 
Also, due to the fact that the F pilus is depolymerized after the infection, each bacterium can only be 
infected by one phage, resulting in the representation of one specific phage encoding a unique peptide 
or antibody in each bacterial clone. Finally, filamentous phages are easy to manipulate and resistant 
to extreme conditions such as acidic pH, high temperatures, and enzymatic cleavage, which makes 
them adaptable to the panning process and even suitable for in vivo applications (Ebrahimizadeh and 
Rajabibazl, 2014). 
All Ff phage coat proteins have been used as fusion proteins for phage display, but the most 
common choices are pIII and pVIII, both coded by a single gene, respectively gIII or gVIII (Bazan et 
al., 2012; Carmen and Jermutus, 2002). The main differences when considering these two options are 
the length and the density or copy number of the displayed foreign proteins in the progeny phages. 
Compared to pVIII, the pIII can tolerate considerably longer peptide fusions, but given that there are 
only 4 or 5 copies of pIII protein per viral particle, the maximum amount of displayed fusion proteins is 
5 copies per phage. If the aim is to display a higher number of peptides or small protein fragments 
pVIII fusion partner is recommended, once it can append up to hundreds or thousands of copies, 
depending on the display system used. However, the increase in the copies displayed highly restricts 
the length of displayed peptides toleration that could decrease to as little as 5-12 amino acid residues 
(Ebrahimizadeh and Rajabibazl, 2014; Scott, 2001; Qi et al., 2012). pVIII fusions multivalent display is 
then suitable for tests such as avidity assessment, protein–protein interactions, immunological assays 
or whenever enhancement of the detection signal is needed, once it results in selection of high avidity 
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but possibly low-affinity binders. On the other hand, type III display is most appropriate for 
experiments such as antibody isolation, resulting in selection of high-affinity binders in the panning 
processes (Ebrahimizadeh and Rajabibazl, 2014; Qi et al., 2012).  
1.4.3.2 Phagemid vectors 
Initially, phage vectors that carried all the genetic information required for the phage life cycle 
were used, but phagemids have become the most widely used vector system for display 
(Hoogenboom et al., 1998). 
Phagemids are plasmids that encode both plasmid and phage origins of replication, a phage 
packaging signal and an antibiotic resistance marker. Phage display appropriate phagemids also carry 
a cloning restriction site between sequences encoding the signal sequence and the phage coat protein 
gene  (Rakonjac et al., 2011; Scott, 2001). Phagemids are generally smaller than phage genomes 
(≈4,6 kilobases), so they have higher transformation efficiencies, facilitating the construction of large 
and highly diverse repertoires. These vectors can accommodate larger foreign DNA fragments and 
usually are genetically more stable than recombinant phages under multiple propagations (Carmen 
and Jermutus, 2002; Qi et al., 2012; Scott, 2001). A phagemid cannot produce infective phage 
particles alone, once the genes essential for phage replication and assembly are missing. As such, the 
use of a helper phage is essential for phagemid systems since it will supply all the other proteins 
required to make functional phages. For that, cells already containing the phagemid vector are 
superinfected with a helper phage. These are normal Ff phages with a number of modifications: they 
usually carry antibiotic resistance genes, they contain a defective origin of replication and their 
packaging signal is severely disabled so that the phagemid genome is preferentially replicated and 
packaged (Carmen and Jermutus, 2002; Scott, 2001). 
  The phagemid system is one of the alternatives to overcome limitations like the lack of 
appropriate restriction enzyme recognition sites in the vicinity of the coat protein genes in wild-type 
phages. Also, this avoids the loss of coat protein functionality that could result from using the unique 
copy of that protein-encoding gene in the phage genome for the insertion of foreign DNA; in this case, 
the fusion protein will be provided by the phagemid and the wild-type version of coat protein by the 
helper phage (Bazan et al., 2012; Hoogenboom et al., 1998). 
1.4.3.2.1 pCOMB3XSS phagemid vector 
pCOMB3X vectors were developed at The Barbas Laboratory, The Scripps Research 
Institute®, La Jolla, CA, USA. They were designed for Fab (and other proteins) display on the surface 
of filamentous phage, and also to allow their expression as soluble proteins (Rader and Barbas III, 
1997). In those vectors the proteins are fused to the C-terminal domain of the phage coat protein pIII 
(Scott, 2001). 
 Fab library construction can be accomplished using a single SfiI cloning step, given that 
pCOMB3X vectors include two asymmetric SfiI restriction sites that allow directional cloning. 
Alternatively, it can be done by sequential cloning of the LC using SacI and XbaI enzymes followed by 
HC Fd fragment cloning with XhoI and SpeI (Scott, 2001). The pCOMB3XSS variant includes two 
stuffers, a 1200 bp stuffer in the LC cloning region and a 300 bp stuffer in the HC cloning region  (The 
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Scripps Research Institute, 2014). pCOMB3XSS holds a single lacZ promoter and a combination of 
ompA and pelB leader sequences to direct the expression of antibody LC and HC Fd-pIII fusion 
proteins, respectively (Scott, 2001). 
 Production of soluble, isolated Fab can be done by proteolysis of the labile fusion protein or by 
excision of the gIII portion of the fusion fragment from the phagemid genome using SpeI and NheI 
restriction enzymes. A third hypothesis is propagating the phagemid in a non-suppressor bacteria 
strain (e.g., TOP10) to turn-of the expression of the fusion protein, once this vector contains an amber 
stop codon (TAG) at the 5’ end of gIII. Naturally, this implies that gIII fusion proteins will only be 
produced in suppressor strains, like those containing supE (e.g., TG1) or supF genes (Scott, 2001), in 
which mutant tRNA inserts a specific amino acid at UAG codons, thus suppressing its translation 
termination effect (Sigma-Aldrich, 2014).  
pCOMB3XSS also carries an ampicillin-resistance gene and two peptide tags at the C-
terminus of the displayed protein: a hexa-histidine tail (His6) that facilitates purification, and the 
influenza hemagglutinine (HA) epitope tag that facilitates detection of the protein using an anti-HA Ab 
(Scott, 2001). A sketch of the vector is shown in Figure 1.7. 
 
Figure 1.7 - pCOMB3XSS phagemid vector sketch. Adapted The Scripps Research Institute, 2014. 
1.5 Aim of the Thesis 
 The aim of this thesis was the generation of an immune phage display Fab library for the 
development of new therapeutic Abs for breast cancer. This included the following secondary aims: 
- Construction of two Fab libraries (κ and λ) by recombining the IgG repertoire of several 
breast cancer donors. 
- Characterization of the library by assessing its size and diversity. 
- Validation of the library by selection of Fab’s for a general target – BSA – and a well 
established breast cancer target – HER2. 
- Selection of specific Fab’s against a target protein that intervenes in the Notch1 signaling 
pathway – the DLL1 ligand. 
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2. Materials and Methods 
2.1 Materials  
Restriction enzymes, T4 DNA ligase, Taq and Pfu DNA polymerase were purchased from 
Thermo Scientific, except BstNI that was from New England Biolabs. All primers used in this work are 
described in Table 6.1 (appendix, section 6.1). Primers used for Ab fragments construction were 
designed based on previously described primers for Ab libraries construction (Andris-Widhopf et al., 
2011; de Haard et al., 1999; Marks et al., 1991; Shen et al., 2007; Zhu and Dimitrov, 2009) and 
synthesized by STAB Vida. Milli-Q purified (MQ) water was used for molecular biology procedures. 
DPBS (GIBCO® Life TechnologiesTM) was used for mononuclear cells processing and for protein, Ab 
and phage dilutions, unless specified otherwise. 2YT or LB medium were used for bacterial growth 
and dilutions. 2YT or LB agar plates with 100 µg/mL ampicillin (Sigma-Aldrich®) and 1% glucose 
(Sigma-Aldrich® or Applichem) (amp/glu) were used for bacteria selection in solid medium. 2YT or LB 
agar plates with 50 µg/mL kanamycin (Sigma-Aldrich®) and 1% glucose (Sigma-Aldrich® or 
Applichem) (kan/glu) were used as controls for detection of helper phage-infected TG1 cells. 
2.1.1 Strains and plasmids 
The E. coli strains used were: TG1 (Lucigen®) - F' [traD36 proAB+ lacIq lacZΔM15]supE thi-1 
Δ(lac-proAB) Δ(mcrB-hsdSM)5, (rK-mK); TOP10 (InvitrogenTM) - F- mcrA Δ(mrr-hsdRMS-mcrBC) 
φ80lacZΔM15 ΔlacX74 nupG recA1 araD139 Δ(ara-leu)7697 galE15 galK16 rpsL(StrR) endA1 λ-. 
The plasmid used for construction of the phage libraries was pCOMB3XSS, and it was kindly 
provided by Carlos F. Barbas III, The Scripps Research Institute, La Jolla, CA, USA. 
The helper phage used for the libraries phagemid rescue was M13KO7 (InvitrogenTM). 
2.2 Molecular Biology General Procedures 
2.2.1 Nucleic acid quantification and purity assessment 
Nucleic acid quantification and purity assessment were performed by spectrophotometry using 
NanoDrop ND-1000 spectrophotometer (Alfagene) or NanoVueTM (GE Healthcare). 
2.2.2 Agarose Gel Electrophoresis 
Nucleic acid samples were run in 1% agarose (Lonza) gel in 1x Tris-acetate-EDTA (TAE) 
buffer (5 Prime) in dH2O at 80V-120V, unless stated otherwise. Loading buffer used was TrackIt™ 
Cyan/Orange Loading Buffer 6x (Life TechnologiesTM), and molecular weight marker was GeneRuler 1 
kb DNA Ladder (Thermo Scientific). Gels were stained by incubating in a solution of 0,1 M NaCl 
(Sigma-Aldrich®) and 3x Gel Red (Biotium) with agitation. Gels were observed and photographed on 
GelDocTM XR+ System (Bio Rad). 
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2.2.3 DNA Fragments Separation and Purification by Agarose Gel 
Electrophoresis  
DNA preparation, gels run and staining were performed as described in section 2.2.2, except 
that lower voltages were generally used (70V-90V). Lanes containing the ladder and a small volume of 
the sample to be purified (typically 2-6 µL, depending on its concentration) were cut and separated 
from the main gel and exposed to UV light in Benchtop UV Transiluminator (UVP). This allowed the 
identification of the exact position of the DNA band of interest, whose expected size was known. That 
position was marked with a scalpel and used to guide the cut of gel bands in the same position on the 
lanes that contained the DNA to be purified. DNA contained in the bands was purified with illustraTM 
GFX PCR DNA and Gel Band Purification Kit (GE Healthcare) following the manufacturer’s protocol 
for purification of DNA from TAE and TBE agarose gels. The following modifications were performed: 
agarose bands were melt with 450 rpm agitation, and DNA elution was carried out with 50 µL of MQ 
water. This method was applied to avoid nicking of DNA that can be caused by exposing it to the UV 
light and can affect subsequent manipulation steps (Clark, 2002). 
2.2.4 DNA Purification from Solutions 
DNA Purification from Solutions was performed with illustraTM GFX PCR DNA and Gel Band 
Purification Kit following the manufacturer’s protocol for purification of DNA from solution or an 
enzymatic reaction, except that DNA elution was made with MQ water. 
2.2.5 Plasmid isolation by Miniprep 
Bacterial clones were grown overnight (O/N) at 37º C, 250 rpm in 3 mL-7,5 mL of medium with 
100 µg/mL ampicillin, and the cultures used for phagemid isolation either with NZYMiniprep kit 
(NZYTech) or GeneJET Plasmid Miniprep Kit (Thermo Scientific), following the respective 
manufacturer’s instructions, except that DNA elution was performed with MQ water. 
2.2.6 Electrocompetent Cells – Preparation and Electroporation 
An O/N culture of E. coli TG1 was diluted in medium to an initial OD600nm=0,05 and incubated 
at 37ºC, 250 rpm, until reaching an OD600nm≈0,5 (mid-exponential growth phase). The culture was 
cooled on ice for 15’-30’ and centrifuged at 3220 x g for 20’-40’ at 4º C. The pellet was resuspended in 
the same volume of chilled sterile MQ water and the centrifugation repeated. After this, pellet was 
again resuspended but in 1/2 vol of chilled sterile MQ water, and the centrifugation step repeated. The 
pellet was resuspended in 1/50 vol of chilled sterile 10% glycerol (Scharlau) and the centrifugation 
step repeated. Finally, the pellet was resuspended in 1/400 vol of chilled sterile 10% glycerol and 
divided in 100 µL aliquots that were kept on ice and immediately used for electroporation.  
Electroporation was performed using Eporator® electroporator (Eppendorf) and 2 mm gap 
electroporation cuvettes (Bio Rad) with the following settings: 25 µF, 2,5 kV and 200 Ω. After the 
electrical impulse, the transformed cells volume was made up to 1 mL with warm medium and the 
cells incubated at 37 °C, 250 rpm, for 45’-1h before plating. 
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2.3 RNA Isolation 
Peripheral blood samples from 16 breast cancer patients were collected to heparinised tubes 
at CUF Descobertas Hospital. These included 15 female adults with ages between 48 and 84 and one 
male with age of 71. All patients signed an informed consent form prior to donation. 
For mononuclear cells isolation, the blood samples were added to the same volume of 
Histopaque®-1077 (Sigma-Aldrich®) solution and centrifuged at 1260 x g for 90’ at RT with no break. 
Buffy coats were washed by adding 10 mL of DPBS and centrifuging at 250 x g for 20’ at RT. Washing 
steps were repeated twice with 5 mL and 10 mL of DPBS, respectively. Pellets were resuspended in 
500 µL of DPBS. 
Mononuclear cell suspensions were centrifuged at 400 x g for 5’. Total RNA was extracted 
from pellets using GeneJET RNA Purification Kit (Thermo Scientific) following the manufacturer’s 
protocol for Mammalian Cultured Cells Total RNA Purification, starting on step 2. Extracted RNA was 
treated with DNase TURBOTM DNA-free Kit (Ambion®) following the manufacturer’s protocol. Total 
RNA was quantified and its quality assessed by agarose gel electrophoresis. 
2.4 cDNA synthesis 
A RNA pool was formed by adding the same quantity of total RNA from each donor’s sample. 
The RNA pool was used to synthesize specific first strand cDNA using primers for IgG-derived HC 
CH1 region, κ LC and λ LC conserved regions mRNA. 1 µg of RNA was used to produce HC cDNA in 
120 µL of reaction with 20 pmol of primer IgG CH1 Rv. Each LC cDNA was synthesized from 0,76 µg 
of RNA in 75 µL of reaction. For κ cDNA, 20 pmol of primer CLκ Rv were used, and for λ cDNA, 10 
pmol of primer CLλa Rv plus 10 pmol of primer CLλb Rv. Additionally, each reaction contained 200 U 
of RevertAid Reverse Transcriptase (Thermo Scientific), 1x reaction buffer, 20 U of Ribolock RNase 
Inhibitor (Thermo Scientific) and 1mM of dNTP mix (NZYTech). Reactions were incubated at 42º C for 
60’. The enzyme was inactivated by heat, incubating at 70º C for 10’. 
2.5 Light Chain and Heavy Chain Fd Fragments Construction 
PCRs were performed in My CyclerTM Thermal Cycler (Bio Rad) in a volume of 50 µL 
containing the following components: 10 ng of template (except for cDNA template; in reactions with 2 
different templates, 5 ng of each were used), 0,2 mM of dNTPs, 20 pmol of each primer (forward, Fw, 
and reverse, Rv), 1,25 U of Pfu DNA polymerase (Thermo Scientific) and 1x buffer. Different 
annealing temperatures were set depending on the primers used in each reaction. Extension time 
varied accordingly to each product expected size, being at least 2’/kb, which is the recommended for 
Pfu DNA polymerase. Other conditions were common, namely: initial denaturation at 95º C for 2’, 
followed by 30 cycles of denaturation at 95 °C for 30’’, annealing for 30’’, and extension at 72º C; and 
1 last cycle of final extension at 72º C for 10’. A “no template” control was performed for all reactions. 
5 µL of each PCR product was analyzed by electrophoresis on 1% agarose gel. Subsequently, the 
remaining volume of all successfully amplified products (generally 45 µL) was gel purified before being 
further manipulated. All exceptions to those conditions are indicated. 
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2.5.1 Amplification of VH gene repertoire 
VH gene repertoire was constructed in three essential steps, represented in Figure 2.1. In the 
first step, HC cDNA was used as template for VHCH1 amplification. Two sets of VHCH1 fragments 
were prepared: 
A) 4,8 µL of template were used per reaction. 6 separate reactions were performed using 6 
different Fw primers (VH1-6 Fw) and the same Rv primer (IgG CH1 Rv). Reactions were prepared with 
10 pmol of each primer. Annealing temperature was 59º C and extension time 1,5’. Exception was 
VH6CH1 product, which was amplified in two separate reactions with different annealing 
temperatures, namely 53,9º C and 52,5º C.  
B) 1,2 µL of template were used per reaction. The same primer combinations of set A were used, 
but reactions contained 20 pmol of each. Annealing temperature was 59º C and extension time 2’. 
In the second step, the first step products were used as template for CH1 (set A) and VHJH 
(set B) segments amplification. A different reaction was prepared with each type of template. For CH1 
amplification, 10 pmol of each primer and 40 ng of template were used per reaction, except for 
VH4CH1 (32 ng) and VH5CH1 (33 ng). Fw primer was CH1 Fw and Rv primer IgG CH1 Rv. Annealing 
temperature was 55º C and extension time 26’’. For VHJH amplification, 2,5 µL of template and 20 
pmol of each primer were used per reaction. Fw primer was the same used for the respective VHCH1 
template production. 4 Rv primers were used (JH 1/2, 3, 4/5 and 6 Rv) for each different template, so 
24 different reactions were performed. Annealing temperature was 57º C and extension time 1,5’. 
 
Figure 2.1 - PCR amplification steps for VHCH1 (HC Fd) fragments construction. Adapted from a scheme 
provided by Inês Barbosa. 
The third step consisted on reamplification and assembly of the produced VHJH and CH1 
fragments by overlap PCR. A CH1 pool was used as CH1 template and was formed by adding the 
same quantity of all 6 CH1 products from step 2. 6 different pools were formed with the VHJH 
products. For each, the same quantity of the 4 products obtained from the same template was added. 
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Each VHJH pool was combined with the CH1 pool in a different reaction. Fw primer was the same 
used for the production of the fragments that composed the respective VHJH pool and Rv primer was 
IgG CH1 Rv. Two overlap PCRs were performed with different combinations of annealing temperature 
and extension time, namely 55º C and 2’, or 59º C and 1,75’. The products (VHCH1 – Fd – fragments) 
obtained from the same template by both amplifications were added before gel purification.  
The 6 VHCH1 (Fd) fragments were reamplified from the respective VHCH1 (Fd) purified 
overlap products, using the same primers used for the overlapping PCR. Annealing temperature was 
59º C and extension time 1,75’. 
2.5.2 Amplification of κ LC gene repertoire 
κ LC repertoire was constructed in two steps, represented in Figure 2.2. In the first, κ LC 
cDNA was used as template to separately amplify the VLκ and CLκ domains, namely 3 µL per 
reaction. For VLκ amplification, 9 separate reactions were performed using 9 different Fw primers 
(VLκ1, 2, 3a, 3b, 3c, 3d, 4, 5 and 6 Fw) and the same Rv primer (VLκ Rv). CLκ region was amplified 
with primers CLκ Fw and CLκ Rv. Annealing temperature was 50º C and extension time 1’. Exception 
was VLκ5 product, which was amplified in two separate reactions with different annealing 
temperatures, namely 48,1º C and 47,1º C. 
The second step consisted on reamplification and assembly of the produced VLκ and CLκ 
fragments by overlap PCR. Each VLκ product was combined with the CLκ fragment in a different 
reaction. Fw primer was the same used for the respective VLκ fragment production and Rv primer was 
CLκ Rv. Annealing temperature was 50º C, except in the reactions with VLκ4 Fw and VLκ5 Fw 
primers, which was 48º C. Extension time was 1,67’. 
	  
Figure 2.2 - PCR amplification steps for VLκCLκ fragments construction. Adapted from a scheme 
provided by Inês Barbosa. 
2.5.3 Amplification of λ LC gene repertoire 
λ LC repertoire was constructed in two steps (Figure 2.3). In the first, λ LC cDNA was used as 
template to separately amplify the VLλ and CLλ domains, namely 3 µL per reaction. For VLλ 
amplification, 12 separate reactions were performed using 12 different Fw primers (VLλ1a, 1b, 1c, 2, 
3a, 3b, 4, 6, 7/8a, 7/8b, 9 and 10 Fw) and the same Rv primer (VLλ Rv). For CLλ region amplification, 
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2 separate reactions were performed using the same Fw primer (CLλ Fw) and 2 different Rv primers 
(CLλa Rv and CLλb Rv). Annealing temperature was 62º C for VLλ fragments amplification and 50º C 
for CLλ’s. Extension time was 1’. Exception was VLλ10 product, which was amplified in three separate 
reactions with different annealing temperatures, namely 55º C, 53º C and 50,9º C. 
The second step consisted on reamplification and assembly of the produced VLλ and CLλ 
fragments by overlap PCR. Each VLλ product was combined with each CLλ fragment in a different 
reaction, making a total of 24 reactions. Fw primer was the same used for the respective VLλ fragment 
production and Rv primer the one used for the respective CLλ fragment production. Annealing 
temperature was 50º C. Extension time was 1,5’. 
 
Figure 2.3 - PCR amplification steps for VLλCLλ fragments construction. Adapted from a scheme 
provided by Inês Barbosa. 
2.6 Libraries Construction 
Restriction enzyme digestions were performed following the manufacturer’s instructions. 
Briefly, reactions contained 0,3 µg-1,5 µg of DNA, 1x recommended buffer and excess of enzyme (at 
least 10 U per 1 µg of DNA). Final volume varied between 20 µL-100 µL, once upscale was performed 
when necessary. Reactions were performed at 37º C for 1h-4h. 
Dialysis was performed with MFTM membrane filter (Millipore) 0,025 µm VSWP. Products to be 
dialysed were deposited on a membrane floating on distilled water in a petri dish placed on ice, for 1h. 
Prior to ligation, digested vectors were gel purified as described in section 2.2.3, quantified 
and dephosphorylated. Dephosphorylation was performed with FastAP Thermosensitive Alkaline 
Phosphatase (Thermo Scientific) following the manufacturer’s instructions but for longer times (1h-3h). 
Briefly, reactions contained 0,2 µg-4 µg of DNA, 1x buffer and excess of enzyme (1 U-2 U per 1 µg of 
DNA). Final volume varied between 20 µL-80 µL, once upscale was performed when necessary. 
Digested PCR products were purified and quantified prior to ligation, as well as ligation 
products before large scale transformation, as indicated in section 2.2.1. Ligation reactions were 
performed with T4 DNA ligase (Thermo Scientific) following the manufacturer’s instructions. Briefly, 
reactions contained 0,11 µg-3 µg of DNA, 1x buffer and excess of enzyme (at least 5 U per 1 µg of 
DNA). Final volume varied between 20 µL-300 µL, once upscale was performed when necessary. 
	   27	  
Reactions were performed at RT for 1,5h-5h at RT, and an excess of enzyme was used. Small scale 
trial ligations were performed with different verctor:insert molar ratio (calculated following Formula 2.1) 
and as well as ligation reactions containing dephosphorylated vector but no insert were also 
performed.  
𝑣𝑒𝑐𝑡𝑜𝑟  𝑞𝑢𝑎𝑛𝑡𝑖𝑡𝑦   𝑛𝑔 ×  𝑖𝑛𝑠𝑒𝑟𝑡  𝑠𝑖𝑧𝑒  (𝑘𝑏)  
𝑣𝑒𝑐𝑡𝑜𝑟  𝑠𝑖𝑧𝑒  (𝑘𝑏)
  ×  𝑚𝑜𝑙𝑎𝑟  𝑟𝑎𝑡𝑖𝑜
𝑖𝑛𝑠𝑒𝑟𝑡
𝑣𝑒𝑐𝑡𝑜𝑟
=   𝑖𝑛𝑠𝑒𝑟𝑡  𝑞𝑢𝑎𝑛𝑡𝑖𝑡𝑦  (𝑛𝑔) 
Formula 2.1 – Insert quantity calculation considering the verctor:insert molar ratio. 
Ligations were transformed by electroporation into electrocompetent E. coli TG1 cells freshly 
prepared as described in section 2.2.6. Every time, 10 pg of the plasmid pUC19 (Lucigen) was also 
electroporated into the bacterial cells in order to calculate the transformation efficiency, and for vector 
self-ligation transformation, 10 µL of digested vector was used. Aliquots from each transformation 
were plated in amp/glu plates. 100 µL of untransformed cells were plated in amp/glu and kan/glu 
plates for control purposes. Plates were incubated O/N at 37 °C. For small scale trials, colonies were 
counted and the number of transformants per µg of DNA calculated following Formula 2.2. This 
allowed determining the optimal verctor:insert molar ratio to create the libraries and to assess the 
background levels of vector self-ligation.  
  #𝑐𝑜𝑙𝑜𝑛𝑖𝑒𝑠  ×  𝑡𝑜𝑡𝑎𝑙  𝑡𝑟𝑎𝑛𝑠𝑓𝑜𝑟𝑚𝑒𝑑  𝑐𝑒𝑙𝑙𝑠  𝑣𝑜𝑙𝑢𝑚𝑒   𝜇𝐿   ×  10!
𝑡𝑟𝑎𝑛𝑠𝑓𝑜𝑟𝑚𝑒𝑑  𝐷𝑁𝐴  𝑞𝑢𝑎𝑛𝑡𝑖𝑡𝑦   𝑝𝑔   ×  𝑝𝑙𝑎𝑡𝑒𝑑  𝑣𝑜𝑙𝑢𝑚𝑒   𝜇𝐿
=   #𝑡𝑟𝑎𝑛𝑠𝑓𝑜𝑟𝑚𝑎𝑛𝑡𝑠 𝜇𝑔   𝐷𝑁𝐴   
Formula 2.2 – Number of transformants (#transformants) per µg of transformed DNA calculation. 
For the libraries construction (large scale), ligation reactions were prepared with a 1:5 
vector:insert molar ratio. Several transformations of 1 µL-2 µL of DNA into 100 µL of cells were 
performed for each ligation. The number of colonies in the test plates was used to calculate the library 
size. The remaining transformation volumes were pooled together and processed as specified ahead. 
2.6.1 Cloning of the LC repertoires 
 For LC repertoires cloning, SacI and XbaI enzymes (Thermo Scientific) were used. Prior to 
digestion, a VLκCLκ pool was formed by adding the same quantity of all 9 VLκCLκ PCR products. For 
the λ repertoire, two pools were prepared, namely for VLλCLλa and VLλCLλb fragments, each 
containing the same amount of the respective 12 PCR products. For VLκCLκ pool a double digestion 
was performed. For VLλCLλ pools and pCOMB3XSS vector, sequential digestions were performed. 
SacI digestion products were dialysed before digestion with XbaI. After purification and quantification, 
the same quantity of digested VLλCLλa and VLλCLλb were pooled together. 
VLλCLλ*SacI/XbaI pool and VLκCLκ*SacI/XbaI were ligated into pCOMB3XSS*SacI/XbaI in 
separate reactions. For VLκCLκ sub-library construction, 23 transformations of 2 µl of 
pCOMB3XSS+VLκCLκ ligation were performed. For VLλCLλ sub-library construction, 23 
transformations of 1 µl of pCOMB3XSS+VLλCLλ ligation were performed. 
For each sub-library, 5 mL of the transformation pool were plated in 10 large amp/glu plates 
(NunclonTMΔ 245x245x25 mm, Nunc) (500 µL/plate) and incubated O/N at 37º C. Colonies on the 
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large plates were scraped off using medium with 25% glycerol. Resulting pool was aliquoted and then 
stored at -80º C as bacterial stock. 
The remaining pool volume of the transformation was made up to 100 mL with medium and 
incubated at 37 °C, 250 rpm, for 1h. Ampicillin was added to a final concentration of 100 µg/mL and 
the culture incubated at 37 °C, 250 rpm, for 1h. 400 mL of medium with ampicillin at 100 µg/mL were 
added to the culture and it incubated O/N at 37 °C, 250 rpm. Suspension culture was centrifuged for 
30’ at 3220 x g and the pellets used to prepare phagemid DNA with NZYMaxiprep kit (NZYTech) 
following the manufacturer’s instructions for low copy number plasmids isolation starting on step 2. 
DNA pellets were reconstituted in MQ water. 
2.6.2 Cloning of the VH repertoire 
 For VH repertoire cloning XhoI and SpeI enzymes (Thermo Scientific) were used. Prior to 
digestion, a VHCH pool was formed by adding the same quantity of all 6 VHCH PCR products. VHCH 
pool, pCOMB3XSS+VLκCLκ and pCOMB3XSS+VLλCLλ vectors were digested with XhoI, dialysed 
and then digested with SpeI. 
 VHCH*XhoI/SpeI was ligated into pCOMB3XSS+κ*XhoI/SpeI and pCOMB3XSS+λ*XhoI/SpeI 
in separate reactions. For VLκCLκ-VHCH library construction (κ library), 19 transformations of 2 µl of 
pCOMB3XSS+VLκCLκ+VHCH ligation were performed. For VLλCLλ-VHCH library construction (λ 
library), 17 transformations of 2 µl of pCOMB3XSS+VLλCLλ+VHCH ligation were performed. 
For each library, the transformation pool was centrifuged for 30’ at 3220 x g. Resuspended 
culture was approximately 3 mL; this volume was plated in 6 large amp/glu plates (~500 µL/plate and 
incubated O/N at 37º C. Colonies were scraped off into medium with 25% glycerol. Resulting pool was 
aliquoted and then stored at -80º C as bacterial glycerol stock. 
2.6.3 Libraries Phage Rescue 
Phage rescue protocol was adapted from de Haard, 2002. Aliquots of both libraries bacterial 
glycerol stock were separately diluted in 400 mL of medium with 1% glucose (Sigma-Aldrich®) and 100 
µg/mL ampicillin to an initial OD600nm=0,05. Cultures were incubated at 37ºC, 200 rpm, until reaching 
an OD600nm≈0,5 (growth phase in which F piliation reaches a maximum (Kotlan and Glassy, 2009)). At 
this stage 1,6 x 1012 cfu of helper phage was added to each culture, so that the multiplicity of infection 
(MOI) would be 20:1 (#phage particles:#host cells) (Marks and Bradbury, 2004a). The relation 
between the OD600nm and the number of viable TG1 bacteria was determined following the growth 
curves. During the infection step with the helper phage cultures were incubated statically at 37º C for 
40’, plus 50’ with shaking at 100 rpm (de Haard, 2002). 320 mL of each culture were centrifuged at 
3220 x g for 25’. Pellets were resuspended in the same volume of medium with 100 µg/mL ampicillin 
and 25 µg/mL kanamycin, and incubated O/N at 30º C, 250 rpm. On the following day, cultures were 
centrifuged at 3220 x g for 30’. 64 mL of 20% PEG 2,5 M NaCl (1/5 vol) was added to each culture’s 
supernatant, and phages precipitated on ice for 1h. Phage suspensions were centrifuged at 6200 x g 
for 20’ at 4º C. A second precipitation step was carried out, in which phage pellets were resuspended 
in 32 mL of DPBS (1/10 vol) and 6,4 mL of 20% PEG 2,5 M NaCl (1/50 vol) was added. Phages 
precipitated on ice for 1h and centrifugation was repeated. Pellets were resuspended in 15 mL of 
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DPBS and filtered with a 0,45 µm filter (Millipore) to remove any residual bacteria. In the final 
precipitation step 3 mL of 20% PEG 2,5 M NaCl (1/5 vol) was added and phages precipitated on ice 
for 1h. Centrifugation was repeated and final pellets were resuspended in 3,2 mL of DPBS with 10% 
glycerol (1/100 vol of the initially centrifuged culture). Phages were aliquoted and stored at -80º C. 
One aliquot from each library was used to titer and determine the phage libraries size. An O/N 
grown E. coli TG1 culture was diluted in medium to an initial OD600nm=0,05 and incubated at 37ºC, 250 
rpm, until reaching an OD600nm≈0,5. Serial dilutions of each phage library were prepared in medium. 90 
µL of TG1 culture at OD600nm≈0,5 was added to 90 µL of each phage dilution and incubated at 37º C 
for 30’, 50 rpm. 10 µL of dilutions 10-5 to 10-12 were plated in amp/glu plates. Uninfected TG1 cells 
were also plated in amp/glu and kan/glu plates for control purposes. Plates were incubated O/N at 37º 
C. Colonies were counted and cfu/mL were calculated following Formula 2.3. 
#𝑐𝑜𝑙𝑜𝑛𝑖𝑒𝑠  ×  𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛  𝑓𝑎𝑐𝑡𝑜𝑟
𝑝𝑙𝑎𝑡𝑒𝑑  𝑣𝑜𝑙𝑢𝑚𝑒   𝜇𝐿
  ×  1000 = 𝑐𝑓𝑢/𝑚𝐿 
Formula 2.3 – Colony forming units (cfu) per mL calculation from colonies count on growth plates. 
2.7 Libraries Characterization and Quality Assessment 
2.7.1 Colony PCR 
Serial dilutions of Fab κ and λ libraries bacterial glycerol stocks were prepared in medium, 
spread in amp/glu plates and incubated O/N at 30º C. The inserts presence was screened by PCR on 
100 randomly selected isolated colonies of each library. A pinch of each colony was directly picked 
from the agar plate and added to a reaction mixture containing 0,4 mM of dNTPs, 20 pmol of pCOMB 
Fw primer, 20 pmol of pCOMB Rv primer, 2 mM MgCl2 and 1x buffer. Mixtures incubated at 95º C for 
10’ and 1,25 U of Taq DNA polymerase (Thermo Scientific) was added to the reaction, with a reaction 
final volume of 50 µL. PCR was performed with the following conditions: initial denaturation at 95º C 
for 2’, followed by 30 cycles of denaturation at 95 °C for 30’’, annealing at 60º C for 30’’, and extension 
at 72º C for 2’; and 1 last cycle of final extension at 72º C for 10’. The following controls were 
performed: “no template” reaction; untransformed TG1, pCOMB3XSS, pCOMB3XSS+VLκCLκ and 
pCOMB3XSS+VLλCLλ libraries’ DNA amplification. 5 µL of each PCR product was analyzed by DNA 
gel electrophoresis as described in section 2.2.2. 
2.7.2 DNA Fingerprinting 
The DNA fingerprinting profile of 44 κ and 47 λ clones that presented the correct size fragment 
of the constructed Fab by the PCR was analyzed. For that, 5 µL of these selected PCR products were 
digested with 1 µL of BstNI restriction enzyme (New England Biolabs) in a 20 µL reaction for 
approximately 2h at 60º C. 9 µL of each digestion product was analyzed by electrophoresis as 
described in section 2.2.2. As an exception the agarose gel concentration was 3% to allow separation 
of the very small fragments generated from the BstNI digestion, and the run was performed at 80V for 
about 2h. 
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2.7.3 DNA Sequencing 
Clones whose DNA fingerprinting profile was analyzed were also sequenced. Clones’ 
phagemid DNA was extracted by miniprep as described in section 2.2.5. DNA was quantified as 
described in section 2.2.1 and several samples were run in 0,8%-0,9% agarose gel electrophoresis 
(see section 2.2.2). Sequencing was performed at STAB Vida or GATC Biotech with pCOMB Fw and 
pCOMB Rv primers. Sequences were submitted to VBASE2 database analysis tool (Retter et al., 
2005) for sequence analysis and V-genes identification. 
2.7.4 ELISA 
Enzyme-linked immunosorbent assays (ELISA’s) were executed in 96-well Nunc Maxisorp 
plates. Plates were coated with 50 µL of protein or Ab at 5 µg/mL and incubated O/N at 4º C or for 1h-
1h20’ at room temperature (RT). After coating plates were washed 3 times with 300 µL of PBST 1x in 
WellWash Versa (Thermo Scientific). Wells were blocked with 250 µL of PBST-MP 3% for 1h-3h20’ at 
RT. 50 µL of testing solution was added to each well and incubated for 1h-1h45’ at RT. Washing step 
was repeated. 50 µL of detection Ab (Fab-on-phage ELISA: HRP-Anti-M13 Ab, 1:5000 – GE 
Healthcare; sFab ELISA: HRP-Anti-Human IgG Ab, 2,5 µg/mL – Sigma-Aldrich®) were added to the 
wells and incubated for 1h at RT. Washing step was repeated. 50 µL of RT colorimetric substrate for 
horseradish peroxidase 3,3’,5,5’-tetramethylbenzidine (TMB, InvitrogenTM) was added to the wells and 
incubated in the dark before the color reaction became saturated, or until negative controls started to 
react. Reaction was stopped by addition of 50 µL of 2N H2SO4 (AVS Titrinorm®) per well. Plates 
absorbance was measured at 450 nm in MultiskanTM FC (Thermo Scientific). Exceptions to the above 
statements will be mentioned. 
2.7.4.1 Titration Fab-on-Phage ELISA 
 Two assays were performed. In each, 1:2 serial dilutions of each library, starting at 1x1012 
cfu/mL to 7,81x109 cfu/mL, were tested in duplicate. In assay 1, the coatings were: 1) anti-M13 Ab 
(Acris); 2) anti-Fab Ab (Sigma); 3) uncoated. In assay 2, the coatings were: 1) anti-M13, 2,5 µg/mL 
Ab; 2) anti-Fab Ab; 3) anti-LC Ab (anti-κ or anti-λ Ab, respectively – Sigma-Aldrich®); 4) anti-histidine 
Ab (GE Healthcare); 5) uncoated.  
2.8 Libraries’ Selection by Panning 
2.8.1 Panning 
Panning was performed against three targets: bovine serum albumin (BSA) for library 
construction validation, human HER2 for breast cancer biomarker validation, and human DLL1 (Table 
2.1). Selection with HER2 and DLL1 was performed only for λ library. Three rounds were performed 
for each panning. The panning protocol was adapted from Rader et al., 2001. 
The panning was performed on immobilized antigen. The protocol was executed in 96-well 
Nunc Maxisorp plates. Coatings were performed O/N at 4º C or for 1h at RT as follows: BSA – 20 
µg/mL, 100 µL per well; HER2 and DLL1 – 15 µg/mL, 50 µL per well. As a depletion step, uncoated 
wells were used to eliminate the unspecific plastic phage binders. Coated and depletion wells 
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(uncoated) were blocked with 250 µL of DPBST-MP 3% for 1h-2h at RT. 50 µL or 100 µL of phages 
(the same volume of coating solution) were added to the depletion wells and incubated 30’ at RT with 
gentle shaking. In the 1st round of selection, 1x1012 phages from the phage libraries glycerol stock 
were used. In the following rounds, 50 µL of amplified phages from the previous round were used (for 
BSA panning, those were diluted in 50 µL of DPBS, so that the final volume was 100 µL). Since the 
HER2 molecule used is Fc tagged the panning strategy for this antigen had an extra depletion step, 
after the general one, in a well coated with human IgG1 (Sigma-Aldrich®) at 15 µg/mL to eliminate any 
Fc binders. Before proceeding to selection, 20 µL – for BSA panning – or 12 µL of phages – for HER2 
and DLL1 pannings – were set aside for later determination of the number of input phages. Phages 
were transferred from the depletion wells to the selection wells and incubated 1h at RT with gentle 
shaking – selection step. In the 1st round, phages were selected twice, by transferring the phages to 
another selection well after the first selection and repeating the process. Selection well(s) were 
washed with 250 µL of 0,05% PBST buffer, by pipetting up and down and incubating 5’. This process 
was repeated 5 times in the 1st round and 10 times in the following. Specifically bound phages were 
eluted by adding 50 µL or 100 µL (the same volume of coating solution) of triethanolamine (TEA, 
Sigma-Aldrich®) 100 mM to the selection well(s) and incubating 10’ at RT with gentle shaking. After 
pipetting up and down, eluted phages were transferred to a tube containing the same volume of 1 M 
Tris-HCl buffer (GIBCO® Life TechnologiesTM), pH 7,5 for neutralization. 
Table 2.1 - Antigens used for panning 
Target Supplier Molecular Weight Characteristics 
BSA Sigma-Aldrich® 66,43 kDa --- 
HER2 Sino Biological 96,1 kDa Extracellular domain of human ErbB2 (Met 1 - Thr 652) fused with the Fc region of human IgG1 at the C-terminus 
DLL1 
Produced in house 
in HEK293-EBNA6 
cells 
33,52 kDa 
Extracellular domain portion of human DLL1 (Trp 159 – Val 
444, domains DSL to EGF-like 6) fused with a polyhistidine-
tag (His8) at the N-terminus 
2.8.2 Phage Amplification 
A previously grown E. coli TG1 culture was diluted in medium to an initial OD600nm=0,05 and 
incubated at 37ºC, 250 rpm, until reaching an OD600nm≈0,5. 125 µL – for BSA panning – or 62,5 µL – 
for HER2 and DLL1 pannings – of selected phages were added to 5 mL of TG1 culture at OD600nm=0,5 
and incubated 15’ at RT with gently shaking for infection. 20 µL of infected bacteria were set aside for 
later determination of the number of output phages. 3 mL of pre-warmed medium with ampicillin (to a 
final concentration of 100 µg/mL) was added to the infected bacteria and incubated 1h at 37ºC, 250 
rpm. Helper phage at a MOI of 20:1 and 92 mL of pre-warmed medium with ampicillin 100 µg/mL was 
added and incubated at 37ºC, 250 rpm. After 1,5h-2h, kanamycin was added to a final concentration 
of 50 µg/mL (Lee et al., 2007) and cultures incubated O/N at 37ºC, 250 rpm. On the next day, cultures 
were centrifuged at 3500 x g for 15’-20’. Supernatants were filtered with a 0,45 µm filter to remove any 
residual bacteria. 20 mL of 20% PEG 2,5 M NaCl (0,2 volumes) was added to each culture 
supernatant and phages precipitated on ice for 1h-2h. Phage suspensions were centrifuged at 6200 x 
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g for 20’ at 4ºC and pellets resuspend in 2 mL of DPBS. Phages were used for the next panning 
rounds and/or screening. 
2.8.3 Titration of input and output phages 
For titration of input phages, the phages set aside after selection were serial diluted in 
medium. 90 µL of TG1 culture at OD600nm≈0,5 was added to 90 µL of each phage dilution and 
incubated 15’ at RT with gentle shaking for infection. Several dilutions (10-8 to 10-11 for the 1st round 
and 10-6 to 10-9 for the following) were plated in amp/glu plates. For titration of output phages, bacteria 
set aside after infection with selected phages was serial diluted in medium. Dilutions 10-1 to 10-4 were 
plated in amp/glu plates. Uninfected TG1 cells were also plated in amp/glu and kan/glu plates as 
controls. Plates were incubated O/N at 37º C. Colonies were counted and cfu/mL were calculated 
following Formula 2.3 and then used to calculate the final phage input, considering the volume that 
was placed in the selection well (after setting apart the volume for input titration) and the phage output 
(considering the output infection volume, namely 5 mL). The percentage of phage recovery was 
calculated following Formula 2.4 and the enrichment between rounds following Formula 2.5. 
𝑜𝑢𝑡𝑝𝑢𝑡  𝑝ℎ𝑎𝑔𝑒𝑠  𝑖𝑛  𝑟𝑜𝑢𝑛𝑑  𝑛
𝑖𝑛𝑝𝑢𝑡  𝑝ℎ𝑎𝑔𝑒𝑠  𝑖𝑛  𝑟𝑜𝑢𝑛𝑑  𝑛
  ×  100   =   𝑃ℎ𝑎𝑔𝑒  𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑦  𝑖𝑛  𝑟𝑜𝑢𝑛𝑑  𝑛  (%) 
Formula 2.4 – Percentage of phage recovery in a determined round of selection calculation, following 
Arbabi-Ghahroudi et al, 2009. 
𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐  𝑝ℎ𝑎𝑔𝑒𝑠  𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑦  𝑖𝑛  𝑟𝑜𝑢𝑛𝑑  𝑛  
𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐  𝑝ℎ𝑎𝑔𝑒𝑠  𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑦  𝑖𝑛  𝑟𝑜𝑢𝑛𝑑  𝑛 − 1
  =   𝐸𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡  𝑖𝑛  𝑟𝑜𝑢𝑛𝑑  𝑛 
Formula 2.5 – Enrichment: increase in recovered phage in a determined round of selection relatively to 
the previous round calculation, following Arbabi-Ghahroudi et al, 2009. 
2.9 Analysis of Selected Phage Pools  
2.9.1 Phage Pools Screening by Fab-on-Phage ELISA 
For pools screening by ELISA, 1:2 serial dilutions of phage pools were tested in duplicate, 
unless stated otherwise. 
2.9.1.1 BSA Selected Phages 
 Two assays were performed. In assay 1, there were no duplicates. Both eluted and amplified 
phages from round 1 of both libraries and round 2 of λ library were assayed. In assay 2, amplified 
phages from round 3 of the λ library and from round 2 of κ library were assayed. For both assays, 
coatings were: 1) anti-Fab Ab; 2) anti-LC Ab (anti-κ or anti-λ Ab, respectively); 3) BSA; 4) uncoated. 
   2.9.1.2 HER2 Selected Phages 
 Two assays were performed. In assay 1, round 2 amplified phages were tested and coatings 
were: 1) anti-Fab Ab; 2) HER2; 3) uncoated. In assay 2, round 2 and 3 amplified phages were tested. 
Round 2 was tested for the following coatings: 1) HER2; 2) IgG1. Round 3 was tested for the following 
coatings: 1) anti-Fab Ab; 2) HER2; 3) IgG1; 4) uncoated. 
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2.9.1.3 DLL1 Selected Phages 
 Two assays were performed. In assay 1, round 2 and 3 amplified phages were tested and 
coatings were: 1) anti-Fab Ab; 2) DLL1; 3) uncoated. In assay 2, round 3 amplified phages test was 
repeated for the same coatings, but more dilutions were tested. 
 2.10. Analysis of Selected Clones 
2.10.1 Fab-on-Phage ELISA of Selected Clones  
2.10.1.1 Clones Rescue 
 Individual colonies were picked from round 3 output plates and used for phage rescue. 
Protocol was adapted from Steinberger, 2001. Although both libraries were selected against BSA, only 
clones originating from the λ library panning were rescued and individually screened.  
 10 λ clones selected for BSA and 20 for HER2 or DLL1 were picked. Each clone was 
inoculated in 5 mL (for BSA-selected clones) or 7,5 mL (for HER2- and DLL1-selected clones) of 
medium with 100 µg/mL of ampicillin and incubated for 4h40’-5h20’ at 37º C, 250 rpm. Helper phage 
was added at a MOI of 20:1 to each culture and incubated for 2h at 37º C, 250 rpm. Kanamycin was 
added to a final concentration of 50 µg/mL and cultures incubated O/N at 37º C, 250 rpm. On the 
following day, cultures were centrifuged at 2800 x g for 15’. 20% PEG 2,5 M NaCl was added to a final 
concentration of 20% and phages precipitated on ice for 1h10’-1h30’. Phage suspensions were 
centrifuged for 20’-30’. Phage pellets were resuspended in 200 µL (for BSA-selected clones) or 350 
µL (for HER2- and DLL1-selected clones) of DPBS. 
   2.10.1.2 Clones Fab-on-Phage ELISA 
 Selected individual clones were tested by Fab-on-phage ELISA, in which phages were used 
directly from rescue. For BSA-selected clones test, coatings were: 1) anti-Fab Ab; 2) anti-λ Ab; 3) 
BSA; 4) uncoated. For HER2-selected clones test, coatings were: 1) anti-Fab Ab; 2) HER2; 3) IgG1; 4) 
uncoated. For DLL1-selected clones test, coatings were: 1) anti-Fab Ab; 2) DLL1; 3) uncoated. 
Duplicate tests were performed for the phages affinity against the antigen for which they had been 
selected.  
2.10.2 sFab ELISA of Selected Clones  
   2.10.2.1 Clones sFab Induction 
Clones that were considered positive for specific binding on Fab-on-phage ELISA were 
induced to express soluble Fab’s (sFab’s). Each clone phagemid DNA was extracted using GeneJET 
Plasmid Miniprep Kit as described in section 2.2.5. 1 µL of DNA was transformed by electroporation 
into 50 µL of electrocompetent TOP10 cells (from glycerol stock at -80º C) as described in section 
2.2.6. Transformed cells were plated in amp/glu plates, which was incubated at 37º C O/N. Following 
steps (Fab expression induction protocol) were adapted from Steinberger, 2001. For each clone, a 
streak of TOP10 transformed bacteria was inoculated in 5 mL of medium with 100 µg/mL of ampicillin 
and incubated for 6h30’-8h at 37º C, 200-250 rpm. IPTG (NZYTech) was added to a final 
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concentration of 2 mM and cultures incubated O/N at 37º C, 250 rpm. Induced cultures were 
centrifuged for 10’ at 2000 x g and pellets were resuspended in 750 µL of DPBS. Cells were lysed by 
3 cycles of freezing in dry ice and ethanol bath for 3’-5’ and thawing at 37º C in water bath for 3’. 
Lysates were centrifuged at 15000 x g for 5’ and supernatants containing Fab’s were kept for further 
usage. 
   2.10.2.2 Clones sFab ELISA 
Clones that were considered positive for specific binding in Fab-on-phage ELISA were further 
tested by sFab ELISA. Supernatants obtained from centrifugation of induced bacteria lysates were 
directly tested in duplicates. Coatings were the same as for Fab-on-phage ELISA, but only uncoated 
wells were used as negative controls for HER2-selected clones and an extra coating was used for 
DLL1-selected clones test, namely a histidine-tagged protein to eliminate any his tagged specific 
binders. 
2.10.3 Positive Clones Analysis 
2.10.3.1 Genetic tests 
Clones’ phagemid DNA was used as template for PCR. Reactions containing 20 ng of 
template, 0,4 mM of dNTPs, 20 pmol of pCOMB Fw primer, 20 pmol of pCOMB Rv primer, 1,25 U of 
Pfu DNA polymerase and 1x buffer were prepared in a final volume of 50 µL. PCR was performed with 
the following conditions: initial denaturation at 95º C for 2’, followed by 30 cycles of denaturation at 95 
°C for 30’’, annealing at 60º C for 30’’, and extension at 72º C for 3’; and 1 last cycle of final extension 
at 72º C for 10’. For control purposes, pCOMB3XSS amplification and a “no template” reaction were 
also performed.  
Clones’ phagemid DNA was double digested with FastDigest SacI and FastDigest SpeI 
(ThermoScientific) restriction enzymes following the manufacturer’s instructions for 32’.  
Clones’ phagemid DNA (150 ng), PCR products (5 µL) and double-digestion products (150 
ng) were analyzed by electrophoresis in 0,8% agarose gel.  
BSA- and HER2-selected clones’ PCR products were purified with NZYGelpure kit (NZYTech) 
following the manufacturers instructions for PCR clean-up. Purified PCR products and phagemid DNA 
of all selected clones was sequenced and results analyzed as decribed in section 2.7.3. Sequences 
were aligned to allow identification of unique clones using ApE – A Plasmid Editor software.  
DLL1-selected clones PCR products were digested with BstNI enzyme as described in section 
2.7.2. BstNI products (9 µL) were analyzed by electrophoresis on 3% agarose gel. 
2.10.3.2 SDS-PAGE and Western Blot 
DLL1-selected clones sFab’s were run on SDS-PAGE under reducing conditions. 5 µL of 
supernatants obtained from centrifugation of induced bacteria lysates were added to 5 µL of XT 
sample loading buffer 4x (Bio Rad) and 10 µL of DPBS and incubated 5’ at 99º C before being loaded 
in a CriterionTM XT Precast Gel (Bio Rad). NZYColour Protein Marker II (NZYTech) was used as 
molecular weight marker. Gel ran at 120 V for 2h in 1x XT MOPS running buffer (Bio Rab) diluted in 
distilled water. 
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Proteins were transferred to a nitrocellulose membrane using the iBlotTM Dry Blotting System 
(InvitrogenTM) following the manufacturer’s instructions to use the device with iBlot® Gel Transfer 
Stacks, Nitrocellulose (InvitrogenTM). Blotting parameters were 20V for 7’ (device P3 default program). 
Membrane was blocked with PBST-MP 3% for 30’ with shaking and washed 3 times by shaking in 
PBST for 5’. Membrane incubated with HRP-anti-Fab Ab at 2,5 µg/mL in DPBS for 55’ and washing 
was repeated. Membrane was photographed on ChemiDocTM XRS+ System (Bio Rad) under EPI 
white light. Western blot revelation was performed by covering the membrane with 1 mL of Western 
Lightning® Plus-ECl, Enhanced Chemiluminescence Substrate (Perkin Elmer), previously prepared as 
indicated by manufacturer’s instructions. Membrane was exposed to chemiluminescent light and 
photographed after different exposition times on ChemiDocTM. 
2.11 Antigens Titration ELISA 
A 96-well Nunc Maxisorp plate was coated overnight at 4º C with 1:2 serial dilutions of each 
antigen used for panning, ranging from 20 µg/mL to 0,16 µg/mL. 2 columns were coated with either 
BSA or HER2 and 4 columns were coated with DLL1. After washing and blocking as described in 
section 2.8.3, the following primary Abs were added: 1) to BSA coated wells: sheep anti-human serum 
albumin Ab (Abcam®) – cross reactive with BSA –, 18,17 µg/mL; 2) to HER2 coated wells: mouse anti-
rhesus HER2 Ab (Sino Biological), 0,5 µg/mL; 3) to DLL1 coated wells (2 columns): mouse anti-DLL1 
Ab (Sino Biological), 0,5 µg/mL; 4) to DLL1 coated wells (2 columns): mouse anti-histidine Ab, 1,4 
µg/mL. Primary Ab incubated at RT for 1h25’. Washing was repeated and the following detection Abs 
at 2,5 µg/mL were added: 1) BSA coated wells: donkey anti-sheep IgG-HRP Ab (Santa Cruz 
Biotechnology®); 2-4) HER2 and DLL1 coated wells: anti-mouse IgG-HRP Ab (Sigma-Aldrich®). 
Following procedures were performed as described in section 2.8.3. 
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3. Results 
3.1 Construction of two immune Ab Fab fragment libraries (κ and λ) 
The biological material for the generation of the two Fab fragment immune libraries (κ and λ) 
was obtained at CUF Descobertas Hospital from peripheral blood from 16 breast cancer patients. The 
samples were drawn from female adults with ages between 48 and 84 one male with age of 71. 
3.1.1 Light Chain and Heavy Chain Fd Fragments Construction 
Total RNA was isolated from the peripheral blood mononuclear cells of breast cancer patient 
donors. Isolated RNA quality was evaluated by determination of its quantity, purity and integrity. 
Isolated RNA quantity ranged from 2,3 ng/µL to 109,3 ng/µL (Table 3.1). A260/A280 ratio, which is 
indicative of purity, also varied from 1,3 to 1,94, but it was higher than 1,65 for most of the samples 
(Table 3.1). Most of the samples were therefore in an acceptable level of purity, once this ratio optimal 
results are between 1,7 and 1,9 (Kotlan and Glassy, 2009).  
Table 3.1 - RNA isolated from donors’ peripheral blood mononuclear cells spectrophotometry results: 
quantification and A260/A280 ratio. 
Sample # Quantity (ng/µL) A260/A280 
1 7,6 1,60 
2 19,3 1,54 
3 10,8 1,44 
4 2,3 1,56 
5 13,9 1,57 
6 6,5 1,57 
7 82,3 1,90 
8 21,2 1,30 
9 33,4 1,93 
10 92,8 1,93 
11 109,3 1,94 
12 77,2 1,90 
13 75 1,90 
14 17,3 1,66 
15 13,2 1,68 
16 26 1,77 
The integrity of the extracted samples was also analyzed by running an agarose gel 
electrophoresis, where the presence of intact 18S and 28S ribosomal RNA species (approximately 1,9 
kb and 5 kb in size, respectively) was observed. Examples of three of the samples prepared are 
shown in Figure 3.1.  
    
 
1 2 3 
28S 
18S 
	  
RNA Integrity  
Figure 3.1 - Integrity of RNA isolated from peripheral blood mononuclear cells from 3 donors. The two 
major subunits of rRNA - 18S and 28S – are detected. Lanes: 1 – Sample 14; 2 – Sample 15; 3 – Sample 16.   
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After verifying that all the RNA samples passed the set quality criteria, a pool containing the 
same quantity of each donor total RNA was used to synthesize three different specific cDNA’s. These 
three reactions were performed with three different primers designed to anneal with mRNA encoding 
either the CH1 domain of IgG, the CLκ domain or the CLλ domain. cDNA’s obtained were used as first 
strand template to construct the HC Fd fragment, κ LC and λ LC repertoires, respectively. 
Repertoires amplification was conducted in more than one step. Since the purpose was the 
construction of Fab libraries, both variable and constant domains (for the HC, only the first constant 
domain, CH1) were amplified. HC Fd and LC fragments were divided into segments (variable and 
constant) that were separately amplified and subsequently randomly assembled, and reamplified by 
overlap PCR. For the variable and CLλ segments amplification, several primer combinations were 
used for coverage of the different VH- and VL-gene families. Primers’ design had other specifications; 
flanking (overlap) primers included restriction sites that were introduced in the final products 
extremities so that they could be cloned into the phage display vector; variable segments interior (Rv) 
primers included tails that were complementary to the 5’ portion of the constant segment, so that both 
segments overlapping sequences would anneal, allowing their assembly by overlap PCR (see Table 
6.1, appendix section 6.1, and Figures 2.1-2.3).  
Results of the fragments construction are summarized in Table 3.2. The number of products 
obtained in each construction step depended on the number of primer combinations used in that 
stage, except for CH1 fragments, which were all constructed with the same combination of primers, 
but derived from different templates. Before proceeding, electrophoresis analysis of each PCR product 
was performed to check if bands of the correct size were obtained after each reaction. The bands of 
the amplified fragments with the expected sizes were gel purified to separate them from unspecific 
products and remaining template DNA, and hence avoid their interference in subsequent procedures.  
HC cDNA synthesis with a primer specific for the IgG CH1 region allowed that the VH 
repertoire construction was exclusively based on V regions originated from this Ig class. VH repertoire 
construction comprised three essential steps. The first step consisted in the amplification of complete 
VHCH1 fragments from cDNA, and the 6 different products obtained presented the expected size of 
750 bp (Figure 3.2 A). However, the agarose gel also showed that amplification of two of the six 
fragments – VH2CH1 and particularly VH6CH1 – was less efficient. Regarding this, several attempts 
were made to optimize VH6CH1 amplification by testing different annealing temperatures, but none 
had significantly better results (data not shown). Nevertheless, the amount of DNA obtained from 
these products was still sufficient and thus used in the following steps. In the second step the VHJH 
and CH1 segments were individually amplified from the previous step products, resulting in, 
respectively, 24 and 6 different PCR products. Those had the expected sizes of 430 bp and 364 bp, 
respectively, as verified by gel electrophoresis (Figure 3.2 B). In the third step, both segments 
obtained from the second step were assembled by overlapping PCR, originating the final HC Fd 
fragments. DNA gel electrophoresis analysis showed that all overlapping products were amplified 
successfully and presented the correct size of approximately 730 bp. However, as shown in Figure 3.2 
C, besides detection of the DNA templates some unspecific bands were also present. Increasing the 
annealing temperature and reducing the extension time to the minimum recommended did not 
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improve the results, so the bands of the expected size were gel purified. An extra step was also 
performed in which the 6 purified overlap fragments were used as templates for their own 
reamplification to allow having more DNA available for the following cloning steps.  
 
Figure 3.2 - HC Fd fragment construction PCRs. M – Gene ruler 1 kb. A – VHCH1 amplification (1st step); 
Lanes: 1 – VH1CH1; 2 – VH2CH1; 3 – VH3CH1; 4 – VH6CH1, amplified with 59º C of annealing temperature. 
B – VHJH and CH amplification (2nd step); Lanes: 5 – VH2JH4/5; 6 – VH2JH6; 7 – 5CH1; 8 – 6CH1. C – HC 
Fd (VHCH1) overlap amplification (3rd step); Lanes: 9 – VH1CH1; 10 – VH2CH1. 
Both κ LC and λ LC construction was performed in two steps, first the VL and CL segments 
were individually amplified and then subsequently assembled. The first step resulted in 9 VLκ, 1 CLκ, 
12 VLλ and 2 CLλ products. DNA gel electrophoresis results showed that all the fragments had the 
expected sizes – approximately 370 bp for the VLs, 337 for CLκ and 317 bp for CLλ (Figure 3.3 A and 
Figure 3.4 A). Moreover, the results showed that the amplification of some VL segments was less 
efficient, namely VLκ4 and particularly VLκ5 and VLλ10, so the amplification of those two was 
optimized. Better PCR results were achieved with other annealing temperatures, namely 47,1º C and 
48,1º C for VLκ5 amplification (Figure 3.3 B), and 55º C, 53º C and 50,9º C for VLλ10’s (Figure 3.4 B). 
Still, these results were not as good as for the respective remaining variants (data not shown). 
Considering the optimization results in the PCR assembly reaction, VLκ4CLκ and VLκ5CLκ fragments 
were thus constructed using an annealing temperature of 48º C. Results were equivalent to those of 
the remaining VLκCLκ fragments construction, 9 of which were obtained in total.  
 
Figure 3.3 - VLκCLκ construction PCRs. M – Gene ruler 1 kb. A – VLκ and CLκ amplification (1st step); 
Lanes: 1 – VLκ3c; 2 – VLκ3d; 3 – VLκ4; 4 – CLκ. B – Lanes 5: VLκ5 amplified with 48,1º C of annealing 
temperature (optimization). C – VLκCLκ overlap amplification (3rd step); Lanes: 6 – VLκ3cCLκ; 7 – 
VLκ3dCLκ; 8 – VLκ4CLκ. 
24 VLλCLλ fragments were constructed also with variable yields. DNA gel electrophoresis of 
the VLCL assembly products resulted in bands of 700 bp as expected (Figure 3.3 C and Figure 3.4 C). 
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Figure 3.4 – VLλCLλ construction PCRs. M – Gene ruler 1 kb. A – VLλ and CLλ amplification (1st step); 
Lanes: 1 – VLλ7/8a; 2 – VLλ7/8b; 3 – VLλ9; 4 – CLλa. B – Lanes 5: VLλ10 amplified with 50,9º C of 
annealing temperature (optimization). C – VLλCLλ overlap amplification (3rd step); Lanes: 6 – VLλ1aCLλa; 
7 – VLλ2CLλa; 8 – VLλ7/8bCLλb; 9 – VLλ9CLλb. 
A summary of all the fragments construction results is presented below (Table 3.2).  
Table 3.2 - LC and HC Fd fragments construction: Amplification steps’ results summary. 
Repertoire Amplification Step Product # of different products Approximate size (bp) 
HC Fd 
1 VHCH1 6 750 
2 
VHJH 24 430 
CH1 6 364 
3 HC Fd (VHCH1) 6 730 
κ LC 
1 
VLκ 9 362 
CLκ 1 337 
2 VLκCLκ 9 700 
λ LC 
1 
VLλ 12 370 
CLλ 2 317 
2 VLλCLλ 24 700 
3.1.2 Libraries Construction 
 Fab libraries construction was performed by cloning the PCR generated fragments into 
pCOMB3XSS, by digestion with compatible restriction enzymes. Two cloning steps were performed. In 
the first, VLκCLκ and VLλCLλ fragments were separately cloned into the vector using the enzymes 
SacI and XbaI. Subsequently, HC Fd fragments were cloned into the vectors already containing the κ 
or λ LC repertoires, resultant from the first cloning step, with two different enzymes – XhoI and SpeI. 
After these cloning steps, vectors for two libraries, VLκCLκ-VHCH1 (“κ library”) and VLλCLλ-VHCH1 
(“λ library”), were obtained. 
Before proceeding with the construction of the large scale libraries, small scale ligation trials 
were performed to optimize ligation and transformation conditions, and their results are summarized in 
Tables 3.3 and 3.4. 1:3 and 1:5 vector:insert molar ratios were tested for LC-vector ligation and the 1:5 
ratio resulted in a higher #transformants/µg DNA, namely 9,80x106 for VLκCLκ and 1,07x107 for  
VLλCLλ ligation. This was a positive result since the threshold was set at 1x107 transformants/µg DNA 
according to literature (Clark, 2002). Small scale trials also demonstrated that the vector self-ligation 
background levels were very low, only with 4x103 transformants/µg DNA. Since this is <0,1% of both 
LC-vector ligations’ transformation efficiencies (Clark, 2002), one can assume that the vector was 
correctly digested and dephosphorylated (Figure 3.5 A). Consequently, LC large scale ligation was 
performed with a 1:5 vector:insert molar ratio and with the same vector batch that was used for small 
scale. The obtained VLκCLκ sub-library contains 5,17x108 transformants and VLλCLλ sub-library 
1,25x109 transformants. 
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Table 3.3 - LC small scale ligation trial results 
Transformed DNA 
#transformants/µg DNA # self-ligation transformants / # 1:5 ratio 
vector-insert ligation transformants --- 1:3 ratio 1:5 ratio 
pUC19 3,74x1010 --- --- --- 
pCOMB3XSS self-ligation 4,00x103 --- --- --- 
pCOMB3XSS + VLκCLκ ligation --- 2,56x106 9,80x106 0,04% 
pCOMB3XSS + VLλCLλ ligation  --- 2,35x106 1,07x107 0,04% 
HC Fd ligation to LC-vector small scale trials were also performed but this time  only with the 
1:5 ratio, once this condition was the one that allowed obtaining the best results before. The first trial 
ligation resulted in a transformation efficiency higher than 1x107 transformants/µg DNA, as desired, 
but both LC-vectors’ self-ligation background levels were >0,1%, in the 3% range. LC-vectors 
digestion products analysis by DNA gel electrophoresis showed that besides the band of interest 
(approximately 4 kb) there was another of similar size (approximately 3,5 kb) (Figure 3.5 B-C). As 
such, digested LC-vectors were ran in an agarose gel for longer to assure a clear separation of the 
bands, and ensure that only the band of interest was purified and used for the following cloning step; 
also, purified LC-vectors were dephosphorylated for longer times (3h instead of the initial 1h) to 
prevent self-ligation of the products. This resulted in a significant reduction of the self-ligation levels to 
the range of 0.2-0.3%, values still slightly >0,1%. Nevertheless, the self-ligation rates were still quite 
low when compared to the total number of transformants, and thus large scale ligations were followed 
and the libraries constructed. VLκCLκ-VHCH ligation transformation for the κ library construction 
resulted in 1,69x109 transformants and VLλCLλ-VHCH ligation transformation for the λ library 
construction resulted in 4,58x108 transformants. 
 
Figure 3.5 - Vectors digestion. M – Gene ruler 1 kb. A – pCOMB3XSS. Lanes: 1 – Undigested; 2 – Digested 
with SacI and XbaI enzymes. Smaller fragment corresponds to the LC stuffer. B – pCOMB3XSS+VLκCLκ. 
Lanes: 3 – Undigested; 4 – Digested with XhoI and SpeI enzymes. C – pCOMB3XSS+VLλCLλ. Lanes: 5 – 
Undigested; 6 – Digested with XhoI and SpeI enzymes.  
In both small scale and large scale ligations’ transformation, a transformation with a 
commercial pUC19 was performed to determine the transformation efficiency of the competent TG1 
cells. The value obtained was always above 1x109 transformants/µg DNA, which indicates a high 
transformation efficiency of the TG1 cells that were used (Marks and Bradbury, 2004b) (values 
obtained in the small scale trials are indicated in Tables 3.3 and 3.4; for the large scale libraries 
construction it was 1,07x1010). 
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Table 3.4 - HC small scale ligation trial results 
Transformed DNA 
#transformants/µg DNA # self-ligation transformants / # 1:5 ratio vector-insert ligation transformants 
1 2 1 2 
pUC19 4,79x1010 1,07x1010 --- --- 
pCOMB3XSS-κ self-ligation 5,22x105 4,56x104 --- --- 
pCOMB3XSS-λ self-ligation 1,32x106 1,88x104 --- --- 
pCOMB3XSS-κ + VHCH1 ligation 1,92x107 1,40x107 2,71% 0,33% 
pCOMB3XSS-λ + VHCH1 ligation  3,70x107 1,17x107 3,56% 0,16% 
3.1.3 Libraries Rescue 
Phage libraries were prepared by phagemid rescue from the Fab bacterial libraries with 
M13K07 helper phage. Rescue resulted in the production of 3,2 mL of each Fab phage library, 
resulting in the following concentrations:  κ library – 5,25x1013 cfu/mL; λ library – 5,63x1013 cfu/mL. 
Each phage library was split into 16 aliquots of 200 µL, which were stored at -80ºC until further usage. 
  3.1.4 Libraries Characterization and Quality Assessment 
Several tests were performed to characterize and evaluate the libraries quality. Libraries 
actual size was calculated considering the percentage of clones that were correctly constructed and 
did not contain errors. For that, the percentage of clones that contained both LC and HC inserts was 
firstly estimated by insert-site amplification, and then the percentage of those who were error-free was 
determined by analyzing their sequences. Diversity was estimated by assessing the percentage of 
different DNA fingerprinting patterns, V gene and CDR3 length distribution, and CDR3 sequence 
variability of Fab-containing clones. Results are summarized on Table 3.5. Finally, Fab-on-phage 
display was assessed by phage pools test by ELISA. 
Table 3.5 - Libraries characterization 
Library Total size
a (# 
transformants) 
Fab-containing 
transformants 
Error-free 
Fabs 
Functional 
library 
Actual sizeb (# 
transformants) 
Fingerprint 
diversity 
Fingerprint + 
Sequencing diversity 
κ 1,69x109 51% 69% 35% 5,93x108 88,6% 93,2% 
λ 4,58x108 52% 83% 43% 1,98x108 85,1% 91,5% 
a – Calculated from the result of library transformants count in test plates; b – Taking into account the % of successful cloning 
and error-free Fab (functional library). 
3.1.4.1 Colony PCR and BstNI Fingerprinting 
The percentage of clones that contained both the LC and HC inserts was assessed by 
amplifying the DNA of 100 clones of each library with primers that anneal to the pCOMB3XSS vector 
in the regions flanking the Fab construct insertion place. The resultant PCR product should present a 
band of ≈1500 bp for all positive clones, corresponding to a correct construction of the Fab fragment 
(with both the complete HC and LC), as represented in a small sample of the clones in Figure 3.6. 
Considering this, and by analyzing all the clones it was estimated that 51% of κ library and 52% of λ 
library contained correctly constructed Fab-encoding inserts. 
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Figure 3.6 - Example of Fab insert amplification (colony PCR). M – Gene ruler 1 kb. A – κ library clones. B 
– λ library clones.  Lanes: 7 and 14 – pCOMB3XSS vector PCR product, 1,7 kb band (control). Clones oin 
lanes 1, 3, 4, 6, 11, 12 and 13 were considered positive, as their amplification resulted in a 1,5 kb band. 
44 κ and 47 λ clones that were considered positive were further analyzed by BstNI 
fingerprinting and sequencing. BstNI is a frequent-cutter enzyme and provides a DNA fingerprinting 
profile of the clones, which allows an estimation of the libraries’ diversity. Clones digestion showed 
that 88,6% of the κ and 85,1% of the λ analyzed clones had different fingerprinting patterns (an 
example is represented in Figure 3.7). 
 
Figure 3.7 - Example of BstNI fingerprinting. M – Gene ruler 1 kb. Lanes 1-5 – κ library clones. Lanes 7-11 
– λ library clones.  Lane 6: empty. 
3.1.4.2 Sequencing 
Clones that were digested with BstNI were further analyzed by sequencing using the same 
primers as for the colony PCR. Clones’ Fab insert sequencing allowed a deepest analysis of the 
clones diversity, identity and presence or absence of mutations, frameshifts or other cloning derived 
errors.  Sequencing results are summarized on Table 3.6.  
In total, DNA of 44 clones of the λ and 47 of the κ libraries were sent for sequencing at STAB 
Vida or at GATC. For 29 of the κ and 27 of the λ clones a complete sequence was obtained. For 6 of 
the κ and 5 of the λ clones a partial sequence was received, correspondent to only one of the chains 
(LC or HC Fd fragment), and 9 of the κ and 15 of the λ clones sequencing did not render any data. 
Table 3.6 - Summary of Sequencing Data 
Library Total sequenced 
Complete 
sequence 
1 chain 
sequenced 
Unmatched 
chains 
Chains 
containing errors 
No sequence 
obtained 
κ 44 29 6 5 15 9 
λ 47 27 5 5 4 15 
	  
A B 
1 kb  
M 1 2 3 4 5 6 7 
1,5 kb  
2 kb 
1,7 kb  
M 8 9 10 11 12 13 14 
1 kb  
1,5 kb  
2 kb 
1,7 kb  	  
κ library clones λ library clones 
M 1 2 3 4 5 6 7 8 9 10 11 
500 bp  
250 bp  
	  
BstNI fingerprinting 
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Obtained sequences were submitted to VBASE2 database analysis tool (Retter et al., 2005) 
that provides information about the V-genes source by aligning the sequences with known V-genes 
and finding the closest matches. Furthermore, it indicates when the sequences contain possible errors 
and finds the position and sequence of key features (like the FRs and CDRs). The results showed that 
most of the analyzed sequences (>91%) were comparable to the variable regions of human Igs and 
allowed the identification of the germ-line V genes, showing the closest nucleotide match to the 
clones’ VH and VLκ or VLλ domains. Most of the V-gene families were represented, and VH genes 
were evenly distributed by all the present families in both repertoires (Figure 3.8 B and D). On the 
other hand, a clear dominance was seen in VL genes distribution, with a higher number of genes 
belonging to the VLκ3 family and VLλ1 and VLλ2 families in the respective libraries (Figure 3.8 A and 
C). 
A  B  
C  D  
Figure 3.8 - V-gene families’ distribution of the libraries’ clones. Sequences containing errors were not 
considered. A – VLκ families in the κ library. B – VH families in the κ library. C – VLλ families in the λ 
library. D – VH families in the λ library. 
In general, there was a fair distribution of different V genes. 11 VLκ and 13 VH genes were 
identified in the κ library clones (Figure 3.9 A and B). IGKV3-20*01 was by far the most frequent VLκ 
gene, although there were 3 more genes derived from the VLκ3 family. 14 VLλ and 18 VH genes were 
identified in the λ library clones (Figure 3.9 C and D), being IGLV2-23*03,IGLV2-23*01 and IGLV1-
44*01 the two most frequently found VLλ genes. Despite the even VH family distribution, IGHV2-
5*10,IGHV2-5*02 had the higher number of VH matches in both libraries. 
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A  B  
C  D  
Figure 3.9 - V gene distribution by family of the libraries’ clones. Sequences containing errors were not 
considered. A – VLκ genes in the κ library. B – VH genes in the κ library. C – VLλ genes in the λ library. D 
– VH genes in the λ library. 
VBASE2 analysis tool also revealed the V region organization of the clones, including CDR3 
sequence and length. VH CDR3 length had a distribution between 10 and 22 amino acid residues for 
the κ library, and 9 and 21 for the λ library (Figure 3.10 B and D). VL CDR3 lengths were less variable, 
presenting between 9 and 11 residues for the κ library, and 9 and 13 residues for the λ library, as 
shown in Figure 3.10 A and C. Independently of the length, CDR3 sequences were also diverse. 
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Excluding error-containing sequences, for the κ library 24 out of the 25 clones revealed different VL 
CDR3 sequences, and all 19 VH CDR3 were different; for the λ library, all 24 VL CDR3 detected were 
different, and 23 out of the 25 clones had distinctive VH CDR3 sequences (Tables 6.2 and 6.3, 
appendix section 6.2). 
A  B  
C  D  
Figure 3.10 – Libraries’ CDR3 length distribution. Sequences containing errors were not considered. A – 
VL CDR3 in κ library. B – VH CDR3 in κ library. C – VL CDR3 in λ library. D – VH CDR3 in λ library. 
There were 5 κ and 7 λ library clone pairs that obtained similar DNA fingerprinting patterns. A 
comparison of the sequence analysis results of the two clones in each pair was performed when 
enough sequence information of both clones was available, namely for 2 κ and 3 λ library pairs. 
Results are shown in Table 3.7. All clones presented at least one variation, including that all the VH 
CDR3 sequences analyzed were different. Therefore, the clones were considered different despite the 
similar fingerprinting pattern, and only the clones that had the same pattern and no sequence 
information were regarded as possibly identical for the final library diversity assessment. Hence with 
this data the diversity of the libraries was higher than the previously estimated based only on DNA 
fingerprint (Table 3.5). 
Table 3.7 - Sequencing results of clones that obtained identical BstNI fingerprinting patterns 
Library Clone Pair VL gene family VL gene 
VH gene 
family VH gene 
VL CDR3 
sequence 
VH CDR3 
sequence 
κ 
K1/K8 Common IGKV3 
Common 
IGKV3-20*01 
Different 
IGHV1/IGHV5 Different Same Different 
K10/K22 Common IGKV3 
Different 
IGKV3-11*01/  
IGKV3-20*01 
Different 
IGHV2/IGHV5 Different Different Different 
λ 
L4/L8 Common IGLV7 
Different 
Not attributed/  
IGLV7-46*01 
Different 
IGHV3/IGHV2 Different Different Different 
L5/L15 Different IGLV1/IGLV2 Different 
Different 
IGHV2/IGHV3 Different Different Different 
L10/L28 Common IGLV2 
Common 
IGLV2-23*01 
Common 
IGHV1 
Different 
IGHV1-2*02/ IGHV1-18*01 Unknown Different 
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   3.1.4.3 Fab Display 
The libraries Fab display was assessed by titration of the phage pools by Fab-on-Phage 
ELISA. Two assays were performed where phage quantity and Fab display were evaluated, the first 
with an anti-M13 Ab and the last with an anti-Fab specific Ab. In a second assay the specificity for the 
his-tag, present in the C-terminal of the Fab, was also tested using an Ab against Histidine (for His-tag 
detection), and to verify the correct conformation of the LC, Abs against κ or λ LC were also used 
(respectively). Results are shown in Figure 3.11. 
A  B  
C  D  
Figure 3.11 - Fab-on-Phage ELISA of unselected libraries’ phage pools. Values presented are a mean of 
the respective duplicates and have the background signal subtracted. A – κ library, assay 1. B – λ library, 
assay 1. C – κ library, assay 2. D – λ library, assay 2. 
In the first assay, the signal obtained for phage detection was very strong and saturated 
quickly, so no dose response was possible to be observed. Therefore, in a second assay the plates 
were coated with half the concentration (2,5 µg/mL) of anti-M13 Ab and the ELISA protocol followed 
was the same. The results were however identical, indicating that phages were still captured in very 
high quantities. For a more thorough assessment of the number of phage particles the ELISA protocol 
must be further optimized. For display assessment, signal in anti-Fab Ab coated wells had identical 
results in both individual experiments. All Fab display tests resulted in dose responsive signals that 
were stronger in the highest concentrations tested, demonstrating that both libraries were correctly 
constructed, since phages were displaying the Fabs correctly. Anti-Fab Ab signal for κ library was on 
average 1,5 fold higher than for the λ library. The difference was more pronounced for the signal 
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obtained with the anti-LC Abs, which was 3 to 4 fold higher for the κ library highest dilutions, but this 
might have been caused by the use of a different coating Ab for each assay. On the other hand, anti-
his Ab signal was slightly higher for λ library, but the difference was mostly below 1,3 fold, including in 
the highest dilutions. Samples were analysed 2 fold each, and the signals detected for the duplicates 
were identical, and no significant background signal was found in uncoated wells. 
3.2 Libraries Panning 
 For validation, the two constructed Fab phage display immune libraries (κ and λ) were initially 
selected against a commercial model antigen – BSA, which usually is highly immunogenic (Hayworth, 
2014). Furthermore, and since the goal is to generate new potential cancer therapeutic Abs, selection 
was also pursued using as an antigen a validated breast cancer biomarker – HER2. Finally, and since 
the aim of this thesis is to generate function blocking Abs for Notch1 ligands, in order to inhibit Notch1 
signaling pathway, selection against DLL1 was performed once this target is a known Notch1 receptor 
ligand. 
Solid phase panning using 96-well Nunc Maxisorp plates was followed to select against all the 
three antigens assayed. Three rounds of selection were carried out in each case, with amplification of 
phages after all rounds of panning. The size and diversity of the libraries may imply that there are 
relatively few copies of each individual displayed Ab, as such the theoretical number of phages used 
in the 1st round was 1x1012. Considering the size of each library, the number of phages used per 
selection ensures that each phage of the κ library is represented at least ≈590-fold, and each phage of 
λ library ≈2180-fold. As a depletion step uncoated wells were used to eliminate the unspecific plastic 
phage binders. Also, to increase the probability of interaction between specific phage binders and the 
target, in the 1st round of selection the phages were incubated twice consecutively with the antigen.  
For each round, the total amount of phages added and recovered was measured and this 
allowed calculating the titer of the input and output phages, and determining the percentage of input 
recovery and enrichment values. 
The amplified phage pools resultant from the output were analyzed by Fab-on-phage ELISA to 
check if target-specific phages were being recovered and enriched. Amplified phages concentration 
was not determined, so the ELISA results are used as a qualitative indication. After three rounds of 
selection, individual clones were picked and analyzed by Fab-on-phage ELISA. Moreover, clones that 
showed a good Fab display, reactivity for the respective antigen and no background reaction were 
considered positive, and thus further tested by sFab ELISA. The sFab ELISA data allows checking the 
clone ability to produce reactive soluble Fab fragments. In cases where samples were analysed 2-fold 
each, the signals detected for the duplicates were identical. 
 Positive clones were further characterized. Phagemid DNA of the hit clones was extracted and 
the presence of the Fab insert was evaluated by PCR using the primers that anneal to the 
pCOMB3XSS vector in the regions flanking the Fab construct insertion place (the same that were 
used for the libraries size characterization). Phagemid DNA was also digested with SacI and SpeI and 
the restriction pattern analyzed.  
 
	   49	  
3.2.1 BSA 
Selection was carried out using 20 µg/mL of the BSA antigen molecule. Input and output 
phage titers, the percentage of input recovery and enrichment values are indicated in Table 3.8. 
Table 3.8 - BSA panning 
Target Panning round Phage input (cfu) Phage output (cfu) % of input phage recovery (x10-4) Enrichment* 
BSA 
κ 
1 1,73x1012 2,85x106 1,65 --- 
2 8,44x1012 5,00x102** 0,0001** 3,60x10-5x** 
3 4,80x1011 5,00x105 1,04 17583,33x** 
λ 
1 1,27x1013 3,76x104 0,003 --- 
2 2,46x1011 2,65x104 0,11 36,27x 
3 2,33x1011 4,98x106 21,35 198,21x 
*-fold increase in recovered phage, compared to the previous round of panning 
** The data obtained is not within the acceptance quality criteria (Rader, 2012) (see discussion section)  
In the 1st round of selection, the κ library input calculated value (1,73x1012) was close to the 
expected, once 1x1012 phages had been initially added for selection. For the λ library, however, it was 
considerably higher (in the 1013 range – 1,27x1013), which indicates that more phages were added 
than intended, possibly due to a dilution error. The number of phages added to selection was only 
predetermined in the 1st round. For the subsequent rounds a defined volume of the previous round 
amplified phages was added instead. In the 2nd and 3rd rounds, the results obtained for the titration of 
the input were in the range of 1011-1013 phages for κ library, which means they were in the range of 
the 1st round’s. For λ library, 2nd and 3rd round values were very similar (~2x1011) but differed slightly 
from that of the respective 1st round, nevertheless the results are in the typical expected range of 1011-
1012 total phages (Rader, 2012). 
For the κ library the output titration for the 1st round presented the value of 2,85x106 phages, 
which decreased dramatically in the 2nd round, to 5,00x102. This output value was lower than 
expected, once the expected value usually ranges from 104 to 107 (Rader, 2012). Nevertheless, a 
decrease in the output is typically seen from the 1st to the 2nd round and it could have been 
exacerbated by a possible tittering error. In the 3rd round the output increased to 5,00x105. Due to the 
significant difference in the 2nd and 3rd round output values, the calculated 3rd round enrichment value 
was extremely high. Assuming that, as referred, the 2nd round output was miscalculated, this 
enrichment value should not be taken into consideration for further discussion. 
Output titration of the λ library selection showed a slight decrease from the 1st to the 2nd round, 
from 3,76x104 to 2,65x104, which was much less significant than for the κ library. In the 3rd round, the 
output increased to 4,98x106, which can be translated in a significant enrichment value. 
3.2.1.1 BSA Selected Phage Pools Reactivity 
Since this was the first target to be assayed, for BSA, both eluted and amplified phage pools 
were analyzed by Fab-on-phage ELISA. Eluted phages concentration was calculated based on the 
phage output values. In addition to an anti-Fab Ab, Abs against κ or λ LC (depending on the library) 
were also used to evaluate Fab expression. 
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When analyzing the Fab-on-phage ELISA results for the eluted phages of the 1st and 2nd 
rounds of selection no signal was detected neither for Fab display nor for BSA reactivity, for both 
libraries. In an attempt to obtain better signals, revelation reactions with TMB were allowed to take 
longer but with no significant improvement (data not shown). This was probably due to the fact that the 
eluted phages concentration was not high enough to reach the assay detection limit. 
As such, amplified phages were analyzed for all rounds of selection. In the case of κ library  
(Figure 3.12), the results obtained showed that there was a dose-dependent behavior for Fab 
presence as can be seen in the curves obtained for both the anti-Fab and anti-LC assay. Moreover, 
the values obtained for both Abs were in the same range. However, no significant signal or response 
was detected for BSA reactivity, indicating there was not a BSA-specific phage enrichment in the 
selection strategy followed. 
A  B  
 
C  
 
Figure 3.12 - Fab-on-Phage ELISA of amplified phage pools resultant from κ library selection against BSA. 
Values presented are a mean of the respective duplicates and have the background signal subtracted. A – 
1st round of selection. B – 2nd round of selection. C – 3rd round of selection 
When analyzing the results for the Fab-on-phage ELISA for the λ library amplified phages 
there was a dose response towards the anti-Fab and the anti-LC Abs, indicating correct display of the 
Fab’s and respective LC. In regards to BSA reactivity the results obtained show that there was a 
specific dose-responsive signal, which increased from round to round suggesting the enrichment of 
BSA-specific phages. Moreover the ELISA signals obtained for the highest concentrations tested were 
at least 3,5-fold over the background (Figure 3.13). 
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A  B  
 
C  
 
Figure 3.13 - Fab-on-Phage ELISA of amplified phage pools resultant from λ library selection against BSA. 
Values presented are a mean of the respective duplicates and have the background signal subtracted. A – 
1st round of selection. B – 2nd round of selection. C – 3rd round of selection. 
Considering the previous results, only the λ library was used to continue with our studies, and 
thus this was used to select against the other two antigens. 
3.2.1.2 BSA Selected Individual Clones Reactivity 
Since the κ library selected phage pool analysis showed that it was not reactive for BSA, only 
selected λ clones were further tested. 10 individual clones were randomly picked from the 3rd round 
output of the λ library selection and analyzed by Fab-on-phage ELISA. Similarly to before, Fab 
expression was also evaluated using Abs against Fab and λ LC. 
A  B  
Figure 3.14 - ELISA of λ library individual clones selected against BSA after 3 rounds of panning. Values 
presented are a mean of the respective duplicates and have the background signal subtracted. A – Fab-
on-Phage ELISA. B – sFab ELISA. 
0 
0,3 
0,6 
0,9 
1,2 
3,00E-04 3,00E-02 
O
D
 4
50
 n
m
 
Log(Phage Dilution) 
λ Library - Round 1 BSA-selected 
phage pool 
Anti-Fab Ab Anti-λ LC Ab BSA 
0 
0,3 
0,6 
0,9 
1,2 
3,00E-04 3,00E-02 
O
D
 4
50
 n
m
 
Log(Phage Dilution) 
λ Library - Round 2 BSA-selected 
phage pool 
Anti-Fab Ab Anti-λ LC Ab BSA 
0 
0,3 
0,6 
0,9 
1,2 
3,00E-04 3,00E-02 
O
D
 4
50
 n
m
 
Log(Phage Dilution) 
λ Library - Round 3 BSA-selected 
phage pool 
Anti-Fab Ab Anti-λ LC Ab BSA 
0 
1 
2 
3 
1 2 3 4 5 6 7 8 9 10 
O
D
 4
50
 n
m
 
Clone 
BSA-selected Fab-phage clones 
Anti-Fab Ab Anti-λ LC Ab BSA 
0 
0,5 
1 
1,5 
2 
1 4 5 6 10 
O
D
 4
50
 n
m
 
Clone 
BSA-selected sFab clones 
Anti-Fab Ab Anti-λ LC Ab BSA 
	   52	  
5 out of 10 (50%) of the BSA tested clones (B1, B4, B5, B6 and B10) were considered positive in both 
Fab-on-phage and sFab ELISAs, since the ELISA signals obtained for BSA reactivity were about 40-
fold higher than the background for the Fab-on-phage assay, and over 20-fold higher than the 
background for the sFab assay (Figure 3.14).	  
3.2.1.3 BSA Positive Clones Characterization 
The clones that gave a positive signal upon Fab-on-Phage and sFab ELISA analysis were 
further characterized. This was done by an initial PCR amplification of the Fab insert to confirm the 
size and by a SacI/SpeI digestion of the extracted phagemid DNA. It was expected that the PCR 
products presented a band of ≈1500 bp, however by observing the DNA agarose gel (Figure 3.15) it 
can be seen that the bands of the amplified products have a higher molecular weight of ≈1800-1900 
bp. Moreover, B10 clone amplification was less efficient than the remaining, resulting in a faint band 
as seen on the gel. In regards to the phagemid digest, the pattern obtained showed that the digestion 
products were smaller than expected (about 1400 bp instead of 1500 bps), so apparently the clones 
selected and analyzed might not have the correct Fab sequence. 
 
Figure 3.15 - BSA-reactive clones genetic characterization. Lanes: M – Gene ruler 1 kb; a – Undigested 
phagemid DNA; b – PCR amplification of the Fab insert from phagemid DNA; c – Phagemid DNA digestion 
with SacI/SpeI. 
In order to better understand the previously described results, phagemid DNA from the 5 
clones was sent to both Stab Vida and GATC for sequencing. However, after several attempts, the 
results were not satisfactory since the data delivered always presented a very short sequence or none 
at all. To try and overcome this issue sequencing was also tried with the Fab insert amplification 
products, but this also failed. Thus no clear conclusion could be drawn in regards to the BSA clones 
that were identified by both Fab-on-phage and sFab ELISAs. In the future, a more thorough analysis 
must be carried out to allow clarifying the obtained results. 
3.2.2 HER2 
λ library selection was carried out using 15 µg/mL of the HER2 (Fc tagged) antigen molecule. 
An extra depletion step was performed with a human IgG1-coated well, after the plastic binders 
depletion, to eliminate any Fc binders. Input and output phage titers, the percentage of input recovery 
and enrichment values are indicated in Table 3.9. 
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Table 3.9 - HER2 panning 
Target Panning Round Phage input (cfu) Phage output (cfu) % of input phage recovery (x10-4) Enrichment* 
HER2 
1 3,77x1011 4,82x105 1,28 --- 
2 2,66x1011 6,63x103 0,02 0,02x 
3 1,37x1011 1,24x106 9,06 364,46x 
*-fold increase in recovered phage, compared to the previous round of panning 
Input phage value was stable between rounds, in the 1011 range. Considering that two 
depletions were performed before selection, the number of phages that were effectively selected is in 
accordance to the number of phages theoretically added in the 1st round (1x1012).  
The 1st round, output titration value was 4,82x105 phages, decreasing to 6,63x103 in the 2nd 
round, and increasing to 1,24x106 in the 3rd, which can be translated in a significant enrichment. 
3.2.2.1 HER2 Selected Phage Pools Reactivity 
For the HER2 target, polyclonal ELISA analysis was performed for the 2nd and 3rd rounds 
using the amplified phage pools. Due to the fact that the HER2 molecule used for this panning 
presented an Fc fusion, the specificity for this moiety of the target was also assessed. Results are 
shown in Figure 3.16. 
A  B  
 
C  
 
Figure 3.16 - Fab-on-Phage ELISA of amplified phage pools resultant from λ library selection against 
HER2. Values presented are a mean of the respective duplicates and have the background signal 
subtracted. Exception is the values for assay 2 for the 2nd round of selection, in which the background 
signal was not assessed. A – 2nd round of selection, assay 1. B – 2nd round of selection, assay 2. C – 3rd 
round of selection. 
HER2 selected phages’ assays demonstrated that there was a dose response signal for 
HER2 reactivity in the 2nd and 3rd rounds and the values obtained for the highest concentrations tested 
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were at least 4-fold over the background. In the 3rd round there is an abnormal result for the highest 
concentration of phages, but since all the dilutions follow the same dose response tendency we will 
disregard this value for further discussion. Fab display signal was dose responsive in the 2nd round for 
the lowest dilutions, but then it stabilized. For the 3rd round, the Fab display signal was not as 
expected; typically, the signal increased along with the phage concentration, but when analyzing the 
last three values the data shows a contrary behavior. For clarification of this matter another 
experiment will have to be performed. Nevertheless, the signal values obtained were at least 2-fold 
over the background and therefore are indicative of Fab presence. In all cases, no signal was obtained 
for Fc reactivity, as expected.	  
3.2.2.2 HER2 Selected Individual Clones Reactivity 
20 individual clones were randomly picked from the 3rd round output of the λ library selection 
and analyzed by Fab-on-phage ELISA. 4 out of 20 (20%) HER2 tested clones (H3, H9, H19 and H20) 
were considered positive in both Fab-on-phage and sFab ELISA (Figure 3.17) by showing strong 
signals for Fab display and HER2 reactivity, and also no signal for Fc affinity. Signal for HER2 
reactivity was over 20-fold higher than the background for the Fab-on-phage assay, and over 17-fold 
higher than the background for the sFab assay. Fc affinity was not screened in sFab ELISA because 
the detection Ab used is specific for IgG Fab and this would detect the IgG1 utilized as Fc target; 
nevertheless, since the result was negative in the Fab-on-phage format the same would be expected 
and thus extrapolated for the sFab format. 
A  B  
Figure 3.17 - ELISA of λ library individual clones selected against HER2 after 3 rounds of panning. Values 
presented are a mean of the respective duplicates and have the background signal subtracted. A – Fab-
on-Phage ELISA. B – sFab ELISA. 
3.2.2.3 HER2 Positive Clones Characterization 
The positive hits for HER2 identified in both the Fab-on-phage and sFab ELISA were further 
analyzed. As such, a PCR reaction was pursued for HER2 positive clones from extracted phagemid 
DNA to determine the size of the Fab insert. Clones DNA PCR had variable yields and as one can 
observe in Figure 3.18 H20 clone amplification was the most efficient, while H9 clone apparently did 
not work at all. The PCR products’ bands were larger than expected, with ≈1700-1800 bp instead of 
the 1500 bp determined for the Fab insert. Clones’ phagemid DNA was also analyzed by SacI/SpeI 
digestion. By observing the gel it was visible that instead of the two bands of ≈3500 bp and 1500 bp 
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for pCOMB3XSS and Fab insert, the digestion products of the clones presented two bands with 
different molecular weights, ≈4500 bp for the vector moiety and 1300 bp-1400 bp for the insert. Thus it 
is clear that there was an error in the construction of these selected clones, and no correct Fab 
sequence is present. 
  
Figure 3.18 - HER2-reactive clones genetic characterization. Lanes: M – Gene ruler 1 kb; a – Undigested 
phagemid DNA; b – PCR amplification of the Fab insert from phagemid DNA; c – Phagemid DNA digestion 
with SacI/SpeI. 
DNA of the 4 clones was sent for sequencing to obtain more specific and clarifying data. 
Similarly to what happened to the BSA clones, despite the several attempts, HER2 clones sequencing 
was not possible with the phagemids DNA neither with the Fab insert amplification products. Very 
small or no sequences at all were obtained, and according to the companies’ these issues could be 
linked to low amount and purity of the samples. Thus for a new assessment, new DNA extraction 
would have to be carried out. 
3.2.3 DLL1 
The λ library panning strategy was carried out using 15 µg/mL of the DLL1 antigen molecule in 
all rounds. Input and output phage titers, the percentage of input recovery and enrichment values are 
indicated in in Table 3.10. 
Table 3.10 - DLL1 panning. 
Target Panning Round Phage input (cfu) Phage output (cfu) % of input phage recovery (x10-4) Enrichment* 
DLL1 
1 5,17x1011 1,01x106 1,96 --- 
2 3,10x1011 1,43x104 0,05 0,02x 
3 2,93x1011 2,62x106 8,97 194,90x 
*-fold increase in recovered phage, compared to the previous round of panning 
Input phage titration results obtained were in the 1011 range for the three rounds, values that 
are the vicinity of the number of phages used in the 1st round, and the slight decrease is probably due 
to the initial depletion of the plastic binders. 
The output titration decreased from 1,01x106 phages to 1,43x104 from the 1st to the 2nd round, 
and the results obtained were in the usual expected range. In the 3rd round, the titration of the output 
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phages gave the value of 2,62x106, superior to the one obtained in the 2nd round, indicating that there 
was a significant enrichment from one round to another.  
3.2.3.1 DLL1 Selected Phage Pools Reactivity 
Polyclonal ELISA analysis was performed for the 2nd and 3rd rounds of the selection against 
DLL1 using the amplified phage pools. The results demonstrated that there was signal for both Fab 
display and DLL1 reactivity with 2nd round phages (Figure 3.19 A). Dose response was observed, 
especially for DLL1 affinity, for which the values obtained for the highest concentrations tested were at 
least 5,5-fold over the background. However, the same was not verified with 3rd round phages. 
Although Fab presence and DLL1 reactivity were apparent, no dose response pattern could be 
detected, thus the assay was repeated with more dilutions. The results obtained were similar (Figure 
3.19 B), which suggests that the unexpected behavior might not have derived from an error in the 
assay itself but could come from a problem with the amplification process. For further assessment a 
new amplification of the 3rd round phages would be recommended.  
A  B  
Figure 3.19 - Fab-on-Phage ELISA of amplified phage pools resultant from λ library selection against 
DLL1. Values presented are a mean of the respective duplicates and have the background signal 
subtracted. A – 2nd round of selection. B – 3rd round of selection, assay repetition. 
   3.2.3.2 DLL1 Selected Individual Clones Reactivity 
Although the results of the 3rd round amplified phage pools tests were not ideal, they still 
suggested reactivity for DLL1, so 20 individual clones were randomly picked from the 3rd round output 
and analyzed by Fab-on-phage ELISA. The results analysis was not straightforward, since none of the 
tested clones presented a strong signal for Fab display and DLL1 reactivity (Figure 3.20 A). Yet, the 3 
out of the 20 clones tested by Fab-on-phage ELISA that showed a higher signal (clones D2, D3 and 
D19) and thus stronger DLL1 reactivity (at least 2,3-fold over the background) were also tested in the 
sFab ELISA format. In a 1st sFab assay, D2 and D3 clones did not show a significant signal neither for 
Fab display nor for DLL1 reactivity. In the 2nd sFab assay, D2 and D3 clones were retested and the 
D19 clone tested for the first time; clones’ histidine reactivity was also assessed, once the DLL1 
protein used for selection was His-tagged. The clones showed inconsistent responses and very low 
signals were obtained towards DLL1 binding (Figure 3.20 B). Nevertheless, and due to the data 
obtained for these clones in the Fab-on-phage format further characterization was pursued to allow 
identifying possible DLL1 specific candidates. 
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A  B  
Figure 3.20 - ELISA of λ library individual clones selected against DLL1 after 3 rounds of panning. Values 
presented are a mean of the respective duplicates and have the background signal subtracted. Exception 
is the values for assay 2 for sFab clones 2 and 3, in which no duplicates were performed. A – Fab-on-
Phage ELISA. B – sFab ELISA; 2 - clone 2, assay 1. 3 - clone 3, assay 1. 2.2 - clone 2, assay 2. 3.2 - clone 
3, assay 2. 9 - clone 9, assay 2. 
3.2.3.3 DLL1 Clones Characterization 
A PCR reaction of the three clones that gave a positive hit in the Fab-on-phage ELISA was 
carried out. Subsequently, the Fab insert amplification of the DLL1 positive clones was analyzed on an 
agarose gel and the results are shown in Figure 3.21 A. For D2 and D19 clones both PCR products 
resulted in a band of ≈1500 bp as expected. Contrarily, the results obtained for the D3 clone PCR 
amplification showed that the reaction was not efficient. Simultaneously, phagemid DNA of all three 
clones was subjected to a SacI/SpeI digestion for restriction pattern analysis. By observing the gel 
both D2 and D19 presented the expected pattern of 1500 bp for the insert, and 3794 bp for the 
remaining moiety of the pCOMB3XSS vector. However, the D3 clone digestion products had totally 
unexpected sizes, but this was in total agreement with the results obtained for the undigested 
phagemid DNA run in an agarose gel. As such from this analysis clones D2 and D19 seemed to be in 
perfect condition to continue with further characterization. 
 
Figure 3.21 - DLL1-reactive clones genetic characterization. M – Gene ruler 1 kb; A – Lanes: a – 
Undigested phagemid DNA; b – PCR amplification of the Fab insert from phagemid DNA; c – Phagemid 
DNA digestion with SacI/SpeI enzymes. B - BstNI digestion of D2 and D19 clones 
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In order to verify if the two positive clones D2 and D9 had the same sequence an initial 
assessment was carried out by digestion of the PCR products with BstNI. The results are shown in 
Figure 3.21 B, and as can be seen the clones present a similar fingerprinting pattern. 
Phagemid DNA from all three clones had been initially extracted and sent for sequencing. The 
sequencing results obtained confirmed that D2 and D19 clones were identical. The sequence is shown 
in appendix section 6.3 As expected due to the results previously obtained for the D3 clone, this 
clone’s sequence was shorter and corresponded to the LC sequence alone.  
Clones’ V domain characterization, obtained from VBASE2 analysis tool, is indicated in Table 
3.11. D2/D19 LC gene belongs to the IGLV4 V-gene family and the HC to the IGHV3 V-gene family. 
LC CDR3 comprises 9 amino acid resides and HC CDR3 15, a medium size considering the lengths 
distribution obtained for the λ library. 
Table 3.11 - DLL1 clones’ V domain characterization 
 
Clone 
D2/D19 D3 
VL 
V-gene family IGLV4 IGLV8 
V-gene IGLV4-69*01 IGLV8-61*01 
CDR1 SGHKNFA CSVSTNNY 
CDR2 LDSEGSH NTN 
CDR3 QTWATDGVS VLYIHVGIWV 
VH 
V-gene family IGHV3 --- 
V-gene IGHV3-33*01 --- 
CDR1 GFTFSSYG --- 
CDR2 IWYDGSNK --- 
CDR3 ARDANSWYSGNYFDH --- 
After the genetic characterization of both D2 and D19 clones, a further analysis was pursued 
to verify the expression levels of the Fab’s. As such, the same samples of D2 and D19 that were 
tested for sFab expression in the ELISA format, were analyzed by SDS-PAGE under reducing 
conditions. Their expression was assessed by Western Blot using an anti-Fab specific Ab. The results 
show that a band of ≈25 kDa was detected for both clones, correspondent to the LC and the Fd 
fragment in monomeric form (Figure 3.22). 
 
Figure 3.22 - DLL1-reactive clones’ sFab expression analysis. sFab’s were run on SDS-PAGE under 
reducing conditions and Western Blot detection was performed with an anti-Fab Ab.  
 A significant difference between the intensity of the bands of the two clones was however 
noticed. Since these clones are identical it would be expected to obtain bands with an identical 
intensity for both clones, once no variation should be detected in the expression yield. However, the 
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sample used for Western Blot was the same in terms of volume and not in terms of cell OD and this 
could support the difference reported. However, for a more clear assessment of the expression of 
each clone should be carried out in optimized conditions.  
3.3 Antigens Titration 
 Antigens titration was performed to evaluate the panning targets quality. Duplicate samples 
gave identical results. As shown on Figure 3.23, BSA and HER2 titration had a dose dependent 
signal, suggesting these proteins are in good conditions and responding properly to the doses 
assayed. In the case of DLL1, the detection was performed with an anti-DLL1 Ab and an anti-His Ab 
because this protein was His-tagged. The ELISA signals obtained for the detection with the anti-His 
Ab were very low, but a small dose response effect was revealed in the higher concentrations of DLL1 
tested. However, detection with the anti-DLL1 Ab had no significant signal, and this can be due to the 
fact that the antigen used in the panning does not comprise the whole extra-cellular domain of the 
protein (see discussion).  
 
Figure 3.23 - ELISA analysis of the antigens used for panning. Values presented are a mean of the 
respective duplicates and have the background signal subtracted. 
The difference in the ELISA signals obtained can also be due to the fact that all the antigens 
were tested simultaneously in the same plate. Although the proteins concentration was the same their 
detection was carried out with different specific Abs, and as such the best time for development of 
each reaction might not be the same for all. For a better assessment the titration of each antigen 
should be optimized. 
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4. Discussion 
The undeniable burden and impact of breast cancer in today’s world emphasize the need of 
persistent research in this area, including the exploration of novel therapy alternatives. Targeted 
therapy has an increasing importance given the present recognition of breast cancer molecular 
heterogeneity as a restraint to find a single or very limited number of broadly effective therapy 
strategies. Abs are one key component of molecularly targeted therapy and there are currently 3 FDA- 
and EMA-approved mAbs directed to breast cancer treatment, all regarding HER2-positive tumors 
(Landes Bioscience, 2014). 
Phage display technology plays an important role in the generation and identification of highly 
specific human mAbs (Hoogenboom et al., 1998), and it has also revealed appealing for breast cancer 
research. Among the explored applications for this technology in the area are the identification of new 
targets (Minenkova et al., 2003), epitope mapping (Gabrielli et al., 2013), identification of peptides with 
affinity for breast cancer cells (Feng et al., 2014; Fu et al., 2014; Lu et al., 2013) and related targets 
(Dai et al., 2014) for therapeutic and diagnostic purposes, as well as Abs with therapeutic potential 
(Schier et al., 1995).  
Some investigators have constructed phage display libraries specifically for this end. Pavoni et 
al (2007) constructed several scFv libraries from breast cancer patients’ biologic material, namely 
three deriving from tumor-infiltrated B lymphocytes of different individual donors, one with the same 
type of cells but from four different donors and one library from the peripheral blood lymphocytes of 
one donor, and selected them against known tumor antigens. Ayat et al (2013) generated two scFv 
libraries from lymph nodes of breast cancer patients that expressed HER2 and CEA antigens in their 
tumors, and selected them against these same antigens. Rothe et al (2004) also constructed a scFv 
library from lymph nodes of three breast cancer patients, but this was intended for the isolation Ab 
fragments that recognize potentially new antigens for this disease. 
4.1 Libraries Construction and Characterization 
Although the examples from the literature described above mention mostly scFv libraries, in 
this work, two immune phage display Fab libraries (κ and λ) were created in order to obtain a tool for 
the development of new therapeutic Abs for breast cancer. Unlike scFv’s, Fab’s are well known 
fragments that do not tend to multimerize, which facilitates Ab selection and characterization, and 
allows the isolation of high affinity clones. Furthermore, Fab conversion into whole Ab molecules has a 
less significant impact in the initial molecule functionality (Burton, 2001). 
Regarding the proposed application, the Ab gene source chosen for the library repertoire 
construction was the peripheral blood B cells of 16 breast cancer patients. Evidence has been found 
that tumor cells elicit a humoral immune response in patients (Pavoni et al., 2006; Pavoni et al., 2007); 
consequently, breast cancer donors are expected to provide genetic information of highly specific Abs 
against breast tumor-related proteins for the library construction. On the other hand, considering each 
individual response peculiarities, breast cancer heterogeneity and molecular variability, using a 
relatively high number of donors is expected to increase the Ab repertoire variability in terms of 
different Abs for a single antigen, as well as Abs for a considerable amount of different antigens.  
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Besides the number of donors, other strategies were used to enhance the constructed 
repertoire’s variability. For HC Fd and LC fragments construction, multiple segments were first 
separately amplified, with several primer combinations, and then subsequently randomly merged. The 
use of several primer combinations intended to preserve the original repertoires diversity by allowing 
the access to as many different V-gene segments available from the recovered cDNA as possible 
(Burton, 2001; Hammers and Stanley, 2014; Tohidkia et al., 2012). On the other hand, the random 
assembly of segments by overlap PCR, as well as LC and HC Fd random combination by sequential 
cloning, should significantly contribute to diversity maximization. 
The libraries final characteristics and application success will not only depend on its design 
but also on the techniques and the outcome of each step of the construction (Shahsavarian et al., 
2014; Tohidkia et al., 2012), which starts with the donors’ biologic material recovery and RNA 
preparation. RNA isolation yield varied considerably between samples. However, common side-effects 
of cancer treatment, including several chemotherapy drugs, radiotherapy and even some targeted 
therapies are neutropenia and lymphopenia (Breastcancer.org, 2014b; van der Most, 2009). The only 
information gathered about the donors was their age and sex, therefore it was not known if some were 
suffering from this type of side-effects. Nevertheless, it is possible that the patients presented 
considerably variable numbers of mononuclear blood cells, from which RNA was isolated, resulting in 
RNA yield fluctuation. RNA purity of the samples was also assessed through A260/A280 ratio 
spectrophotometry measurement, which is generally expected to be close to 2,0. The results we 
obtained presented values in the range 1.3-1.94. However, the value A260/A280=2 is standardized for 
RNA eluted in TE buffer (pH 8.0), while the samples we prepared were eluted in nuclease-free water, 
which may have a lower pH. It has been shown that even small changes in the pH of the solution may 
cause the ratio to vary, more specifically, acidic solutions will under-represent it by 0,2-0,3 (Biomedical 
Genomics, 2007; Thermo Fisher Scientific, Inc, 2008) and thus this could explain the slight difference 
obtained. Furthermore, RNA treatment with DNase TURBOTM DNA-free Kit (Ambion®) may slightly 
decrease the ratio when the RNA concentration is lower than 25 ng/µL (Life Technologies 
Corporation, 2012). Indeed, the samples that presented lower ratios were those that were quantified 
below 25 ng/µL, whose measurement might have been cumulatively decreased by these two reasons. 
The remaining samples all had ratios above 1,77, hence it was considered that purity levels were 
acceptable for all cases. Isolated RNA integrity was preserved, as indicated by the presence of 18S 
and 28S ribosomal RNA species in agarose gel electrophoresis, with the last one being more intense, 
as expected. 
In order to have the same contribution from each donor to the library, the same quantity of 
each sample’s RNA was used to form the pool from which the repertoires were constructed. Although 
the RNA quantity contained in the pool was known, the quantity of Ig mRNA it contained and to which 
the specific primers used for cDNA synthesis could anneal was not. Consequently, the produced 
cDNA quantity, which also depended on the reverse transcription reaction efficiency, was not known 
either. This was used as template in the first step of amplification of each gene repertoire. As a 
different specific cDNA was produced for HC Fd fragment, κ LC and λ LC construction, the template 
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quantities in this step might have been different for each repertoire, influencing the final yield of the 
reactions. 
During the HC Fd and LC fragments construction process, some PCRs rendered lower 
amounts of products. In these cases, attempts were made to optimize the reactions in order to 
improve their yields, however with limited success. Nevertheless, variation in the amount of PCR 
products is not unexpected, once the reactions’ results depend on the efficiency intrinsic to each 
primer combination, and the amount of template matching to that primer combination available from 
the pool (as explained before) (Hogrefe and Shopes, 1994). Furthermore, V-gene length variations 
(especially in the HC CDR3) cause the gel electrophoresis bands too look broader than those formed 
by typical uniform amplification products. Indeed, sharp bands instead of broad bands could be an 
indication that the complexity of the amplified Ab repertoire is not very high (Welschof et al., 2003). 
The Ab fragments amplification and assembly resulted in the construction of three DNA 
repertoires: HC Fd, κ LC and λ LC. Fab libraries were constructed by cloning these repertoires into 
pCOMB3XSS, a phagemid vector appropriated for Fab phage display. This vector also facilitates 
downstream analysis of selected clones, once it allows the expression of sFab’s that carry tags for 
purification (His6-tag) and detection (HA-tag).  
Inserts restriction enzyme digestion efficiency is critical for the library final size and diversity, 
once undigested fragments cannot be ligated to the vector and therefore will not be integrated in the 
library (Shahsavarian et al., 2014; Tohidkia et al., 2012). Inappropriate digestion will reflect in the 
number of ligation-transformed bacteria, so small scale trials are not only useful to assess the best 
vector:insert molar ratio for ligation and the vector self-ligation background levels, but also to check if 
the inserts were appropriately digested. Therefore, although several transformations can be performed 
to increase the library size, the transformation efficiency should be higher than 1x107 transformants/µg 
DNA (Clark, 2002; Marks and Bradbury, 2004b). Transformation efficiency must always be evaluated 
taking into account the competent cells own transformation efficiency, to allow determining if the 
possibility of obtaining poor results is not caused by low cell competency, but instead due to problems 
with DNA digestion, dephosphorylation, and/or ligation. For this purpose, a transformation control, like 
a pUC plasmid, for example, pUC19, is usually used, and in this test the transformation efficiency in 
highly competent cells is expected to be higher than 1x109 (Marks and Bradbury, 2004b), to exclude 
problems concerning the transformation itself. By performing small scale trial ligations, it was possible 
to confirm that all of these conditions were regarded. Vector self-ligation levels, on the other hand, 
should be lower than 0,1% (Clark, 2002) to minimize the library portion constituted by phagemid not 
containing Fab genetic information. This condition was not strictly fulfilled for the Hc Fd fragments’ 
cloning into the vector already containing the LC. However, after a second and more careful gel 
purification and a longer dephosphorylation reaction of the digested LC-containing vectors, the self-
ligation background levels were only marginally higher than 0,1% and therefore considered 
acceptable. 
Immune libraries should comprise at least 1x107 transformants, which is less than what is 
required for naïve libraries (1x109) (Marks and Bradbury, 2004b), once these are more dependent on 
the size to provide high affinity and specific Abs (Bazan et al., 2012; Hoogenboom et al., 1998; 
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Hoogenboom, 2005). Small scale trials’ results also indicate how many transformations are 
approximately needed to construct a library of the desired size with each particular vector-insert 
combination. This is usually achieved by transforming all the ligation products available, and thus 
allowing all potential components in the DNA library to be present in the final phage repertoire (Kotlan 
and Glassy, 2009). This strategy was followed and the sizes of the newly generated libraries was in 
the 108 range. Other reports have shown similar values for immune library sizes: for example, the 
libraries constructed by Pavoni et al (2007) sizes ranged from 4,7x105 to 2,6x107 clones, Rothe et al 
(2004) obtained a repertoire of 5x108 clones, and human Fab libraries generated from patients with 
other malignancies have been reported, comprising 1,3x106 to 1,45x108 transformants (Clark et al., 
1997; Coomber et al., 1999; Coomber and Ward, 2001; Dantas-Barbosa et al., 2005). As such, we 
can conclude that the sizes of the two newly immune libraries constructed in this work are standard 
comparing to other human immune libraries derived from cancer patients material. Also, comparing to 
immune libraries in general, and according to Frenzel et al (2014), the size of our κ and λ immune 
libraries are in the acceptable range, since the author indicates that these types of libraries usually 
comprise sizes between 106-108 independent clones. 
 After the construction an initial validation step was followed, and the libraries were 
characterized by assessing the percentage of clones that were estimated to contain a correctly 
constructed Fab fragment. Besides the input of possible self-ligated vectors (containing no Fab 
inserts), incorrectly constructed vectors may also contribute significantly to the undesired library 
components. This occurs mainly because smaller phagemids (for example, due to deletions or cloning 
errors) are preferentially transformed and later packaged into the phage coat (Scott, 2001). A small 
but significant sample of each library (100 clones) was analyzed regarding the number of correctly 
constructed Fab fragments. Our results indicated that the κ library contained 51% correct clones, while 
the λ library presented 52%. Other authors have reported variable results, like 40% (Wu et al., 2010), 
90% (Rothe et al., 2004) or 100% (Dantas-Barbosa et al., 2005). Although some of these numbers 
appear substantially higher than those obtained in this work, it is important to emphasize that the study 
from Rothe et al (2004) does not indicate the number of clones tested. Moreover, Dantas-Barbosa et 
al (2005) only analyzed a very small sample of 10 clones for Fab presence, which is scarcely 
representative, and thus the value reported could be easily altered with a higher number of clones 
tested. The same is verified for diversity, as in both cases, these authors obtained 100% of diversity 
by DNA fingerprinting of only 10 clones. In this work, BstNI fingerprinting analysis was performed to 
more than 40 clones of each library, and the data obtained suggested that over 85% of the clones 
were different, which means the libraries are highly diverse. Diversity was further analyzed by 
sequencing, which is the ultimate test and provides additional information such as the inserts 
identification (and thus presence confirmation) and allows determining if they are full-length and free of 
cloning errors (mutations, deletions, frameshifts, among others). The high diversity of the generated 
libraries was not only confirmed by the sequencing results but also reinforced (>91% of different 
clones), once it was verified that some of the clones whose fingerprinting pattern was identical actually 
presented different sequences. This supports the fact that, comparing to libraries of less restricted 
diversity (like naïve), fingerprinting analysis is less sensitive when performed in immune repertoires, 
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whose diversity (partially enhanced by affinity maturation) might not be translated in gain and loss of 
restriction sites (Bradbury and Marks, 2004). 
The correctly sequenced clones were further analyzed recurring to VBASE2 software (Retter 
et al., 2005) that allows sequence analysis, providing information about the prevalence of possible 
errors, the position and sequence of key features (like the FRs and CDRs) and the V-genes source. 
Analyzed clones were related to most of the human V-gene families and a significant number of 
correspondent V genes. However, it is not known if the detected distribution was representative of the 
original repertoire, once it was derived from various individual repertoires of donors that should be 
biased by each unique immune history, besides the common factor of having breast cancer. 
The CDR3 regions of both the HC and LC were also analyzed as an indicator of diversity, 
given its importance to Ab variability, specificity and antigen binding. Of all the CDRs, CDR3 is the 
most diverse, particularly that of VH region which also contributes the most to antigen binding, since 
CDR3 residues are responsible for most of the surface contact area and molecular interaction with the 
antigen (Goldsby et al., 2003; Murphy, 2012). Clones’ CDR3 analysis results were in accordance to 
these facts, once sequences were highly variable and HC CDR3 length distribution (9 to 22 amino 
acid residues) was clearly wider than that of LC CDR3 (9 to 13 amino acid residues). Human immune 
libraries described by other authors present similar distributions. Unselected clones from a Fab 
immune library constructed from the repertoires of ten donors vaccinated against rabies presented HC 
CDR3 with lengths from 6 to 18 amino acid residues (Houimel, 2014). Sblattero and Bradbury (1999) 
reported a scFv non-immune library with CDR3 lengths ranging from 7 to 22 amino acid residues for 
the HC and 8 to 11 for the LC. Another scFv non-immune library presented a HC CDR3 length 
distribution from 5 to 18 amino acid residues (Sheets et al., 1998). 
 Besides the importance of library size and diversity, genetic characterization may not reflect 
the functionality (Carmen and Jermutus, 2002). A clone that contains a complete and in-frame Fab 
sequence may not result in the production of a functional protein if the expression system is not 
compatible, for example due to protein interference with the phage assembly, cell toxicity or folding 
machinery limitations (Carmen and Jermutus, 2002; Hammers and Stanley, 2014). The own 
characteristics of the phagemid system results in a high frequency of monovalent display, so the vast 
majority of phage will display only one copy of the Fab, or even none (Carmen and Jermutus, 2002). 
This is an advantage if the purpose is to select for high affinity binders (Ahmad et al., 2012), but an 
efficient phagemid rescue is needed to keep the display levels high enough so that the library’s 
functionality is not lost and its potential is still represented (Tohidkia et al., 2012). 
 After libraries rescue, phages were shown to be present in high quantities (even exceeding 
the ELISA sensitivity limit in the conditions tested), and their display was as expected since there was 
expression of Fab’s in a dose dependent manner. When comparing the two immune libraries 
generated, the κ library appeared to have slightly higher Fab expression levels. Although a 
pronounced difference between the signals obtained with the anti-LC Abs was verified, it has to be 
taken into account that two different Abs (for each library LC specificity) were used, and their intrinsic 
characteristics may influence the displayed Fab’s detection results. Altogether, these results indicated 
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that the rescue protocols followed were successful and phage libraries aliquots were prepared to be 
subsequently used for panning. 
4.2 Libraries Selection 
Selection of Abs or other peptides and proteins with specific binding affinities from millions of 
variants is the whole purpose of phage display technology (Ahmad et al., 2012). Therefore, a phage 
display library is only fully validated after testing its performance in phage panning selections (Carmen 
and Jermutus, 2002). In the present study, selection was performed using three different targets. For 
general performance validation, libraries were tested against BSA, a foreign, stable, and highly 
immunogenic protein (Hayworth, 2014). Secondly, HER2, a well-established breast cancer biomarker 
and Ab therapeutic target, was chosen for the library concept validation. The last selection target was 
DLL1, given its involvement in the Notch signaling pathway, and due to the fact that the aim of this 
dissertation is to generate function-blocking Abs against a ligand of the Notch1 receptor. 
In a 1st round of panning, a direct library sample, with a determined number of phages (1012 in 
our case) is used. In this initial step all the clones present in the library are first subjected to a 
depletion step (if available), and the remaining phages are carried over to the selection with the 
specific antigen. In the subsequent rounds the input phage sample will not present the initial variability 
of the library, but will be composed of phages that were recovered from the previous round, and that 
are more specific towards the target. Therefore, it is crucial that the initial sample represents the full 
library diversity and that each different clone is present with sufficient frequency (Kotlan and Glassy, 
2009). As the vast majority of phage is monovalent and a significant number may not be displaying at 
all, large populations of phage, much greater than the library size, are required for an efficient 
representation of the library diversity (Carmen and Jermutus, 2002); indeed, Kotlan and Glassy (2009) 
recommend the addition of sufficient phages to ensure at least 1000-fold representation. However, 
there are limitations considering the practical number of phages that can be used in selection, namely 
1x1013 phages in 1 mL (Sblattero and Bradbury, 2000). Usually, if there is enough antigen available for 
panning, the selection steps are carried out in a final standard volume of 1 mL. However, in the current 
strategies we were faced with scarcity of antigen, and thus we down-scaled the three panning 
procedures. As such the selection strategies were carried out in 96-well Maxisorp plates in a final 
volume of 0,1 mL or 0,05 mL, depending on the antigen used.  
Although it is always defended by several authors that a highly diverse library must be used 
for panning, this may imply that there are relatively few copies of each individual displayed Ab (Marks 
and Bradbury, 2004a). As such, other strategies can be pursued to overcome this, in our case the 
phages were selected twice for the same antigen in the 1st round, in order to increase the chances of 
interaction between specific binders and the target. 
The number of phages that will be recovered from the 1st round will depend on the quantity of 
clones that bind to the antigen and on the stringency applied (Kotlan and Glassy, 2009; Marks and 
Bradbury, 2004a). 1st round results of the performed selections were typical (between 104–106 
recovered phage particles, which is expected to be between 104–107 according to Marks and Bradbury 
(2004a). While the output phage titers and percentage of input recovery should increase between 
rounds of selection, indicating selection is occurring and leading to phage enrichment for the specific 
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target (Marks and Bradbury, 2004a), in some cases it is also typical that the output phage titers are 
lower in the 2nd round (Rader, 2012). This is because stringency is usually increased at this stage to 
favor the removal of low affinity and nonspecific bound Abs. After the 1st round of selection, phage 
diversity should have considerably diminished and at the same time the number of each individual 
clone should be far higher due to amplification of the recovered subset. Therefore, it is safe and 
productive to increase the stringency, so that the output will comprise a higher proportion of positive 
phages (Marks and Bradbury, 2004a). In this work, stringency was increased by doubling the number 
of washing steps from 5 in the 1st round to 10 in the following. Consequently, it was observed that 2nd 
round output phage titers were lower than 1st rounds’.  
4.2.1 BSA 
BSA panning was the first to be performed, and for this strategy we chose to use 1x1012 
phages in 0,1 mL in the 1st round of selection. However, using this number of phages implied that 
there was an unequal representation of the two libraries, considering their different size – 
approximately 590-fold representation of κ library (below recommended) versus 2180-fold of λ library. 
Furthermore, after real input calculation it was found that the λ library input value (1,27x1013 phages) 
was approximately 10-fold higher than κ library’s, contrarily to the intended, and therefore the 
representation difference between the two libraries was significantly increased. The unexpected λ 
library input value was possibly caused by a dilution error.  
Regarding the output titer for the λ library, this value increased approximately 190-fold from 
the 2nd to the 3rd round and a phage enrichment of over 190-fold was also observed, suggesting that 
the panning was successful. For the κ library selection, the 3rd round output values were acceptable 
(in the 105 range) but the values for the 2nd round were lower than usual (in the 102 range), which 
caused a difference of about 1000-fold between the two rounds and an enrichment value atypically 
high (over 17000-fold). Although, as referred, output values can decrease from the 1st to the 2nd round, 
in this case it was not inside the usual parameters, but considering that the 3rd round values were in 
the expected range, it was assumed an error might have occurred in the 2nd round output tittering. 
Therefore, percentage of recovery of the 2nd round and 3rd round enrichment value should not be 
considered. In order to clarify this value the titration of the output phages from the 2nd should be 
repeated. 
Selected phages from all rounds were tested to verify if target-specific Fab’s were being 
recovered for both libraries. The analysis of amplified BSA-selected phages from the κ library 
indicated that the selection failed, and although Fab presence was detected, it seemed to decrease 
from round to round and BSA reactivity was not shown in any case. Some phages might have been 
recovered in the 1st round, once the phage recovery was higher than that of λ library for the same 
round. However, there might have been loss of some clones in the elution step, if the TEA incubation 
time was not the ideal. While phages may not be recovered if this incubation is too short, they may be 
degraded if it takes too long (Charlton and Porter, 2002). Another hypothesis is that the phages 
recovered from 1st round were not specific for BSA, and the higher stringency in the following rounds 
led to their progressive loss. Any of these situations could explain the 2nd round unexpected output 
value and low phage recovery, initially thought to have been caused by a tittering error. Considering 
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the second hypothesis, a possible reason for the panning not having succeeded is the 
underrepresentation of the library diversity on the 1st round phage input. This means that better results 
could be achieved by starting the selection with a higher number of phages despite the practical 
recommendations above mentioned, or by applying a different strategy that would allow the use of 
higher volumes. On the other hand, the κ library itself may not be as functional as the λ; quality and 
characterization tests performed do not indicate that, once both libraries had similar diversity and Fab 
displaying results; the noticeable exception is that κ library, despite being bigger, may contain a higher 
percentage of Fab’s containing errors than λ.  
The ELISA analysis of λ library amplified phages pools results suggested that there was an 
enrichment of BSA-specific phages from the 1st to the 3rd round, as the pools reactivity for the target 
progressively increased, contrarily to the verified for κ library. Considering these results, individual 
clones selected from the λ library were tested for specificity. Clones that were considered positive in 
Fab-on-phage ELISA showed signals for Fab presence and BSA-reactivity far stronger than the 
remaining tested clones. Positive signals were maintained on sFab ELISA but in more modest levels, 
probably due to this test being dependent on the expression yield of the Fab fragments in soluble 
format, which might not be optimized. 
Further tests were performed to characterize the positive clones. Genetic studies aim to 
assess if binders with affinity for a certain target are different or not or if they share features that may 
determine their affinity for a certain target. Sequencing is the more reliable test, once it reveals the 
Fab’s coding information and therefore allows an absolute comparison between clones. However, 
before sequencing, BSA-selected clones were amplified by PCR and the results analysis by gel 
electrophoresis showed a band with a molecular weight 300 bp-400 bp higher than expected. 
Furthermore, SacI/SpeI digestion of the phagemid DNA also presented bands of unexpected lengths, 
once the vector moiety should have the same size as the correspondent fragment resulting from the 
digestion of pCOMB3XSS vector, which was used as a control, but was approximately 1 kb bigger 
instead. These unexpected results suggested that the phagemids were not correctly constructed, and 
due to the patterns obtained we could even suggest all clones were the same. This might have been 
caused by overrepresentation of an incorrectly constructed clone in the selection output, which may 
have superior growth kinetics, resulting in its dominance after several rounds of enrichment of an 
increasingly restricted population. Although performing additional rounds of selection should increase 
the number of positive clones, in this case it could enhance the dominance of the defective clone. 
Therefore, the panning should be repeated and other strategies tested in order to obtain diverse 
output populations from the beginning, when the loss of strong candidates is critical (Carmen and 
Jermutus, 2002). 
4.2.2 HER2 
Considering the results obtained for the κ library selection against BSA, only λ library was 
subjected to panning against HER2 and DLL1, due to limitations in time and resources. 
For HER2 and DLL1 pannings, 1x1012 of phages in a 0,05 mL volume were theoretically used 
in the 1st round. Due to limitations in terms of the target quantity available, it was decided to perform 
the pannings in a smaller volume than that of the BSA selection (0,1 mL). However, in order to keep 
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the library representation levels, the number of phages was not reduced. Although it implies that the 
recommendation in terms of phage concentration was not strictly fulfilled, the limit was not 
substantially surpassed, once 2x1013/mL were used instead of 1x1013/mL. 
In the HER2 selection, the output titer increased approximately 190-fold from the 2nd to the 3rd 
round, which translated in a phage enrichment of 364-fold, suggesting panning success. Subsequent 
analysis of the HER2-selected phage pools from the 2nd and 3rd round showed specific dose 
responsive HER2 reactivity. This suggested that target-specific Fab’s were recovered, although the 
Fab display results using the anti-Fab specific Ab were not typical in terms of dose-response. 3rd 
round HER2-selected clones were tested for specificity and, identically to what was verified for BSA, 
several clones were found positive both on Fab-on-phage and sFab ELISAs, showing stronger signals 
for Fab presence and HER2-reactivity in the first test.  
Moreover, gel electrophoresis analysis of HER2 clones PCR products showed no bands for 
H9 clone and a band of approximately 1700 bp for the remaining clones, instead of the expected 1500 
bp. SacI/SpeI digestion pattern was not the expected either. This suggested that, identically to what 
was verified for BSA, all HER2 positive clones tested presented construction errors. It is possible that 
this selection strategy might also favor defective clones, which compose about 50% of the libraries, 
corroborating the need of trying different panning approaches. For HER2 selection, 2nd round 
polyclonal ELISA showed results in a certain way better than the 3rd round’s. Therefore, testing clones 
from the 2nd round output could result in finding positive specimens with more interesting 
characteristics. Nevertheless, the 3rd round or the whole panning should be repeated, and other 
strategies tested, as referred. 
These preliminary conclusions about BSA and HER2 positive clones should be in any case 
confirmed by sequencing. Therefore, clones’ phagemid DNA was sent for sequencing, but the results 
were not satisfactory for both BSA- and HER2-clones. This DNA presented good values in terms of 
quantification and purity (1,78-1,86) when assessed by spectrophotometry, and when ran in an 
agarose gel electrophoresis, several bands correspondent to the phagemids in different conformations 
were observed as expected. Since these results suggested that there were no obvious problems with 
the DNA, the samples were sent for sequencing in a different company, but once more the results 
quality did not allow an analysis. In a third attempt, sequencing was tried using as template Fab insert 
amplification products, but it was not successful either. Despite the mentioned difficulties, more 
alternatives should be tried before giving it up, namely repeating the phagemids isolation and retrying 
the sequencing with the new DNA batches. Before sending the DNA to sequence, its concentration 
could be assessed by comparison of the intensity of the bands resulting from running it in an agarose 
gel with that of the bands of a DNA sample of known concentration, once some sequencing 
companies consider this method is more feasible than spectrophotometry quantification. 
4.2.3 DLL1 
The recent association between deregulation of Notch signaling and breast cancer (Joo et al., 
2013; Mittal et al., 2009; Reedijk et al., 2005; Rizzo et al., 2008; Sharma et al., 2012) has led to a 
great interest in unraveling the various mechanisms of this association (Izrailit and Reedijk, 2012; Joo 
et al., 2013; Sethi et al., 2011; Takebe et al., 2014), and exploring the potential of the pathway as a 
	   70	  
therapeutic target (Sharma et al., 2012; Simmons et al., 2012; Suman et al., 2013; Wang et al., 2011). 
As a result, different strategies are being developed to block Notch signaling for therapeutic purposes, 
and several Notch-targeting mAbs are currently in early phase clinical development (Takebe et al., 
2014). A great part of the research on this matter has been centered on the pathway’s receptors and 
the first steps in understanding the specific role of some ligands, like Jag1 and DLL4, have already 
been taken (Izrailit and Reedijk, 2012; Sethi et al., 2011). On the other hand, little is known about 
DLL1 ligand’s implication in the breast cancer malignancy condition, although evidence on its 
existence has been found. Several authors have studied patients’ samples in order to evaluate the 
presence of DLL1. Reedjik et al (2005) identified DLL1 mRNA expression in 9,1% of the analyzed 
human breast cancers cases, and Rizzo et al detected high DLL1 expression in 22,2% and 36,7% of 
ductal infiltrating carcinomas and lobular infiltrating carcinomas samples, respectively. Approximately 
81% of invasive ductal carcinoma cases examined by Mittal et al (2009) showed low to moderate 
expression of DLL1, while they failed to detect any significant expression in normal breast tissue. High 
expression of DLL1 was also found in 39,0% of cases analyzed by Yanai et al. (2010). The isolation of 
Abs against DLL1 ligand would constitute one more tool to study the relation between the Notch 
pathway and breast cancer by improving the knowledge underlying the mechanism of action, and 
evaluating the therapy target potential of a promising ligand that has been little explored to date. 
In this work a portion of the extracellular domain of the DLL1 protein (Trp 159 – Val 444, 
domains DSL to EGF-like 6) fused to a His8-tag on its N-terminal was used as a target for selection of 
Abs by phage display, using the newly generated λ library. In a parallel work, several DLL1 protein 
constructions were produced in several vectors, and small scale protein expression tests were carried 
out both in E. coli and mammalian cells in order to assess and optimize expression yields. The DLL1 
protein used for the panning was produced from HEK293-EBNA6 cells since this system presented 
slightly higher expression levels. This work was developed in the context of my colleague Margarida 
Silva Master Thesis and will soon be discussed elsewhere. 
DLL1 selection showed an output titer increase of approximately 190-fold from the 2nd to the 
3rd round, which translated in a phage enrichment of 195-fold, suggesting panning success. DLL1-
selected phage pool analysis results were inconclusive; while 2nd round outcome was satisfactory, the 
lack of dose response in the signal from 3rd round phages test was not. However, there was still 
evidence of DLL1 specific reactivity. Since the phage recovery and enrichment values calculated 
suggested that an efficient selection occurred in the 3rd round and the ELISA results did not excluded 
the presence of antigen-specific Abs, individual clones were tested for specificity to confirm the data. 
None of the clones tested against DLL1 clearly highlighted from the remaining, but 3 had stronger 
signals for DLL1 reactivity on Fab-on-phage ELISA (at least 2,3-fold over the background). Similarly to 
what was observed in BSA- and HER2-selected clones sFab test, DLL1-selected sFab signal was 
weaker than that of Fab-on-phage ELISA. Due to this decrease, DLL1-selected sFab clones signal 
was very weak and only slightly higher than background. Nevertheless, clones’ characterization tests 
were also performed for these clones, hoping to find a binder, which even with a present low affinity 
could be affinity maturated for improvement. Affinity maturation is frequently used to optimize Abs 
initially selected for a target by introducing random or directed mutations in the clones’ V-genes and 
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subsequently selecting the variants of higher affinity by a process similar to panning. This usually 
results in Ab fragments with affinities in the sub-nanomolar range (Hoogenboom et al., 1998; Schofield 
et al., 2014). 
The genetic analysis of DLL1-selected clones was more elucidatory than that performed for 
the clones obtained in the other selections, particularly because sequencing information was obtained. 
D2 and D19 clones were correctly constructed and shared the same sequence, which could have 
been predicted by the BstNI digest. However, these clones have not shown a very strong reactivity for 
DLL1, and Fab expression was also barely detected by ELISA and Western Blot. Although the Fab 
sequence does not contain errors, it is possible that this clone is expressed at low levels, for example 
due to sensitivity to bacterial proteases (Tohidkia et al., 2012), toxicity of the clone to the host cell or 
interference with phage assembly (Hammers and Stanley, 2014). Therefore, even if they have affinity 
for DLL1, they may not be present in quantity enough for being detected in the assays. On the other 
hand, D3 clone’s Fab insert was not correctly constructed, which was predicted, since the  pattern 
detected on agarose gel electrophoresis for the whole phagemid was discrepant from the expected 
(comparing to D2/D19 and pCOMB3XSS pattern, which is similar to that of correctly constructed 
clones). Also, the SacI/SpeI digestion products presented a different size too, indicating that there was 
no Fab fragment present in this clone but a deletion mutant that explains the smaller molecular weight. 
Sequencing was only obtained with the forward primer, and the results obtained agreed with the 
remaining tests by showing that the LC insert started on CDR1, so FR1 was absent. LC inserts were 
cloned by digestion with SacI and XbaI enzymes. Although the XbaI site was found, it was not 
followed by the expected sequence that exists between XbaI site and XhoI site and includes the pelB 
leader. On the other hand, 133 bp downstream of the XbaI site a different part of the pCOMB3XSS 
sequence was detected, so it is possible that part of the phagemid sequence was deleted, namely the 
portion that includes the HC insert and Rv primer site. Therefore, only the LC was being expressed 
and possibly had some affinity for DLL1. 
 
Antigens titration ELISA showed BSA and HER2 proteins were in good condition and 
therefore should not hamper the panning success. Conversely, DLL1 failed to be detected with a 
specific primary mAb. This mAb (Sino Biological Inc., Cat# 11635-MM07) was produced by hybridoma 
technology; B cells were obtained from a mouse immunized with recombinant human DLL1 
extracellular domain (Met 1-Gly 540). The protein used in this work, on the other hand, is only part of 
the extracellular domain (Trp 159 – Val 444), so it is possible that the mAb recognizes an epitope that 
is not represented in that specific DLL1 portion. The protein detection was also performed with a 
primary anti-His Ab and a slight, increasing signal was detected for the highest dilutions. Also, a single 
aliquot of protein was used for these procedures and it was always kept at 4ºC to avoid consecutive 
freezing and thawing cycles. As such, the current batch may have lost quality along time, thus 
explaining the inconsistency between the 2nd and 3rd round results. Protein instability is not surprising 
once this DLL1 is a highly complex protein with a particular pencil-shape conformation bearing 
innumerous pairs of disulfide bonds (Uniprot, 2014). This protein construction was produced in house 
and its expression and purification presented some challenges. Nevertheless, better results could be 
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achieved by repeating the 3rd round or the whole panning with another batch of DLL1 after testing the 
protein by ELISA (including detection with a Anti-his Ab to prevent false negatives), so that its quality 
is verified prior to panning.  
The chemistry of the antigen immobilization may also be responsible for the DLL1 protein not 
maintaining its native structure, since antigen is usually coated onto solid phase by passive 
adsorption, which may cause denaturation of the molecules. Proteins denatured forms may expose 
hydrophobic residues, causing a ‘sticky’ surface that in some cases can favor non-specific phage or 
antibody binding (Carmen and Jermutus, 2002). The density of immobilized antigen may also 
influence epitopes availability (Carmen and Jermutus, 2002), so the concentration used for coating 
with this target may not have been adequate. Performing pannings with various DLL1 target 
concentrations may be needed to find the ideal conditions.  
Although first panning results indicated it was proceeding successfully, isolation of Fab clones 
with characteristics of interest was not accomplished for any of the selections performed, once initial 
results indicate that the BSA and HER2 clones that showed signs of specific binding contain sequence 
errors and the DLL1 tested clones are expressed at low levels. Input recovery and phage enrichment 
values are not absolute indicators, once cases of successful selection with no change in output titer 
and failed selections with increases in titers have both been observed (Marks and Bradbury, 2004a). 
In any case, polyclonal ELISA tests also corroborated target-specific phages were being isolated and 
it is important to notice that only a small number of individual clones was tested for each selection, so 
it was not widely representative; thus, by testing a more numerically relevant sample, different positive 
clones could have been found. Altogether, it can be foreseen that by repeating the selections after 
optimization of the conditions, including the performance of preliminary tests to assess the optimal of 
input phage quantity and target concentration, more satisfactory results will be achieved and ultimately 
result in the isolation of Ab fragments of interest for further research.  
4.3 Conclusions 
In summary, the work reported herein resulted in the construction of two immune phage 
display Fab libraries (κ and λ) containing more than 108 independent clones and a diversity of over 
90%, characteristics equivalent to those of the immune libraries reported by other studies. The two 
first goals of this study were, therefore, achieved. Regarding the libraries validation and selection of 
specific Fab’s against the DLL1 protein, only preliminary results were obtained, so further effort will 
have to be put in this tasks in the future. Nevertheless, a tool for the isolation of Ab fragments specific 
for breast cancer-related targets was successfully created; given its countless applications, including 
the development of new therapeutic agents, it constitutes a positive contribution to research in this 
area. 
4.4 Future perspectives 
With the work developed in this thesis we were able to successfully generate two immune Ab 
human Fab libraries (κ and λ) with a high diversity. However, a bigger investment must be still carried 
out regarding the validation of both libraries upon panning selection. Due to the time available for the 
development of this study, a complete validation process was not carried out as thorough and as 
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successfully as initially planned. The preliminary data obtained with the BSA panning did not render 
the expected results, but we still decided to proceed simultaneously with the pannings using HER2 
and DLL1 antigens, hoping to enrich this dissertation.   
The next steps essential for the continuation of this work will be first to understand why the 
BSA and HER2 sequencing failed. For this task new DNA preparations could be carried out, or even 
the selection of more individual clones could be pursued. Obtaining the sequence for these clones will 
allow clarifying the questions that arose from the previous genetic tests.  
Besides that, the next critical step would be to repeat the libraries selection employing other 
panning strategies. Different concentrations of antigens, or even different antigens could be tested, 
and the selection procedure could also be altered for example to a selection with beads. 
Regarding the clone we obtained for the DLL1 panning the following work will be to further 
characterize it. Also, other clones can be picked and assessed for DLL1 binding, or even another 
selection can be carried out to increase the number of lead candidates. After isolating DLL1-specific 
Fab’s with the desired characteristics, these will be expressed in a relatively larger scale and purified 
in order to be further tested. Selected clones affinity will be measured using the Biacore or the Octet, 
and their performances compared to allow a ranking of the Fab’s. Ab-antigen interaction will also be 
characterized, in terms of determining the specific epitopes and unraveling Ab-antigen complexes tri-
dimensional structure. The Fab clones with the best characteristics will be reformated into the 
complete IgG molecules, and those will be subjected to identical studies so that possible behavior 
alterations can be identified. Potential therapeutic agent candidates will be screened for biological 
function in cell-based bioassays. 
Since this work is integrated in a broader project, in parallel to this work a Fab naïve library 
has also been constructed for the same purposes as the immune library reported herein. Therefore, 
the two libraries performance in selection and the Ab fragments isolated from both will be compared in 
order to investigate to what extent the type of library can influence the outcome of an Ab selection 
against tumor-specific targets. As one of the aims of the referred project is to characterize Notch1 
ligands and their interaction with specific Abs, the constructed immune library can also be selected 
against different constructs of the DLL1 protein and other ligands, like for example Jag1 or Jag2. 
Studies performed with these Abs will help to understand the mechanisms of interaction between the 
receptor and the ligands and would increase the possibilities of finding function-blocking Abs. 
Although immune libraries application is by principle somewhat limited, the design of the 
library reported here keeps a wide range of use possibilities, as it was not restrained to a single 
antigen but instead thought to be used against any breast cancer associated target, thus being a 
valuable tool for the research in this matter.  
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6. Appendix 
6.1 Primers 
Table 6.1  - Primers used for HC Fd and VLCL fragments construction and Fab insert amplification 
Region Name Sense Sequence Tails 
VH 
VH1 Fw Sense 5’CCAGCCTCGAGATGGCCCAGGTGCAGCTGGTGCAGTCTGG-3’ 
3’-XhoI         
VH2 Fw Sense 5’CCAGCCTCGAGATGGCCCAGGTCAACTTGAAGGAGTCTGG3’ 
VH3 Fw Sense 5’CCAGCCTCGAGATGGCCGAGGTGCAGCTGGTGGAGTCTGG 3’ 
VH4 Fw Sense 5’CCAGCCTCGAGATGGCCCAGGTGCAGCTGCAGGAGTCGGG 3’ 
VH5 Fw Sense 5’CCAGCCTCGAGATGGCCCAGGTGCAGCTGTTGCAGTCTGG-3’ 
VH6 Fw Sense 5’CCAGCCTCGAGATGGCCCAGGTACAGCTGCAGCAGTCAGG-3’ 
JH 1/2 Rv Anti-sense 5’CGATGGGCCCTTGGTGGAGGCTGAGGAGACGGTGACCAGGGTGCC3’ CH1 tail 
JH 3 Rv Anti-sense 5’CGATGGGCCCTTGGTGGAGGCTGAAGAGACGGTGACCATTGTCCC 3’ CH1 tail 
JH 4/5 Rv Anti-sense 5’CGATGGGCCCTTGGTGGAGGCTGAGGAGACGGTGACCAGGGTTCC3’ CH1 tail 
JH 6 Rv Anti-sense 5’CGATGGGCCCTTGGTGGAGGCTGAGGAGACGGTGACCGTGGTCCC3’ CH1 tail 
CH1 
IgG CH1 Rv Anti-sense 5’CGGCCCAGCCGGCCACTAGTGTCCACCTTGGTGCTGGGCTT3’ 5’-SfiI/SpeI 
CH1 Fw Sense 5’ GCCTCCACCAAGGGCCCATCGGTC3’  
VLκ 
VLκ1 Fw Sense 5’GGGCCCAGGCGGCCGAGCTCCAGATGACCCAGTCTCC 3’ 
5’-SfiI/SacI 
VLκ1 Fw Sense 5’GGGCCCAGGCGGCCGAGCTCGTGATGACTCAGTCTCC3’ 
VLκ3a Fw Sense 5’GGGCCCAGGCGGCCGAGCTCGTGATGACACAGTCTCC3′ 
VLκ3b Fw Sense 5’GGGCCCAGGCGGCCGAGCTCGTGATGACGCAGTCTCC3’ 
VLκ3c Fw Sense 5’GGGCCCAGGCGGCCGAGCTCGTGTTGACACAGTCTCC3’ 
VLκ3d Fw Sense 5’GGGCCCAGGCGGCCGAGCTCGTGTTGACGCAGTCTCC3’ 
VLκ4 Fw Sense 5’GGGCCCAGGCGGCCGAGCTCGTGATGACCCACACTCC-3’ 
VLκ5 Fw Sense 5’GGGCCCAGGCGGCCGAGCTCACACTCACGCGTCTCC3’ 
VLκ6 Fw Sense 5’GGGCCCAGGCGGCCGAGCTCGTGCTGACTCAGTCTCC-3’ 
VLκ Rv Anti-sense 5’GAAGACAGATGGTGCAGCCACAGT3’ CLκ tail 
CLκ 
CLκ Fw Sense 5’CGAACTGTGGCTGCACCATCTGTC 3’  
CLκ Rv Anti-sense 5’GCGCCGTCTAGAATTAACACTCATTCCTGTTGAA-3’ 3’-XbaI 
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VLλ 
VLλ 1a Fw  Sense 5’GGGCCCAGGCGGCCGAGCTCGTGTTGACGCAGCCGCCCTC 3’ 
5’-SfiI/SacI 
VLλ 1b Fw  Sense 5’GGGCCCAGGCGGCCGAGCTCGTGCTGACTCAGCCACCCTC 3’ 
VLλ 1c Fw  Sense 5’GGGCCCAGGCGGCCGAGCTCGTGGTGACTCAGCCACCCTC 3’ 
VLλ 2 Fw  Sense 5’GGGCCCAGGCGGCCGAGCTCGCCCTGACTCAGCCTCCCTCC3’ 
VLλ 3a Fw  Sense 5’GGGCCCAGGCGGCCGAGCTCGAGCTGACTCAGCCACC-3’ 
VLλ 3b Fw  Sense 5’GGGCCCAGGCGGCCGAGCTCGTGCTGACTCAGCCACC-3’ 
VLλ 4 Fw  Sense 5’GGGCCCAGGCGGCCGAGCTCGTGCTGACTCAATCGCCCTC 3’ 
VLλ 6 Fw  Sense 5’GGGCCCAGGCGGCCGAGCTCATGCTGACTCAGCCCCACTC 3’ 
VLλ 7/8a Fw  Sense 5’GGGCCCAGGCGGCCGAGCTCGTGGTGACCCAGGAGCC3’ 
VLλ 7/8b Fw  Sense 5’GGGCCCAGGCGGCCGAGCTCGTGGTGACTCAGGAGCC3’ 
VLλ 9 Fw  Sense 5’GGGCCCAGGCGGCCGAGCTCGTGCTGACTCAGCCACCTTC3’ 
VLλ 10 Fw  Sense 5’GGGCCCAGGCGGCCGAGCTCGGGCAGACTCAGCAGCT 3’ 
VLλ Rv Anti-sense 5’CGAGGGGGCAGCCTTGGGCTGACC3’ CLλ tail 
CLλ 
CLλ Fw Sense 5’GGTCAGCCCAAGGCTGCCCCC3’  
CLλa Rv Anti-sense 5’GATTCTAGAGTAGGGGCCACTG3’ 
3’-XbaI 
CLλb Rv Anti-sense 5’CATTCTAGAGCAGGGGCCACTG3’ 
 pCOMB Fw Sense 5’AGTGGCACTGGCTGGTTTCGC3’  
 pCOMB Rv Anti-sense 5’CCATGGTGATGGTGATGGTGC3’  
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6.2 Libraries’ CDR3 sequence diversity 
Table 6.2 – CDR3 sequence variability of κ Library tested Fab-containing clones. 
κ Library 
Clone LC CDR3 Clone HC CDR3 
K3 LQDYNYPPT K1 AARIGAPATGFDS 
K13 MHALRTPPS K10 AHNSGHVVYYYYYMDV 
K2 MQATQFPPT K26 AHRRPRGWYVDFDY 
K15 MQGSHWPLT K25 AKVRSTYVRDTFDV 
K26 MQGSHWPYT K6 AQWRWGNWFDP 
K14 MQGTHWPAKDA K13 ARDLHEGHLSGWYLPFY 
K1 QLYGDSPMFT K2 ARDPGLRLGETSVFES 
K8 QLYGDSPMFT K14 AREGLGTTDRALAY 
K18 QLYGYSPLLM K16 AREITPDCSGGSCFFQSHGLDV 
K9 QQRSNWPPLT K18 ARGFESGGLYLGFDY 
K21 QQSFGTPWT K8 ARGYCSGGSCYSEAFDI 
K6 QQTFSFPWT K15 ARMKQLGGFYDFGLDV 
K19 QQYDTYPWT K22 ARQNVLTGYLYNYLDS 
K17 QQYFISPLT K12 ARRYDSGIDH 
K22 QQYGISPYT K9 ARTVGRATNFYCDN 
K10 QQYGNSPQT K27 ARVAYGNHFDF 
K5 QQYGSSPPFT K4 ARVPENFSYSSGSYRGPFDI 
K25 QQYGSSPRYT K11 ASSGRYRYDAFDF 
K11 QQYGSSPTT K23 TRRRNLATGNNGAPDFDY 
K7 QQYNNWPPYT 
  K24 QQYNSYPWT 
  K23 QQYVRSPYT 
  
K16 QQYYQTPYT 
  
K20 QQYYTIPLT 
  K4 QVYGESPTWT 
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Table 6.3 - CDR3 sequence variability of λ Library tested Fab-containing clones. 
λ Library 
Clone LC CDR3 Clone HC CDR3 
L32 AAWDDSLHGVI L5 AALAVAGTGYFDL 
L14 AAWDDSLKGVV L24 AHRRSGDGGEVERGAFDI 
L17 AAWDESLNGWV L8 AHSRGYCAANGCFSRGWSYNY 
L26 ALYMGLGIWV L12 AKVRMITMVRGDAFDI 
L5 ATWDVTLNGPNVV L21 ARAPVGDYSGFYTDSFDI 
L11 CSYAGSNSVI L30 ARATYGNHFDY 
L6 CSYAGSSTFEV L13 ARAVGLTYFDF 
L28 CSYALSRAI L16 ARDLPPYYGLSGNYYFDY 
L3 CSYVGGNSVVV L19 ARDRFQGGYSYGP 
L29 FSYTSRNTGL L6 ARDRVYDYGDYGSMDV 
L1 GTWDSSLGVVL L9 ARDRVYDYGDYGSMDV 
L4 LLSYGGAWV L18 ARERRQLGVYYYGMDV 
L8 LLSYSGGRYVDVI L11 ARGRLQLTRRPTAIRYTPFDV 
L22 QSYDNSLSGSWV L26 ARMKQLGGFYDFGLDV 
L25 QSYDSSNRSWV L15 ARRTVTTPGFDC 
L2 QSYDSSNVV L10 ARVASSGYFSDY 
L20 QTWATDGVS L7 ARVPQNDYGDYYYFEN 
L18 QTWGTGGVA L28 ARWLQCFDY 
L7 QVWDSSSDHVV L17 ASSGRYRYDAFDF 
L31 SAWDDRLSGHVV L23 ASSGRYRYDAFDF 
L24 SSYAGPAEV L27 ATSRGGRNAFDI 
L15 SSYAGSSTSEV L3 VHPKSKGPFYDKPVNAFHV 
L21 SSYTDSSTFIVV L4 VKESEFGYYRTADY 
L30 VLYMGSGIPV L14 VRIYYQYGDYPHFHYMDV 
  
L1 VRNKYYYGSGSRRGRVDGFDV 
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6.3 D2/D19 clone sequence 
A) Nucleotide sequence 
 A.1) LC insert 
  - Length: 634 bp 
  - VBASE2 sequence analysis: 
Legend: - FR1; CDR1; FR2; CDR2; FR3; CDR3; FR4  
GTGCTGACTCATCGCCCTCTGCCTCTGCCTCCCTGGGAGCCTCGGTCAATTTCACCTGCACTCTGGGC
AGTGGACACAAAAACTTCGCCATCGCATGGCATCAGCAGCAGCCAGACAAGGGCCCTCGCTACCTGAT
GAACCTTGATAGTGAAGGCAGCCATACGAAGGGGGACGGGATCCCTGACCGCTTCTCAGGCTCCAGCG
CAGGGGCTGATCGCTACCTCACCATCTCCAGCCTCCAGTCTGAAGATGAGGCTGTCTATTACTGTCAG
ACCTGGGCCACCGACGGTGTGTCATTCGGCGGAGGGACCAAGCTGACCGTCCTAAGTCAGCCCAAGGC
TGCCCCCTCGGTCACTCTGTTCCCACCCTCCTCTGAGGAGCTTCAAGCCAACAAGGCCACACTGGTGT
GTCTCATAAGTGACTTCTACCCGGGAGCCGTGACAGTGGCCTGGAAGGCAGATAGCAGCCCCGTCAAG
GCGGGAGTGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCCAGCAGCTACCTGAG
CCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGCTACAGCTGCCAGGTTACGCATGAAGGGAGCACCG
TGGAGAAGACAGTGGCCCCTGC 
 
 A.2) HC insert 
  - Length: 797 bp 
  - VBASE2 sequence analysis: 
Legend: - FR1; CDR1; FR2; CDR2; FR3; CDR3; FR4  
CCCTTGTCCAGGGGCCTGTCGCACCCAGTGCATATAGTAGTCGGTGATGCTGTATCCAGAAGCCTTGC
ATGAGACCTTCACTGAGGCCCCAGGCATCTTCACCTCAGCCCCAGACTGCAACAGCTGCACCTGGGCC
ATCTCGAGATGGCCGAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTG
AGACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGTAGCTATGGCATGCACTGGGTCCGCCAGGCTCC
AGGCAAGGGGCTGGAGTGGGTGGCAGTTATATGGTATGATGGAAGTAATAAATACTATGCAGACTCCG
TGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAATACGCTGTATCTACAAATGAACAACCTG
AGAGGCGAGGACACGGCTGTCTACTACTGTGCGAGGGATGCCAACAGCTGGTACAGTGGCAATTACTT
TGACCACTGGGGCCAGGGAACCCTGGTCACCGTCTCTTCAGCCTCCACCAAGGGCCCATCGGTCTTCC
CCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTAC
TTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGC
TGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCA
CCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCACCAAGGTGAC 
 
B) Amino Acid Sequence 
 B.1) VL region 
xARADSSPSASASLGASVNFTCTLGSGHKNFAIAWHQQQPDKGPRYLMNLDSEGSHTKGDGIPDRFSG
SSAGADRYLTISSLQSEDEAVYYCQTWATDGVSFGGGTKLTVL 
 B.2) VH region 
EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRF
TISRDNSKNTLYLQMNNLRGEDTAVYYCARDANSWYSGNYFDHWGQGTLVTVSS 
